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Abstract 
 
Pyrrole-imidazole polyamides (PAs) represent a class of synthetic ligands that bind 
to the minor groove of DNA through hydrogen bonds and can be programmed to 
recognize predetermined DNA sequences. Potential applications of these compounds 
include gene expression modulation, antimicrobial activity and cell imaging.  
Studies conducted in our lab in collaboration with NanoVir have shown that large 
PAs exhibit antiviral activity against Human Papillomavirus (HPV), which is the most 
common sexually transmitted infectious agent in the US and the primary factor for the 
development of cervical cancer. PAs act against HPV by targeting the viral DNA and 
promoting its selective elimination from cells with a mechanism involving the DNA 
Damage Response (DDR) pathway, although the details underlining this mechanism are 
still under investigation. In a library of more than 100 PAs, we observed that even minor 
changes in polyamide chemical structure can cause dramatic differences in antiviral 
activity.  
The work presented in this thesis focuses on exploring some of the factors that 
may play a role in determining the different effectiveness of compounds that are 
structurally similar. The first part of this report describes the work intended to assess the 
interactions occurring between pyrrole-imidazole polyamides and HPV-DNA fragments. 
The DNA fragments used in these studies correspond to the Long Control Region of 
HPV, a regulatory region of primary importance for viral replication and transcription. 
The preferred binding sites as well as the strength of the binding were investigated 
ii 
 
through DNase I footprinting and affinity cleavage coupled with capillary 
electrophoresis. This work provided information on a molecular level on the binding 
mode of large PAs with a viral DNA sequence, showing interesting differences in 
comparison to the shorter PAs usually described in the literature and showing how minor 
structural substitutions can change the binding mode of these compounds when 
interacting with DNA. The second part of this report focuses on the investigation of 
cellular uptake of pyrrole-imidazole polyamides in human cells. HPLC and LC-MS/MS 
methods were developed to assess cell-associated polyamide. The methods were 
employed to explore the permeability of polyamides differing in their N-terminal groups 
or polyamides paired with different counterions.  
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CHAPTER 1 
INTRODUCTION 
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1.1 Human Papillomavirus Infection 
 
1.1.1 Introduction 
Human Papillomavirus (HPV) is a small tumor DNA virus known to infect the 
basal layer of stratified squamous epithelia of the skin, anogenital and upper respiratory 
tracts.
1,2
 
To date, more than 120 different HPV genotypes
8
 have been identified and can be 
classified as low- and high-risk according to their association with cancer.
9
 Low-risk 
(LR) HPV types cause predominantly skin and genital warts or benign lesions, while 
high-risk (HR) strains are the causative agents of squamous cell carcinoma (SCC) of the 
anogenital tract and the back of the oral cavity. Nearly all cervical cancers and about 60-
70% of oral and throat carcinoma, are caused by HPV,
10
 with HPV16 and HPV18 types 
alone accounting for about 70% of cervical cancers.
11
 Overall, at least fifteen different 
high-risk human papillomavirus types have been identified to date.
12
  
HPV infection is very common in young 
adults and in fact about 50-80% of sexually 
active women and men will encounter an HPV 
infection at least once in their lifetime.
13
 Up to 50 
% of the women infected with HPV will also 
acquire an infection with a different HPV type.
14
 
Although the infection is very common, in 
most of the cases the immune system is able to 
Figure 1.1
5
 WHO/ICO information center 
on HPV and cervical cancer (Permission 
number 4093280619270) 
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recognize the viral proteins and generate an antibody response against the virus that 
clears the infection in 6-12 months.
13
 However, failure to develop an appropriate 
response results in a persistent active infection, increasing the probability of viral DNA 
integration into the host genome and the progression to precancerous and cancerous 
lesions.
1,15
 
 
1.1.2 HPV Infectious Cycle 
The infection is initiated when the virus enters the epithelial basal cells through 
microabrasions. During productive infection, the viral genome is found in the nucleus in 
an extrachromosomal state (episome) and relies on the host machinery for its replication 
and protein synthesis. In the first stage of the infection the viral DNA is replicated at low 
copy number (50 to 100 episomes per cells) and, although the expression of viral proteins 
E6 and E7 is minimal, it is sufficent to enhance proliferation of infected cells.
1,16
 
Since viral DNA replication is dependent on keratinocyte differentiation, massive 
viral replication and protein expression occurs once the virus reaches the suprabasal 
layers after cell division.
17
 Viral assembly and viral particle release occur only in the 
upper level of the epithelium.
18
  
 
 
 
 
4 
 
 
As mentioned in section 1.1, the infection is in general successfully cleared by the 
immune system.  Nevertherless, in a small percentage of people the infection is not 
spontaneously resolved and persists for several years. A persistent infection increases the 
probability of viral DNA integration into the host genome, a key event for the 
progression to low-grade lesions and eventually to malignant carcinoma.
2
 The main 
consequence of DNA integration is the loss of a regulatory negative feedback loop that 
leads to the uncontrolled expression of the viral oncogenes E6 and E7. Cells with 
integrated HPV exhibit higher proliferation and a propensity to genomic instability.
19,20
  
 
 
 
 
 
 
Figure 1.2 HPV life cycle
1
 (Permission number 4093261369087)  
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                            Figure 1.3 Mechanism of HPV infection in the female genital tract
13
 
 
1.1.3 HPV Genome Organization and Proteins Encoded 
The genome of HPV is a circular double-stranded DNA of ~8000 bp and includes 
eight open reading frames (ORFs).
21
  E1, E2, E4, E5, E6, E7 are defined as “early genes” 
and are encoded during early stages of the infection, while the “late genes” L1 and L2 are 
expressed at late times, although these historical designations are not completely 
accurate. The genome includes also a regulatory region defined as the Long Control 
Region (LCR) containing transcription factors binding sites, promoter elements and the 
origin of replication, and thus important for viral replication and transcription.
22
  
Proteins L1 and L2 constitute the viral capsid and are expressed only in the upper 
layer of the epithelium during virus assembly. These proteins also represent the major 
antigenic components of the virus.
23
 
6 
 
E1 and E2 proteins play a role in viral 
replication, though E1-E2 independent 
pathways are known.
16,24
  E1 is a DNA 
helicase and the only enzyme encoded by the 
virus, while E2 involved in viral transcription 
and replication and may play a role in 
tethering the viral DNA to chromatin during 
cell division.
25
 One of the functions of E2 is 
to maintain low expression of the oncogenes 
E6 and E7 through a negative feedback loop 
early in the HPV life cycle. Integration of the 
viral DNA to the host genome occurs at the 
E2 gene, therefore abrogating the 
repression of the oncogenic proteins E6 and 
E7. The overexpression of E6 and E7 contributes to the cellular transformation that 
ultimately results in cancer.
20
 
The main oncoproteins encoded by HPV are E6 and E7.
26
 The prominent 
functions associated to E6 and E7 are the degradation of p53 and retinoblastoma (Rb).
20
 
The p53 degradation is mediated by E6 and occurs through an ubiquitin-mediated 
process, making the cells more susceptible to DNA damage. The retinoblastoma (Rb) 
protein binds to the E2F transcription factor family known to induce the expression of 
Figure 1.4 HPV genome organization 
4
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proteins that increase DNA replication and cell cycle progression. The E7 mediated 
inhibition of Rb, contributes therefore to tumor progression.
20,27
  
Although the p53 and pRb deregulation contribute to cellular transformation, the 
interaction with other targets involved in cell-cycle, apoptosis, and immune-modulation 
are also of primary importance for malignant progression. Together, E6 and E7 work in 
synergy, inducing a multitude of cellular effects that lead to cellular immortalization and 
are required to develop and maintain a malignant phenotype.  
While the functions of E6 and E7 have been widely studied, the roles of E4 and 
E5 are not fully characterized. E4 seems to play a role in facilitating virus particle 
synthesis, release and transmission
28
 while E5 is involved in viral immune evasion and 
may enhance the activities of E6 and E7 before viral DNA integration.
29,30
 
 
1.1.4 Prevention and Therapies 
Three prophylactic HPV vaccines have currently market approval. Cervarix
®
 is a 
bivalent vaccine covering infections mediated by the HPV types 16 and 18,
31,32
 while 
Gardasil
®
 is a quadrivalent vaccine including HPV types 6, 11, 16 and 18.
33
 Gardasil
®
9 is 
the newest vaccine introduced in the market in 2014 and offers protection against HPV 6, 
11, 16, 18, 31, 33, 45, 52, 58
34
 and will soon be the only vaccine available in the US. 
 All three vaccines are DNA-free subunit vaccines consisting only of the L1 
protein, the main protein constituting the viral capsid. L1 proteins spontaneously 
assemble into virus-like particles (VLP) which are highly immunogenic.
7
 The antibody 
8 
 
response induced by the vaccine is vastly higher than the response produced by a natural 
infection, remaining high for several years.
35
 
 
 
Although the vaccines offer protection against several high-risk HPV types, they 
offer no coverage against the remaining cancer causing HPV strains and are not effective 
for patients that have already been infected. Furthermore, while the vaccines have been 
proved to be largely safe and efficacious, population coverage is still lower than 
expected. 
As for treatments, standard therapies for genital HPV infections are limited to 
surgical excision accompanied to chemoradiation in advanced stages of cancer.
36
 Other 
treatments include mitotic inhibitors such as Podophyllotoxin or immune modulators 
such as Imiquimod,
37
 both approved as topical drugs for non-mucosal tissues. Imiquimod 
activates the innate immune response inducing the production of several cytokines. 
Figure 1.5 Virus-like particle (VLP). The HPV virion and 
the VLP are equal in size and shape. The VLP lacks a 
genome. The L1-VLP lacks the L2 protein in its 
capsomere
7
 (Permission number: 4093270358633)  
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Compared to Podophyllotoxin, Imiquimod is associated with lower recurrence but 
displays several side effects such as severe local inflammation and dermatitis, so 
tolerance can be an issue.
36
 
An extensive body of research has focused on the development of specific viral 
treatments to be used either alone or in combination with current therapies. Examples 
include inhibitors targeting the viral proteins E6, E7, E1 and E2 or therapeutic vaccines, 
nevertheless no treatments have been yet approved.
36
 
Together, the absence of effective treatments and the incomplete coverage offered 
by vaccine prophylaxis underlines the necessity for the development of novel and more 
effective therapies. 
 
1.2 Pyrrole-Imidazole Polyamides 
 
1.2.1 History of Pyrrole-Imidazole Polyamides 
Pyrrole-imidazole polyamides (PAs) are synthetic ligands developed from 
Distamycin A and Netropsin
38
, two natural antibiotics with antitumor and antibacterial 
properties that bind A·T sequences in the minor groove of DNA.
39-41
 Distamicin A 
consists of three N-methylpyrrole rings connected through amide bonds whereas 
Netropsin contains only two N-methylpyrrole rings and a guanidinium tail.  
10 
 
The interaction between the aforementioned ligands and the DNA occurs through 
H-bonds between the polyamide amide hydrogens and the edges of the base pairs in the 
minor groove.
42
 While both ligands can form 1:1 complex with the DNA, Distamycin can 
also form 2:1 ligand-DNA complexes. The peculiar crescent-shape of Distamycin and 
Netropsin and the specificity of the H-bonds account for their high affinity and specificity 
toward DNA. The ability of Netropsin and Distamycin to recognize also G·C DNA 
sequences was predicted by Dickerson
42
 and achieved by Lown
43
  with the replacement 
of N-methyl pyrrole by N-methyl imidazole (Im), so that the extra imidazole nitrogen 
could interact with the exocyclic –NH2 of guanine (which protrudes into the minor 
groove).  
Polyamides are synthetic analogs of Distamycin containing repeating units of the 
aromatic scaffold N-methylimidazole (Im) and N-methylpyrrole (Py) linked through 
amidic bonds. Similarly to the natural antibiotics, these compounds bind to the minor 
groove with high affinity, but do not exhibit significant cellular toxicity.  Over the years 
polyamides have been optimized to enhance DNA binding affinity and sequence 
specificity. For instance, β-alanine is often incorporated to relax the curvature of the 
ligand and allow the synthesis of longer polyamides without losing the ability of the 
ligand to match the pitch of DNA.
44
 The introduction of an γ-aminobutyric acid (GABA) 
Figure 1.6 Distamycin and Netropsin Chemical Structures
3
 (Permission number: 4093271317657) 
11 
 
unit between two antiparallel polyamide strands afforded hairpin polyamides which 
display a binding affinity 100-fold higher than the unlinked strands.
45,46
 While other 
structural variations have been explored such as H-Pin polyamides and tandem hairpin 
polyamides to increase binding affinity or target longer sites, hairpins polyamides are by 
far the most studied and utilized polyamides. 
A further step in expanding the recognition code included the pairing of 
hydroxypyrrole (HPy) to Py with the purpose of distinguishing between A and T bases
47
 
though HPy resulted to be chemically unstable over time, especially in cell culture media. 
Figure 1.7 Hairpin Polyamide bound to DNA
3
 (Permission 
number: 4093271317657) 
 
12 
 
Thus, a set of “polyamides pairing rules” were defined and refer to the ability of short 
polyamides to distinguish between the four DNA bases, with Im/Py pair recognizing G·C 
and Hp/Py recognizing T·A (Figure 1.8). 
 
  
 
 
  
 
 
 
 
 
 
1.2.2   Pyrrole-Imidazole Polyamides Applications 
Small polyamides can be programmed to bind specific DNA sequences with 
specificity and affinity similar to naturally occurring DNA-binding proteins.  
Because polyamides are cell and nucleus permeable, when applied to living 
systems, they can enter the nucleus and interfere with gene transcription disrupting 
protein-DNA interactions. There are numerous reports exploring the applications of PAs 
as gene expression modulators.
48,49
 Sugiyama and Dervan’s groups have shown how 
polyamides can act as transcription repressors by impeding the binding of transcription 
Im/Py target 
G·C 
Py/Py target 
A·T, T·A 
Figure 1.8 Pyrrole-Imidazole Polyamides Pairing Rules (Permission Number 4093290313925)
6
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factors to their DNA target sequences. Examples include the transcription inhibition of 
HIV-1
50
 and the repression of NF-kB, an important mediator of inflammation.
51
 In 
contrast, polyamides can also be used as gene transcription activators by conjugating the 
polyamide to a peptide activator. The polyamide binds the DNA sequence of interest 
acting as a DNA-binding domain while the peptide activator recruits the transcription 
factors necessary to initiate transcription.
52
  
By conjugation to a fluorophore, polyamides can also be employed for in vivo 
imaging.
53
 Polyamide-fluorophore conjugates, for instance, have been utilized to detect 
repeating units in  DNA,
54
 to visualize telomerases
55
 and to stain chromosomes while 
avoiding a denaturation step. 
 
1.2.3 Pyrrole-Imidazole Polyamides as Potential Anti-HPV Drugs 
Studies conducted in our lab and in collaboration with biologists at NanoVir have 
shown that large polyamides exhibit anti-HPV activity in epithelial cell and tissue 
cultures, without evidence of cytotoxicity up to their solubility limit (150-200 µM).
56
 
These minor groove binders enter the HPV-infected cells, triggering the degradation and 
elimination of the HPV DNA. The binding of PA probably induces a structural alteration 
in the viral DNA, eliciting the DDR pathway
57,58
 which mediates the antiviral activity of 
PAs, although the exact mechanism of DNA degradation is still under investigation. PAs 
specifically target the degradation of the viral DNA in the episomal form, since the DDR 
pathway alteration, and all antiviral activity, is solely observed in cells bearing HPV 
episomes and not in cells having HPV DNA integrated in the host genome.  
14 
 
More recently, the antiviral activity of polyamides was demonstrated against 
Simian virus 40 (SV40) and BK virus, viruses belonging to the polyomavirus family, thus 
expanding the spectrum of activity to other double-stranded small DNA tumor viruses.
59
  
To date, a library of more than 100 compounds has been built. It includes PAs 
that differ in length, building-block sequence, C-terminal tail and N-terminal substitution. 
Although we currently know that longer PAs (minimum DNA binding site of 10 bp) and 
N-terminal substitution with guanidinium group (TMG) positively affect the antiviral 
efficacy, no clear structure-activity relationship (SAR) has yet emerged. Even small 
variations in PA chemical structure lead to significant changes in antiviral efficacy. The 
work described in this thesis focuses on the investigation of some of the aspects that may 
be important for antiviral activity. Specifically, we explored the interactions occurring 
between polyamides and HPV DNA sequences as well as the cellular uptake features of 
large polyamides. The latter investigation was important because traditional structure-
activity relationships have not become clear even after extensive analysis based on 
thermodynamic binding constants and antiviral data. 
Pyrrole-imidazole polyamides represent a nontraditional approach toward the 
development of antiviral medications for the treatment of HPV infections, for which a 
cure is currently not available. 
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CHAPTER 2 
BINDING STUDIES OF PYRROLE-IMIDAZOLE POLYAMIDES NV1028 AND 
NV1042 WITH NATURAL HPV DNA SEQUENCES 
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Figure 2.1. Workflow of a DNase I footprinting experiment. 
Electropherograms represent raw capillary electrophoresis (CE) data. 
Figure adapted from “The Cell: A Molecular Approach”, 2nd edition, 
Cooper GM. Sunderland (MA): Sinauer Associates, 2000. 
 
2.1 Introduction 
 
 Pyrrole-imidazole polyamides containing a minimum of ten rings actively 
eliminate the DNA of HPV and other viruses from infected cell.
1-5
 The aim of this study 
is to identify and characterize the interactions occurring between antiviral pyrrole-
imidazole polyamides and natural HPV DNA sequences by means of DNase I 
footprinting and affinity cleavage methods.  
DNase-I 
footprinting is a widely 
used technique employed 
to determine the 
interactions between DNA 
and proteins or other DNA-
binding ligands.
6,7
 A 
scheme of the experiment 
workflow is reported in 
Figure 2.1. In a typical 
footprinting experiment, 
the ligand is incubated with 
the DNA and the 
deoxyribonuclease cleaves the phosphodiester bonds that are not protected by the ligand. 
The resulting DNA fragments are subsequently analyzed by gel-electrophoresis and the 
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fragmentation pattern compared to the cleavage pattern obtained in a control sample 
(DNA cleavage in absence of a ligand) to determine the binding sites. While gel-
electrophoresis is the most common down-stream technique to analyze the fragments, 
capillary electrophoresis can also be employed if the DNA is labeled with a fluorescent 
dye.
8,9
 Advantages of capillary electrophoresis include the elimination of the radioactive 
label as well high throughput. Furthermore, footprinting is extensively used to evaluate 
the binding strength of a DNA-ligand interaction.
10,11
 In this case the DNA is titrated with 
increasing concentrations of ligand (Figure 2.2) and the observed cleavage in inversely 
proportional to the ligand concentration. Binding constants are obtained by plotting the 
fraction bound as a function of concentration and fitting the data to a Hill or Langmuir 
model. 
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Figure 2.2 (A) Representative footprinting electropherograms showing the cleavage pattern 
generated by quantitative DNase I footprinting titration in the presence of increasing ligand 
concentration; (B) Hill binding titration isotherm obtained from DNase I data 
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While footprinting can be useful to locate the ligand position along the DNA and 
to evaluate the energetics of the interaction, affinity cleavage is a complementary 
technique that provides the orientation of the polyamide along a DNA fragment.
12
 This 
method requires the conjugation of the chelating agent ethylenediaminetetraacetic acid 
(EDTA) to the C-terminal amino group of a polyamide, resulting in a PA-EDTA complex 
able to chelate Fe (II). In presence of H2O2, Fe (II) is oxidized to Fe (III) and hydroxyl 
radicals are generated by reduction of the peroxide. The radicals cleave DNA at the end 
of the polyamide binding site by abstracting H· from the deoxyribose in a distance-
dependent manner from the C-terminus of the polyamide.   
Here, I identified and characterized the binding sites of two hairpin 
polyamides, NV1028 and NV1042 (Figure 2.3), in the long control region (LCR) of 
Human Papillomavirus type 18 (HPV18, Genebank No.: X05015) using DNase I 
footprinting and affinity cleavage coupled with capillary electrophoresis. Quantitative 
DNase I footprinting experiments were carried out to determine the dissociation 
constants of each compound. The LCR was chosen because it represents the regulatory 
region in the HPV genome and contains cis-responsive elements regulating the 
transcription and replication of HPV.
13
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2.2 Methods 
 
2.2.1 Materials 
RNA primers were ordered from Integrated DNA Technologies (Coralville, 
Iowa), Taq Polymerase was purchased from New England Biolabs (Ipswich, MA) and 
Fe(NH4)2(SO4)2, MgCl2, CaCl2, Dithiothreitol (DTT) were acquired from Sigma Aldrich 
(St. Louis, MO). Thermo Sequenase Cycle Sequencing Kit and 3-[(3-Cholamidopropyl) 
Figure 2.3. NV1028 (A) and NV1042 (B) chemical structures and correspondent DNA recognition 
motifs 
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dimethylammonio]-1-propanesulfonate (CHAPS) were obtained from Affymetrix  (Santa 
Clara, CA) and DNase I was purchased from Promega (Madison, WI).   
 
2.2.2 DNA and Polyamide Concentration Measurements  
Polyamide concentration was determined by UV-Vis spectrometry. Briefly, 0.1 
mg of lyophilized polyamide was dissolved in 100 µl of DMSO and the absorbance at 
305 nm measured by UV-Vis using a Thermo Scientific Evolution 260 BIO UV 
spectrophotometer. The extinction coefficients used were determined by mass and were 
equal to 88235 M
-1
cm
-1
 for NV1028 and 147400 M
-1
cm
-1 
for NV1042.
2
 The DNA 
concentration was quantified by UV-Vis spectrometry, measuring the absorbance at 260 
nm. 
 
2.2.3 385-bp DNA Fragment Preparation (Fragment I) 
The fluorescently labeled DNA fragment (HPV18 7179-7563 bp) was generated 
by polymerase chain reaction (PCR) using the HPV18-pBR322 plasmid as a template and 
primers 5’ labeled with 6-carboxyfluorescein (FAM) on the top strand and 6-carboxy- 
2',4,4',5',7,7' – hexachlorofluorescein (HEX) on the bottom strand. Primers were designed 
using Primer-3 and their physical properties analyzed using the Oligoanalyzer 3.1 
website. The forward and reverse primer sequences were 5’-Fam-
TATGTCCTGTGTTTGTGTTT-3’ and 5’-Hex-CAAAATATGTAGGAGCAGTG-3’ 
respectively. The PCR cocktail was prepared as described in Table 2.1 and amplification 
was performed over 32 cycles at the conditions shown in Table 2.2. 
26 
 
Reagents Vol (µL) 
H2O 41 µL 
10X standard Taq Buffer with 
MgCl2 
5 µL 
Template DNA 1 µL 
10 µM Reverse Primer 1 µL 
10 µM Forward Primer 1 µL 
10 mM dNTPs 0.5 µL 
Taq Polymerase 0.5 µL 
                                                Table 2.1. PCR Cocktail for a 50 µl reaction 
 
PCR Step Temperature Time 
Denaturing 95 ºC 30 sec 
Annealing 55.4 ºC 30 sec 
Extension 68 ºC 1 min 
       Table 2.2 Optimized PCR conditions for the HPV18 7179-7563 DNA fragment amplification 
                                  
The PCR product was separated by gel electrophoresis (1% agarose gel in Tris-acetate-
EDTA buffer), the band correspondent to the desired product was excised from the gel 
and purified using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). The 
DNA was also sent to the DNA core for Sanger sequencing,
14
 to ensure that the sequence 
was correct.  
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2.2.4 305-bp DNA Fragment Preparation (Fragment II) 
The doubly labeled 305 bp fragment (HPV18 7479-7783) was generated 
following the procedure described in section 2.2.3. The forward and reverse primer 
sequences were 5’-Fam-CTTATGTCTGTGGTTTTCTG-3’ and 5’-Hex-
CAGAAAACCACAGACATAAG-3’ respectively. PCR was performed over 32 cycles at 
the conditions shown in Table 2.3. 
 
PCR Step Temperature Time 
Denaturing 95 ºC 30 sec 
Annealing 48 ºC 30 sec 
Extension 68 ºC 30 sec 
          Table 2.3. Optimized PCR conditions for the HPV18 7479-7783 DNA fragment amplification 
 
Ladder 
500 bp 
1000 bp 
Figure 2.4. Representative agarose gel of the 385 bp DNA fragment. 
Lane 1 and Lane 2 correspond to the desired 385 bp DNA fragment 
 1 
 
 2 
 
100 bp 
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2.2.5 USB and Maxam-Gilbert Sequencing (Indexing) 
Conjugation of a fluorescent dye to the 5’ end of a DNA fragment alters the DNA 
mobility, affecting elution time and size calling during capillary electrophoresis (CE). 
Furthermore, the type of chemistry applied to generate DNA cleavage can also affect 
electrophoretic mobility since different cleavage products are generated.
15
  In order to 
correlate the nucleotide position observed in the CE electropherogram with the real 
nucleotide position in the genome, we used Sanger chemistry
14
 (USB, Affymetrix, Santa 
Clara, CA, USA) and Maxam and Gilbert
16
 chemistry to map DNase-I footprinting and 
affinity cleavage results, respectively. Sanger sequencing involves the use 
of dideoxynucleotides (ddNTPs), nucleotides containining hydrogen on the 3’ carbon 
instead of a hydroxyl group (OH). Once integrated into a sequence by the 
305 bp 
fragment 
 Ladder 
Figure 2.5. Representative agarose gel of the 305 bp DNA fragment 
Lane 1 corresponds to the desired 305 bp DNA fragment 
1 
1000 bp 
 
500 bp 
 
100 bp 
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Thermosequenase enzyme during PCR, ddNTPs prevent the addition of further 
nucleotides.  By amplifying four different reaction mixtures, each containing one of the 
four dideoxynucleotides (ddATP, ddTTP, ddCTP, ddGTP), Thermosequenase and all 
dNTPs and then subjecting each mixture to fragment analysis, it is possible to determine 
the sequence and the position of each nucleotide along the DNA sequence. The results of 
the sequencing are provided in Table SI 1A (HPV 7169-7563) and SI 1B (7479-7789).  
Maxam and Gilbert sequencing is used to map the results obtained by affinity 
cleavage since the chemistry involved best resembles the hydroxyl radical cleavage 
produced by Fenton chemistry. The correlation between capillary electrophoresis position 
and real position is provided in Table SI 2. 
The difference between Sanger and Maxam–Gilbert positions versus the real 
position (Figure 2.6) was determined for the 385 bp fragment (HPV18 7179-7563). 
These results were consistent with those obtained and previously published by our 
group.
15
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2.2.6 DNase I footprinting 
 Briefly, samples (250 µl) of labeled DNA (final concentration: 200 pM) in TKMC 
buffer (10 mM Tris, 10 mM KCl, 5 mM MgCl2 and 5 mM CaCl2), 2 % DMSO and 10 
mM CHAPS were incubated with polyamide (ranging from 0-40 nM) at 37 ºC for 
approximately 4 hours (incubation time can vary from 2 h to overnight). The mixture was 
digested with 0.03-0.09 AU of RQ1 RNase-Free DNase I (Promega, Madison, WI 53711) 
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Figure 2.6. Difference between Sanger and Maxam–Gilbert 
positions versus the real position 
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for 5 min at 37 ºC, stopped by adding 10 µL of 200 mM EDTA.  The DNase I digested 
product was purified with Qiagen PCR purification kit (Qiagen, Hilden, Germany). 
Footprinting results were mapped using USB sequencing and Kd values determined by 
fitting the results to a Hill model. 
 
2.2.7 Affinity Cleavage 
 The polyamide-EDTA-Fe conjugate was prepared by adding 0.8 equivalents of 
Fe(NH4)2(SO4)2 to a solution of polyamide-EDTA in DMSO. Samples of the labeled 
DNA (final concentration: 1 nM) in 100 mM Tris-HCl buffer, 2% DMSO and 10 mM 
CHAPS were incubated with the polyamide-EDTA-Fe
++
 conjugate at 37 ºC for 4 hours. 
The polyamide-EDTA conjugate concentration ranged from 5 nM to 200 nM. Cleavage 
reactions were initiated by adding 5 µL of freshly made 100 mM DTT to the sample and 
incubating the reaction mixture for ~1 h. The reaction was quenched and products 
purified using a Qiagen PCR purification kit. Fragment analysis was conducted by CE. 
Affinity cleavage results were mapped using Maxam-Gilbert sequencing.  
 
2.2.8 Capillary Electrophoresis (CE) 
 Samples of fragmented DNA were sent and processed at the University of 
Missouri DNA Core facility using an ABI 3730xl DNA Analyzer 96-capillary CE 
instrument. Low salt concentration and complete ethanol removal during DNA 
purification were essential for optimal results. DNA concentration, injection time and 
size standard quantity are also  
32 
 
important parameters to optimize. Data were processed using GeneMarker version 1.97 
software (SoftGenetics, State College, PA, USA). Isotherms were generated using 
Kaleidagraph 4.1.3 software (Reading, PA, USA). 
 
2.3 Results and Discussion 
 
 DNA binding studies were carried out on DNA fragments correspondent to the 
Long Control Region (LCR) of HPV18 (Figure 2.7). Because by capillary 
electrophoresis only DNA sequences shorter than ~400 bp can be accurately analyzed for 
footoprinting purposes, three different DNA fragments spanning the whole LCR were 
prepared as shown in Figure 2.7.  
The pyrrole-imidazole polyamides used for these studies were NV1028 and NV1042. 
Polyamide NV1028 is a 12-ring polyamide that, according to the Dervan’s rules,17 should 
recognize the DNA sequence 5’-WWGWWWWWWW-3’ (where W indicates adenine or 
thymine). NV1042 belongs to a class of larger polyamides containing 16 rings that should 
recognize the motif 5’-WWGWWWWGWWWWW-3’. The chemical structures of both 
compounds are reported in Figure 2.3.  
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2.3.1 Binding of polyamide NV1028 on a 385 bp fragment within the LCR of HPV18 
(7179-7563 bp – Fragment I) 
Affinity cleavage experiments were performed in triplicate according to the 
procedure described in section 2.2.6 and results are mapped in Figure 2.8. Affinity 
cleavage is depicted by vertical arrows located above and below the DNA sequence, with 
black arrows representing affinity cleavage observed at 50 nM of NV1028 (high affinity) 
and red arrows representing affinity cleavage sites appearing only at 100 nM polyamide 
(low affinity). 
 
 
Figure 2.7. HPV18 Long Control region (LCR). Representation of the HPV18 LCR and the three 
different fragments (Fragment I: brown, Fragment II: blue, Fragment III: green) used to carry out the 
binding experiments. Red nucleotides indicate begin and end of the LCR, the underlined text indicates 
the nucleotides shared by two adjacent fragments 
Fragment III 
(7647-157) 
Fragment II 
(7479-7783) 
Fragment I 
(7179-7563) 
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Figure 2.8. Map of affinity cleavage and footprinting of HPV18 (7189-7563) with NV1028 
 (overleaf) 
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The map provides a representation of 
observed binding sites along with zero or 
one mismatch sites that are predicted but 
not observed (not observed: site 7247-
7256, site 7391-7400 and site 7398-7389). 
A mismatch site refers to any site within 
the DNA sequence bound to the polyamide that the reported binding rules fail to 
predict.
17,18
 All the observed high affinity cleavage sites can be rationalized by 0, 1, or 2 
mismatches, with the exception of site 18, which can be better explained by a 3-mismatch 
site. At sites 4, 5, 8, 9, 11, 12, 15 the polyamide could bind in either a forward or a 
reverse orientation, while sites 6, 7, 9, 18, 19, due to the resolution of our experimental 
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techniques, cannot unambiguously be assigned to forward, reverse or mismatch number. 
Interestingly, there are two perfect reverse sites to which NV1028 binds only modestly: 
site 5 (7263-7254) and site 8 (7290-7281). For site 8, a plausible explanation for the poor 
binding may be the context in which the perfect binding site is found. Adjacent to it, there 
is in fact a long (13 nucleotide) poly-W sequence corresponding to a very high and broad 
affinity cleavage. Therefore, this W-rich sequence is preferred to a perfect binding site 
having a guanine at the imidazole position. More likely, what is preferred is the 
characteristic local shape of the poly-W tract characterized by a narrow minor groove (or 
its low electrostatic potential
19
). A prediction of DNA hydroxyl radical cleavage for the 
sequence 7239-7358 carried out using ORChID (Tullius Lab., http://dna.bu.edu/orchid/) 
supports the peculiar shape of this W-rich sequence (Figure 2.9). Hydroxyl radical 
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cleavage provides an indirect representation of the groove shape. Narrow minor grooves 
are characterized by low hydroxyl radical cleavage, while where the minor groove is 
wide, and therefore deoxyribose hydrogens are more exposed, cleavage is high.
20
 A 
significant hollow is observed in the plot (Figure 2.9) corresponding to the W-rich tract 
to which the polyamide binds. 
 
When the DNA is incubated with a higher polyamide concentration (100 nM), 
new binding sites are observed and are depicted in Figure 2.8 with red vertical arrows. 
The majorities of these sites usually correspond to a higher number of mismatches and 
higher Kd values and are characterized by sigmoidal binding curves. These sites can be 
described as low affinity sites that are occupied only when all the high affinity locations 
Figure 2.9. Hydroxyl radical cleavage of the sequence 7239-7358 
predicted by ORChID. Low cleavage sites correlates with narrow minor 
grooves. The AT rich sequence correspondoing to Sites 6-7 is marked in blue. 
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are saturated. The binding at these sites occurs once the polyamide binds to the high 
affinity sites, probably by inducing a conformational change in the DNA structure, 
making these site more accessible than previously. 
 
For quantitative DNase I footprinting experiments, DNA (200 pM final 
concentration) was titrated with NV1028 at a concentration ranging from zero to 40 nM. 
The footprinting sites match overall with the affinity cleavage results. Isotherms were 
obtained using data from either the HEX channel or the FAM channel depending on the 
location of the binding site within the fragment. Footprinting is represented in Figure 2.8 
by yellow highlighted (footprinting at 5 nM) and grey highlighted text (footprinting at 20 
nM polyamide). Most of the high affinity sites show Kds between 0.6 and 4.9 nM. 
Almost all of the dissociation constants determined for the low-affinity sites show 
sigmoidal binding curves indicating cooperative binding. A summary of all the 
determined dissociation constants is provided in Table SI 3A and representative 
isotherms are provided in Figure SI 2. 
 
2.3.2 Binding of polyamide NV1042 on a 385 bp fragment within the LCR of HPV18 
(7179-7563- Fragment I) 
Binding analysis of NV1042 was carried out on a 385 bp DNA sequence 
corresponding to nucleotides 7179-7563 of the HPV18 LCR. Figure 2.10 illustrates all 
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the observed binding sites and one and two mismatch sites that were predicted by the 
pairing rules but not observed.  
 
 
Figure 2.10. Map of affinity cleavage and footprinting of HPV18 (7189-7563) with NV1042 
 
NV1042 Map on HPV18 (7179-7563) 
 
      7179                               ta tgtcctgtgt ttgtgtttgt  
                                        at acaggacaca aacacaaaca 
   
 
     7201 tgtatgattg cattgtatgg tatgtatggt tgttgttgta tgttgtatgt 
          acatactaac gtaacatacc atacatacca acaacaacat acaacataca 
 
 
 
 
     7251 tactatattt gttggtatgt ggcatataat aaaatatgtt ttgtggttct 
          atgatataaa caaccataca ccgtaattta ttttatacaa aacaccaaga 
 
 
 
 
 
 
     7301 gtgtgttatg tggttgcgcc ctagtgagta acaactgtat ttgtgtttgt  
          cacacaatac accaacgcgg gatcactcat tgttgacata aacacaaaca 
 
 
 
 
     7351 ggtatgggtg ttgcttgttg ggctatatat tgtcctgtat ttcaagttat  
          ccatacccac aacgaacaac ccgatatata acaggacata aagttcaata 
 
 
 
 
     7401 aaaactgcac accttacagc atccatttta tcctacaatc ctccattttg  
          Ttttgacgtg tggaatgtcg taggtaaaat aggatgttag gaggtaaaac 
 
 
 
 
 
     7451 ctgtgcaacc gatttcggtt gcctttggct tatgtctgtg gttttctgca 
          gacacgttgg ctaaagccaa cggaaaccga atacagacac caaaagacgt 
 
 
 
 
 
# 13 
# 11 # 9 # 10 
# 7 # 6 # 8 
0.8(1) 
# 14 
# 1 
1.1(4) 
1.2(8) 0.7(2) 
# 0 
# 20 # 21 # 17 # 19 
1.1(7) 
1(6) 
0.9(3) 
1.5(4) 1.9(6) 
0.7(1) 
0.7(1) 
# 15 
1.3(5)1.4(5) 
# 16 
0.5(1) 0.6(1) 
# 2 
0.5(1) 
# 3 # 4 
# 12 
# 5 
# 18 
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In contrast to NV1028, for 
NV1042 there are no predicted perfect 
binding sites in the analyzed sequence. 
Nevertheless, 21 binding events were 
observed, most of which can be 
explained only by a higher number of 
mismatch compared to NV1028 (at least 
two mismatches, mostly three mismatches). Conversely, the only two predicted 1-
mismatch sites are not observed. Although, for this compound, the data are easier to 
discriminate between forward and reverse binding compared to NV1028, it is more 
difficult to assign the exact location of the binding sites since NV1042 can bind to a 
considerably higher number of mismatch sites than NV1028.  
Sites 0, 1, 2, 8, 9 can be assigned almost unambiguously to two and three mismatch sites. 
An interesting region is the sequence corresponding to nucleotides 7274-7292 also 
mentioned for NV1028 in section 2.3.1, where the only two predicted 1-mismatch sites 
are not observed and instead the adjacent 3-mismatch site is preferred (Site 4). As 
described in the previous section, the reason behind this observation likely is because 
these bound sites are found within the distinctive W-rich stretch, which perhaps better 
accommodates the polyamide regardless of the number of mismatches (as mentioned 
before both the shape and the electrostatic potential of DNA affect ligand binding). As 
described for NV1028, also for NV1042, low-affinity binding sites are observed when the 
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DNA is incubated with 100 nM ligand. Some of these sites can be rationalized with a 
mismatch number up to six. 
 
For quantitative DNase I footprinting experiments, 200 pM of DNA were initially 
titrated with NV1042 at a ligand concentration ranging from zero to 40 nM, but afterward 
the polyamide concentration was lowered to 0-20 nM since saturation was reached at 
lower concentration than NV1028. The dissociation constants ranged between 0.5 nM 
and 1.8 nM, and, on average, are lower than those observed for NV1028. It is possible 
that we have reached the lower limit of detection for NV1042 with our methodology and 
therefore we may not have converged on the true Kd values for NV1042 yet - they could 
be lower. A table containing all the Kd values is provided in Table SI 3B and 
representative isotherms are reported Figure SI3. 
 
2.3.3. Binding of polyamide NV1028 on a 305 bp fragment within the LCR of HPV18 
(7479-7783 - Fragment II) 
Affinity cleavage experiments were performed in triplicate in order to determine 
the binding sites and orientation NV1028 within the 305 bp DNA sequence. The results 
are shown in Figure 2.11, a map a representing the observed binding sites.  
Overall, only four perfect binding sites (represented as black horizontal arrows) 
and 15 one mismatch sites are predicted for NV1028 in this DNA fragment. The map 
illustrates also zero or one mismatch sites that are not observed (site 2: 7553-7562, site 2-
3: 7561-7570, site 3: 7565-7556, site 11: 7700-7709, site 12: 7708-7699).  
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Figure 11. Map of affinity cleavage and DNAse I footprinting of HPV18 7479-7783 with 
NV1028 
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Sites 0a, 3, 5, 6, 9, 10 and 13 match very well with the affinity cleavage and can be 
assigned to a single binding mode. Conversely, sites 1, 8 and 11 cannot unambiguously 
be explained by a single binding mode due to technique resolution.  In site 11 given the 
shape of the affinity cleavage of the bottom strand, probably more than one polyamide is 
binding. Similarly, for sites 7, 8, and 12 is not possible distinguish if the polyamide is 
binding in the forward or the reverse orientation. Of note, there are no data to indicate 
NV1028 binding to the predicted perfect binding sites 7753-7762 bp and 7565-7556 bp, 
or the binding is, at best, unusually weak for a perfect site relative to observed mismatch 
bindings. Although some affinity cleavage is observed, it is in the noise and does not 
show the characteristic bell shaped curve of a true affinity cleavage site. It may be 
possible that NV1028 is binding to all those sites in the ensemble of DNA molecules in 
solution and consequently provides a low and broad cleavage. NV1028 however, binds to 
one of these perfect binding site (7753-7762 bp) at a higher polyamide concentration 
(100 nM), while no binding is observed for the second site (7565-7556 bp) at the higher 
concentration. The reasons behind this are still not clear. The same sequences are not 
present in any other fragment analyzed so far, so is not possible to make a comparison 
and determine if the polyamide does not bind those particular positions because of the 
peculiar sequence or because the sequence is not in a favorable context. 
The description provided above refers to affinity cleavage experiments and high 
affinity binding sites (observed at 50 nM polyamide concentration) which can all be 
explained by 0, 1 or 2 mismatch sites. As mentioned in section 2.3.1, when the DNA is 
incubated with a higher polyamide concentration (100 nM), new binding sites are 
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observed by affinity cleavage and are depicted with red vertical arrows. Most of these 
sites usually correspond to a higher number of mismatches, excluding the anomalous 
perfect binding site 2. Looking also at the sigmoidal isotherms generated at these 
positions, these sites can be described cooperatively as low affinity sites occurring only 
when all the high affinity sites are saturated.  
 
 In order to determine the binding affinity of NV1028 with the 305 bp DNA 
sequence, quantitative DNase I footprinting experiments were performed in triplicate 
according to the procedure described in section 2.2.6.  DNA (200 pM final concentration) 
was titrated with NV1028 at a concentration ranging from 0 to 40 nM. Footprint sites are 
well defined at 5 nM polyamide and an increase of polyamide concentration leads to the 
appearance of more binding sites up to the point (40 nM) where the footprint covers most 
of the fragment. This protection may be due to polyamide binding or to the inability of 
DNase I to induce DNA cleavage at high polyamide concentration because of poisoning 
or because there not enough space is left for DNase I to cleave between adjacent binding 
sites. Overall, the footprinting data support the affinity cleavage data. 
Table SI 3C provides all the Kd values determined for the fragment 7479-7783 bp. Kds 
range between 0.8 nM and 2.7 nM, and therefore within the acceptable ratio between the 
DNA concentration and the Kd (Kd must be at least five times the DNA concentration). 
Sites 5, 6 and 11, show lower Kd values (Kd= 4 x DNA concentration), but the range is 
still acceptable.  Representative isotherms at three binding sites are reported in Figure SI 
1. 
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2.3 Conclusion 
The results obtained in this study show that polyamides NV1028 and NV1042 
bind strongly to DNA, exhibiting binding affinity in the low nanomolar range (Kd: 0.5-5 
nM). Furthermore, both compounds bind to HPV sequences in a more indiscriminate way 
than predicted by the reported binding rules as previously observed by our group for 
HPV16 DNA sequences.
2,5,21,22
 NV1028 and NV1042, in fact, bind to most of the 
predicted 1-mismatch sites as well as to many 2-mismatch and 3-mismatch sites without 
significant loss in binding affinity. Of note, there are a few perfect sites where no 
polyamide binding is observed, and these may represent sites where the microstructure of 
the DNA becomes an important factor to take in consideration when predicting 
polyamide binding. 
   NV1042, in particular, exhibits a greater tolerance for a higher number of 
mismatch: most of the binding events are explained in fact, by at least 3-mismatch sites. 
The only predicted 1-mismatch sites in the fragment analyzed are not observed and the 
adjacent 3-mismatch sites are instead preferred. At these sites, it is likely that something 
beyond the sequence affects the binding. One possibility is that, the readout of the local 
DNA shape contributes to binding recognition. Readout of minor groove shape and 
electrostatic potential may in fact play a role in the recognition as observed for many 
DNA-specific proteins.
19
 The best example supporting this idea is given in the region 
within Fragment I where NV1028 prefers to bind to a 1-mismatch instead of a perfect 
site. In this case the polyamide prefers having an A or T at the imidazole, demonstrating 
how the insertion of an imidazole to recognize G does not guarantee sequence specificity 
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because other factors play a role. This is corroborated by the fact that NV1042 also binds 
exactly to the same sequence, which corresponds to a 3-mismatch site in that case, 
although an adjacent single mismatch site is available. This observation indicates that 
probably the local DNA shape is driving the binding at this position regardless of the 
DNA sequence or the number of mismatches tolerated.  
Although the binding affinities of NV1028 at all the determined binding sites are 
comparable to those determined for NV1042, the Kd values for NV1042 are on average 
lower than NV1028, although not statistically significant. Furthermore, it is worthwhile 
to mention that we may not have converged on the true Kd values for NV1042 yet (we 
have reached the lower limit of DNA concentration for DNase I footprinting with the 
technique currently employed). 
 The experiments described in this chapter provide a representation of the 
interactions occurring in vitro between polyamides and short DNA fragments. Mapping 
of polyamide along the entire HPV genome in its native conformation and in cells have 
recently been performed in our lab and will certainly provide an even more accurate 
depiction of the interactions occurring between large polyamides and DNA. 
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2.6 Supporting Information 
Table SI 1A. USB Sequencing Results on HPV18 7479-7783  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genome 
Position
Fragment 
Position
Sequence
CE 
postion
Genome 
Position
Fragment 
Position
Sequence
CE 
postion
Genome 
Position
Fragment 
Position
Sequence
CE 
postion
7783 1 T 7663 121 G 114.9 7543 241 C 234.7
7782 2 T 7662 122 T 115.8 7542 242 C 235.6
7781 3 C 7661 123 G 116.9 7541 243 C 236.5
7780 4 A 7660 124 G 117.9 7540 244 A 237.5
7779 5 T 7659 125 A 118.7 7539 245 A 238.5
7778 6 G 7658 126 T 119.8 7538 246 A 239.5
7777 7 T 7657 127 A 120.5 7537 247 A 240.5
7776 8 T 7656 128 T 121.6 7536 248 G 241.8
7775 9 A 7655 129 A 122.4 7535 249 A 262.6
7774 10 A 7654 130 G 123.7 7534 250 T 244
7773 11 G 7653 131 T 124.6 7533 251 T 244.8
7772 12 G 7652 132 T 125.6 7532 252 A 245.7
7771 13 G 7651 133 A 126.4 7531 253 A 246.7
7770 14 T 7650 134 T 127.5 7530 254 A 247.7
7769 15 A 7649 135 G 128.8 7529 255 G 248.9
7768 16 G 7648 136 C 129.5 7528 256 T 249.9
7767 17 A 7647 137 A 130.3 7527 257 T 250.9
7766 18 C 7646 138 A 131.1 7526 258 T 251.8
7765 19 A 7645 139 G 132.5 7525 259 G 252.9
7764 20 G 7644 140 C 133 7524 260 C 253.8
7763 21 A 7643 141 A 134.1 7523 261 A 254.7
7762 22 A 7642 142 A 135 7522 262 A 255.6
7761 23 T 7641 143 T 136.1 7521 263 T 256.7
7760 24 G 7640 144 T 137.2 7520 264 A 257.6
7759 25 T 7639 145 G 7519 265 G 258.8
7758 26 T 7638 146 T 7518 266 T 259.7
7757 27 G 7637 147 T 140.4 7517 267 G 260.9
7756 28 G 7636 148 G 141.8 7516 268 C 261.6
7755 29 A 7635 149 T 142.6 7515 269 C 262
7754 30 C 7634 150 A 143.5 7514 270 A 263.4
7753 31 A 7633 151 G 144.8 7513 271 G 264.6
7752 32 T 7632 152 C 145.5 7512 272 C 265.4
7751 33 G 7631 153 G 146.8 7511 273 G 266.6
7750 34 A 7630 154 C 147.4 7510 274 T 267.4
7749 35 A 7629 155 A 148.3 7509 275 A 268.4
7748 36 A 7628 156 C 149.2 7508 276 C 269.4
7747 37 G 7627 157 C 150 7507 277 T 270.5
7746 38 T 7626 158 T 151.2 7506 278 G 271.6
7745 39 A 7625 159 G 152.5 7505 279 T 272.7
7744 40 G 7624 160 G 153.7 7504 280 A 273.6
7743 41 T 7623 161 A 154.7 7503 281 T 274.7
7742 42 T 7622 162 C 155.7 7502 282 T 275.8
7741 43 G 7621 163 A 156.6 7501 283 G 276.9
7740 44 T 7620 164 G 157.8 7500 284 T 277.9
7739 45 A 7619 165 G 159 7499 285 G 279
7738 46 C 7618 166 A 160 7498 286 C 279.8
7737 47 A 7617 167 A 160.8 7497 287 A 280.7
7736 48 A 7616 168 A 162 7496 288 G 281.8
7735 49 G 7615 169 A 162.6 7495 289 A 283
7734 50 C 7614 170 T 163.8 7494 290 A 283.6
7733 51 C 7613 171 G 164.9 7493 291 A 285
7732 52 A 7612 172 A 165.7 7492 292 A 285.5
7731 53 A 7611 173 C 166.7 7491 293 C 289
7730 54 G 7610 174 T 167.8 7490 294 C 288
7729 55 T 7609 175 A 168.6 7489 295 A 288.3
7728 56 A 46.4 7608 176 A 170 7488 296 C 289.4
7727 57 T 47.9 7607 177 T 170.8 7487 297 A 290.2
7726 58 G 48.8 7606 178 A 171.7 7486 298 G 291
7725 59 C 49.6 7605 179 C 172.7 7485 299 A 292.3
7724 60 A 50.5 7604 180 C 173.5 7484 300 C 293.4
7723 61 A 51.2 7603 181 A 174.4 7483 301 A 294.3
7722 62 T 52.7 7602 182 G 175.7 7482 302 T 295.3
7721 63 T 53.9 7601 183 G 177 7481 303 A 296.3
HEX 
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7720 64 A 54.7 7600 184 T 178 7480 304 A
7719 65 G 56.4 7599 185 G 179.1 7479 305 G
7718 66 C 57.1 7598 186 C 179.7
7717 67 T 58.4 7597 187 G 181
7716 68 T 59.5 7596 188 C 181.7
7715 69 A 60.3 7595 189 C 182.6
7714 70 A 61.4 7594 190 T 183.6
7713 71 G 63.1 7593 191 T 185
7712 72 T 64 7592 192 A 185.7
7711 73 A 64.9 7591 193 T 187
7710 74 A 65.7 7590 194 A 187.8
7709 75 A 66.7 7589 195 T 189
7708 76 A 67.6 7588 196 G 190.3
7707 77 A 68.6 7587 197 C 191.1
7706 78 C 69.5 7586 198 G 192.3
7705 79 A 70.6 7585 199 C 193
7704 80 A 71.5 7584 200 C 193.9
7703 81 A 72.6 7583 201 A 194.8
7702 82 C 73.5 7582 202 A 196
7701 83 T 74.1 7581 203 A 196.9
7700 84 A 74.9 7580 204 G 198.1
7699 85 A 75.8 7579 205 A 198.9
7698 86 A 76.9 7578 206 G 200.2
7697 87 A 7577 207 G 201.2
7696 88 T 7576 208 C 202
7695 89 A 7575 209 G 203.1
7694 90 T 7574 210 C 203.6
7693 91 G 7573 211 G 204.7
7692 92 T 7572 212 C 205.6
7691 93 G 85.9 7571 213 C 206.5
7690 94 C 86.5 7570 214 A 207.5
7689 95 C 87.4 7569 215 A 208.5
7688 96 T 87.8 7568 216 T 210
7687 97 A 89.5 7567 217 T 210.8
7686 98 A 90.5 7566 218 G 212
7685 99 A 91.6 7565 219 T 213
7684 100 A 92.5 7564 220 T 214
7683 101 G 93.9 7563 221 C 215
7682 102 C 94 7562 222 A 215.8
7681 103 A 95.3 7561 223 A 216.8
7680 104 G 96.6 7560 224 A 217.8
7679 105 T 97.5 7559 225 A 218.8
7678 106 T 98.6 7558 226 T 220
7677 107 T 99.7 7557 227 A 220.8
7676 108 T 100.8 7556 228 T 222
7675 109 A 101.7 7555 229 G 223
7674 110 T 103.1 7554 230 T 224.1
7673 111 T 104.2 7553 231 A 224.9
7672 112 A 105.1 7552 232 G 226
7671 113 C 106 7551 233 G 227.2
7670 114 T 107.2 7550 234 A 228
7669 115 T 108 7549 235 G 229.2
7668 116 A 109.2 7548 236 C 229.9
7667 117 G 110.5 7547 237 A 230.8
7666 118 G 111.8 7546 238 G 232
7665 119 G 112.9 7545 239 T 232.9
7664 120 A 113.7 7544 240 G 234
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7479 1 C 7599 121 C 116.1 7719 241 C 236.9
7480 2 T 7600 122 A 117.1 7720 242 T 237.8
7481 3 T 7601 123 C 117.8 7721 243 A 238.7
7482 4 A 7602 124 C 118.7 7722 244 A 240
7483 5 T 7603 125 T 119.7 7723 245 T 240.9
7484 6 G 7604 126 G 120.8 7724 246 T 241.9
7485 7 T 7605 127 G 122 7725 247 G 243.1
7486 8 C 7606 128 T 123.3 7726 248 C 244
7487 9 T 7607 129 A 124.2 7727 249 A 245
7488 10 G 7608 130 T 125.2 7728 250 T 245.9
7489 11 T 7609 131 T 126.2 7729 251 A 247
7490 12 G 7610 132 A 127.2 7730 252 C 248
7491 13 G 7611 133 G 128.2 7731 253 T 249
7492 14 T 7612 134 T 129.2 7732 254 T 250.1
7493 15 T 7613 135 C 130.2 7733 255 G 251.3
7494 16 T 7614 136 A 131 7734 256 G 252.3
7495 17 T 7615 137 T 132 7735 257 C 253.3
7496 18 C 7616 138 T 133 7736 258 T 254.2
7497 19 T 7617 139 T 134 7737 259 T 255.1
7498 20 G 7618 140 T 135 7738 260 G 256.3
7499 21 C 7619 141 C 136 7739 261 T 257.2
7500 22 A 7620 142 C 136.9 7740 262 A 258.3
7501 23 C 7621 143 T 138 7741 263 C 259.3
7502 24 A 7622 144 G 139.1 7742 264 A 260.1
7503 25 A 7623 145 T 140.2 7743 265 A 261
7504 26 T 7624 146 C 141.2 7744 266 C 262
7505 27 A 7625 147 C 142 7745 267 T 262.9
7506 28 C 7626 148 A 143 7746 268 A 264
7507 29 A 7627 149 G 144.1 7747 269 C 265.1
7508 30 G 7628 150 G 145 7748 270 T 266
7509 31 T 7629 151 T 146.2 7749 271 T 267
7510 32 A 7630 152 G 147.4 7750 272 T 268.2
7511 33 C 7631 153 C 148.3 7751 273 C 269.2
7512 34 G 7632 154 G 7752 274 A 270.2
7513 35 C 7633 155 C 150.2 7753 275 T 271.2
7514 36 T 7634 156 T 151 7754 276 G 272.5
7515 37 G 7635 157 A 152 7755 277 T
7516 38 G 7636 158 C 153.1 7756 278 C 274.4
7517 39 C 7637 159 A 154 7757 279 C 275.5
7518 40 A 7638 160 A 155.1 7758 280 A 276.1
7519 41 C 7639 161 C 156.1 7759 281 A 277.1
7520 42 T 7640 162 A 157.1 7760 282 C 278.2
7521 43 A 7641 163 A 158 7761 283 A 279.2
7522 44 T 7642 164 T 159.1 7762 284 T 280
7523 45 T 7643 165 T 160.2 7763 285 T 281.2
7524 46 G 7644 166 G 161.4 7764 286 C 282.3
7525 47 C 7645 167 C 162.4 7765 287 T 283.2
7526 48 A 7646 168 T 163.3 7766 288 G 284.4
7527 49 A 7647 169 T 164.3 7767 289 T 285.3
7528 50 A 7648 170 G 165.4 7768 290 C 286.5
7529 51 C 40.5 7649 171 C 166.4 7769 291 T 287.3
7530 52 T 42 7650 172 A 167.3 7770 292 A 288.4
7531 53 T 43.2 7651 173 T 168.3 7771 293 C 289.3
7532 54 T 44.5 7652 174 A 169.3 7772 294 C 290.2
7533 55 A 7653 175 A 170.3 7773 295 C 291.1
7534 56 A 7654 176 C 171.3 7774 296 T 292
7535 57 T 48 7655 177 T 172.3 7775 297 T 293.7
7536 58 C 49 7656 178 A 173.3 7776 298 A 294.3
7537 59 T 7657 179 T 174.4 7777 299 A 295.3
7538 60 T 7658 180 A 175.5 7778 300 C 296.3
7539 61 T 54.1 7659 181 T 176.4 7779 301 A 297.3
7540 62 T 55.2 7660 182 C 177.4 7780 302 T 298.2
7541 63 G 7661 183 C 178.3 7781 303 G
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7542 64 G 7662 184 A 179.3 7782 304 A
7543 65 G 7663 185 C 180.2 7783 305 A
7544 66 C 59.3 7664 186 T 181.2
7545 67 A 60.2 7665 187 C 182.3
7546 68 C 60.5 7666 188 C 183.2
7547 69 T 61.7 7667 189 C 184.1
7548 70 G 62.9 7668 190 T 185.1
7549 71 C 63.9 7669 191 A 186.4
7550 72 T 65 7670 192 A 187.4
7551 73 C 65.9 7671 193 G 188.5
7552 74 C 66.8 7672 194 T 189.5
7553 75 T 68 7673 195 A 190.6
7554 76 A 69.3 7674 196 A 191.4
7555 77 C 70.2 7675 197 T 192.5
7556 78 A 71.5 7676 198 A 193.5
7557 79 T 72.5 7677 199 A 194.5
7558 80 A 73.7 7678 200 A 195.4
7559 81 T 74.7 7679 201 A 196.4
7560 82 T 75.9 7680 202 C 197.4
7561 83 T 77 7681 203 T 198.4
7562 84 T 78.2 7682 204 G 199.5
7563 85 G 79.3 7683 205 C 200.5
7564 86 A 7684 206 T 201.5
7565 87 A 7685 207 T 202.5
7566 88 C 82.2 7686 208 T 203.5
7567 89 A 83.2 7687 209 T 204.6
7568 90 A 7688 210 A 205.6
7569 91 T 7689 211 G 206.8
7570 92 T 7690 212 G 207.9
7571 93 G 7691 213 C 208.8
7572 94 G 7692 214 A 209.6
7573 95 C 7693 215 C 210.4
7574 96 G 7694 216 A 211.5
7575 97 C 7695 217 T 212.3
7576 98 G 7696 218 A 213.5
7577 99 C 7697 219 T 214.5
7578 100 C 7698 220 T 215.6
7579 101 T 7699 221 T 216.7
7580 102 C 96.1 7700 222 T 217.7
7581 103 T 97.3 7701 223 A 218.7
7582 104 T 98.5 7702 224 G 219.8
7583 105 T 99.8 7703 225 T 220.9
7584 106 G 101.1 7704 226 T 221.9
7585 107 G 102.2 7705 227 T 221.9
7586 108 C 103.3 7706 228 G 223.9
7587 109 G 104.1 7707 229 T 225
7588 110 C 104.6 7708 230 T 226
7589 111 A 105.6 7709 231 T 226.8
7590 112 T 106.7 7710 232 T 228
7591 113 A 107.9 7711 233 T 228.9
7592 114 T 109 7712 234 A 229.9
7593 115 A 110.2 7713 235 C 230.8
7594 116 A 111.2 7714 236 T 231.9
7595 117 G 112.5 7715 237 T 232.8
7596 118 G 113.1 7716 238 A 233.8
7597 119 C 114.4 7717 239 A 234.8
7598 120 G 115.3 7718 240 G 235.9
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   Table SI 1B. USB Sequencing Results on HPV18 7179-7563 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genome 
position
Fragment 
Position
Sequence
CE 
Position
Genome 
position
Fragment 
Position
Sequence
CE 
Position
Genome 
position
Fragment 
Position
Sequence
CE 
Position
7563 1 C 7434 130 A 123 7305 259 C 251.9
7562 2 A 7433 131 G 124.1 7304 260 A 252.8
7561 3 A 7432 132 G 125.1 7303 261 C 253.7
7560 4 A 7431 133 A 7302 262 A 254.7
7559 5 A 7430 134 T 7301 263 C 255.5
7558 6 T 7429 135 A 7300 264 A 256.6
7557 7 A 7428 136 A 7299 265 G 257.7
7556 8 T 7427 137 A 7298 266 A 258.7
7555 9 G 7426 138 A 7297 267 A 259.6
7554 10 T 7425 139 T 7296 268 C 260.5
7553 11 A 7424 140 G 7295 269 C 261.4
7552 12 G 7423 141 G 133.9 7294 270 A 262.5
7551 13 G 7422 142 A 134.8 7293 271 C 263.5
7550 14 A 7421 143 T 135.9 7292 272 A
7549 15 G 7420 144 G 136.9 7291 273 A
7548 16 C 7419 145 C 137.6 7290 274 A
7547 17 A 7418 146 T 138.7 7289 275 A
7546 18 G 7417 147 G 139.7 7288 276 C 268.4
7545 19 T 7416 148 T 140.9 7287 277 A 269.4
7544 20 G 7415 149 A 141.9 7286 278 T 270.5
7543 21 C 7414 150 A 142.8 7285 279 A 271.9
7542 22 C 7413 151 G 143.7 7284 280 T broad peak
7541 23 C 7412 152 G 144.7 7283 281 T
7540 24 A 7411 153 C 7282 282 T
7539 25 A 7410 154 G 147 7281 283 T 275.7
7538 26 A 7409 155 T 148 7280 284 A 276.6
7537 27 A 7408 156 G 149.1 7279 285 T 277.8
7536 28 G 7407 157 C 149.8 7278 286 T 278.8
7535 29 A 7406 158 A 150.7 7277 287 T
7534 30 T 7405 159 G 151.8 7276 288 A
7533 31 T 7404 160 T 152.9 7275 289 A
7532 32 A 7403 161 T 153.9 7274 290 T
7531 33 A 7402 162 T 154.9 7273 291 G 283.7
7530 34 A 7401 163 T 156 7272 292 C 284.6
7529 35 G 7400 164 A 156.9 7271 293 C 285.5
7528 36 T 7399 165 T 158 7270 294 A 286.4
7527 37 T 7398 166 A 159 7269 295 C 287.3
7526 38 T 7397 167 A 159.9 7268 296 A 288.4
7525 39 G 7396 168 C 160.8 7267 297 T 289.5
7524 40 C 7395 169 T 162 7266 298 A 290.4
7523 41 A 7394 170 T 7265 299 C 291.3
7522 42 A 7393 171 G 7264 300 C 292.3
7521 43 T 7392 172 A 7263 301 A 293.3
7520 44 A 7391 173 A 7262 302 A 294.3
7519 45 G 33.5 7390 174 A 167 7261 303 C 295.3
7518 46 T 34.6 7389 175 T 168 7260 304 A
7517 47 G 36.2 7388 176 A 169 7259 305 A
7516 48 C 7387 177 C 169.9 7258 306 A
7515 49 C 7386 178 A 170.9 7257 307 T 299.3
7514 50 A 38.3 7385 179 G 172.1 7256 308 A 300.3
7513 51 G 39.9 7384 180 G 173.2 7255 309 T
7512 52 C 40.3 7383 181 A 174.1 7254 310 A
7511 53 G 42.1 7382 182 C 175 7253 311 G 303.3
7510 54 T 43 7381 183 A 176 7252 312 T 304.3
7509 55 A 44.3 7380 184 A 176.9 7251 314 A 305.3
7508 56 C 45.5 7379 185 T 178 7250 315 A 306.2
7507 57 T 47.6 7378 186 A 179 7249 315 C 307.1
7506 58 G 48.8 7377 187 T 180 7248 316 A 308.1
7505 59 T 49.9 7376 188 A 181 7247 317 T 309.1
7504 60 A 50.8 7375 189 T 182.1 7246 318 A 310.1
7503 61 T 52 7374 190 A 183.2 7245 319 C 311
7502 62 T 53.2 7373 191 G 184.3 7244 320 A 312.1
7501 63 G 54.6 7372 192 C 185 7243 321 A 313
7500 64 T 55.6 7371 193 C 185.9 7242 322 C 313.9
7499 65 G 57 7370 194 C 186.7 7241 323 A 315
7498 66 C 57.5 7369 195 A 187.9 7240 324 T 316.1
7497 67 A 58.5 7368 196 A 188.9 7239 325 A 317.1
7496 68 G 59.9 7367 197 C 189.9 7238 326 C 318.1
7495 69 A 60.5 7366 198 A 191 7237 327 A 319
7494 70 A 61.6 7365 199 A 191.9 7236 328 A 320.1
7493 71 A 7364 200 G 193.1 7235 329 C 321.1
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Genome 
position
Fragment 
Position
Sequence
CE 
Position
Genome 
position
Fragment 
Position
Sequenc
e
CE 
Position
Genome 
position
Fragment 
Position
Sequence
CE 
Position
7179 1 T 7308 130 A 127.4 7437 259 A 257.9
7180 2 A 7309 131 T 128.3 7438 260 A 258.8
7181 3 T 7310 132 G 129.5 7439 261 T 259.8
7182 4 G 7311 133 T 130.5 7440 262 C 260.7
7183 5 T 7312 134 G 131.6 7441 263 C 261.7
7184 6 C 7313 135 G 132.7 7442 264 T 262.6
7185 7 C 7314 136 T 133.6 7443 265 C 263.6
7186 8 T 7315 137 T 134.5 7444 266 C 264.6
7187 9 G 7316 138 G 135.6 7445 267 A 265.7
7188 10 T 7317 139 C 136.4 7446 268 T 266.6
7189 11 G 7318 140 G 137.5 7447 269 T 267.7
7190 12 T 7319 141 C 138.1 7448 270 T 268.8
7191 13 T 7320 142 C 138.9 7449 271 T 269.9
7192 14 T 7321 143 C 139.8 7450 272 G 271.1
7193 15 G 7322 144 T 140.9 7451 273 C 272
7194 16 T 7323 145 A 142 7452 274 T 272.9
7195 17 G 7324 146 G 143.2 7453 275 G 274.2
7196 18 T 7325 147 T 144.4 7454 276 T 275.1
7197 19 T 7326 148 G 145.5 7455 277 G 276.3
7198 20 T 7327 149 A 146.5 7456 278 C 277
7199 21 G 7328 150 G 147.6 7457 279 A 277.9
7200 22 T 7329 151 T 148.6 7458 280 A 278.7
7201 23 T 7330 152 A 149.5 7459 281 C 279.5
7202 24 G 7331 153 A 150.4 7460 282 C 280.5
7203 25 T 7332 154 C 151.2 7461 283 G 281.7
7204 26 A 7333 155 A 152.1 7462 284 A 282.8
7205 27 T 7334 156 A 153.1 7463 285 T 283.8
7206 28 G 7335 157 C 154 7464 286 T 284.9
7207 29 A 7336 158 T 155.1 7465 287 T 285.9
7208 30 T 7337 159 G 156.3 7466 288 C 286.9
7209 31 T 7338 160 T 157.4 7467 289 G 288
7210 32 G 7339 161 A 158.4 7468 290 G 289
7211 33 C 7340 162 T 159.5 7469 291 T 290
7212 34 A 7341 163 T 160.6 7470 292 T 291
7213 35 T 7342 164 T 161.6 7471 293 G 292
7214 36 T 7343 165 G 162.8 7472 294 C 292.5
7215 37 G 7344 166 T 163.8 7473 295 C 293.5
7216 38 T 7345 167 G 165 7474 296 T 294.6
7217 39 A 7346 168 T 165.9 7475 297 T 295.8
7218 40 T 7347 169 T 166.9 7476 298 T 296.8
7219 41 G 7348 170 T 167.9 7477 299 G 298
7220 42 G 7349 171 G 169 7478 300 G 299.1
7221 43 T 7350 172 T 170.6 7479 301 C 299.7
7222 44 A 7351 173 G 171.3 7480 302 T 300.8
7223 45 T 7352 174 G 172.4 7481 303 T 301.8
7224 46 G 7353 175 T 7482 304 A 303
7225 47 T 7354 176 A 174 7483 305 T 304
7226 48 A 7355 177 T 175 7484 306 G 305.1
7227 49 T 7356 178 G 176.1 7485 307 T 306.1
7228 50 G 7357 179 G 177.2 7486 308 C 307
7229 51 G 7358 180 G 178.3 7487 309 T 308
7230 52 T 7359 181 T 7488 310 G 309
7231 53 T 7360 182 G 180.3 7489 311 T 310.1
7232 54 G 7361 183 T 181.3 7490 312 G 311.2
7233 55 T 7362 184 T 182.3 7491 313 G 312.3
7234 56 T 7363 185 G 183.3 7492 314 T 313.3
7235 57 G 7364 186 C 184.1 7493 315 T 314.2
7236 58 T 52.2 7365 187 T 185.2 7494 316 T 315.3
7237 59 T 53.3 7366 188 T 186.1 7495 317 T 316.2
7238 60 G 54.5 7367 189 G 187.2 7496 318 C 317.2
7239 61 T 55.5 7368 190 T 188.3 7497 319 T 318.2
7240 62 A 56.4 7369 191 T 189.4 7498 320 G 319.4
7241 63 T 57.5 7370 192 G 190.5 7499 321 C 320.4
7242 64 G 58.7 7371 193 G 191.6 7500 322 A 321.4
7243 65 T 59.7 7372 194 G 192.8 7501 323 C 322.2
7244 66 T 60.8 7373 195 C 193.6 7502 324 A 323.3
7245 67 G 62 7374 196 T 194.5 7503 325 A 324.2
7246 68 T 63.1 7375 197 A 195.5 7504 326 T 325.2
7247 69 A 64 7376 198 T 196.5 7505 327 A 326.4
7248 70 T 65 7377 199 A 197.6 7506 328 C 327.3
7249 71 G 66.3 7378 200 T 198.5 7507 329 A 328.3
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7250 72 T 67.3 7379 201 A 199.6 7508 330 G 329.3
7251 73 T 68.4 7380 202 T 200.5 7509 331 T 330.3
7252 74 A 69.3 7381 203 T 201.6 7510 332 A 331.4
7253 75 C 69.9 7382 204 G 202.8 7511 333 C 332.2
7254 76 T 71.2 7383 205 T 203.8 7512 334 G 333.4
7255 77 A 72.3 7384 206 C 204.7 7513 335 C 334.2
7256 78 T 73.4 7385 207 C 205.5 7514 336 T 335.1
7257 79 A 74.5 7386 208 T 206.5 7515 337 G 336.3
7258 80 T 75.7 7387 209 G 207.7 7516 338 G 337.3
7259 81 T 76.8 7388 210 T 208.8 7517 339 C 338.3
7260 82 T 77.9 7389 211 A 209.8 7518 340 A 339.4
7261 83 G 79.2 7390 212 T 210.9 7519 341 C 340.1
7262 84 T 80.2 7391 213 T 211.9 7520 342 T 341.1
7263 85 T 81.3 7392 214 T 212.9 7521 343 A 342.3
7264 86 G 82.6 7393 215 C 213.9 7522 344 T 343.2
7265 87 G 83.7 7394 216 A 214.8 7523 345 T 344.3
7266 88 T 84.8 7395 217 A 215.7 7524 346 G 345.5
7267 89 A 85.5 7396 218 G 216.8 7525 347 C 346.3
7268 90 T 86.5 7397 219 T 217.8 7526 348 A 347.5
7269 91 G 87.8 7398 220 T 218.8 7527 349 A
7270 92 T 88.7 7399 221 A 219.8 7528 350 A 349.1
7271 93 G 89.9 7400 222 T 220.9 7529 351 C 350.1
7272 94 G 91.1 7401 223 A 222 7530 352 T 351.2
7273 95 C 91.7 7402 224 A 222.8 7531 353 T 352.2
7274 96 A 92.5 7403 225 A 223.8 7532 354 T 353.2
7275 97 T 7404 226 A 224.7 7533 355 A 354.4
7276 98 T 7405 227 C 225.6 7534 356 A 355.3
7277 99 A 7406 228 T 226.6 7535 357 T 356.4
7278 100 A 7407 229 G 227.8 7536 358 C 357.3
7279 101 A 97.6 7408 230 C 228.7 7537 359 T 358.3
7280 102 T 7409 231 A 229.6 7538 360 T 359.4
7281 103 A 99.6 7410 232 C 230.5 7539 361 T 360.4
7282 104 A 100.7 7411 233 A 231.5 7540 362 T 361.5
7283 105 A 101.5 7412 234 C 232.4 7541 363 G 362.7
7284 106 A 102.5 7413 235 C 233.4 7542 364 G 363.7
7285 107 T 103.7 7414 236 T 233.1 7543 365 G 364.9
7286 108 A 104.6 7415 237 T 7544 366 C 365.7
7287 109 T 105.6 7416 238 A 236.6 7545 367 A 366.6
7288 110 G 106.9 7417 239 C 237.6 7546 368 C 367.3
7289 111 T 108 7418 240 A 238.6 7547 369 T 368.3
7290 112 T 109 7419 241 G 239.7 7548 370 G 369.5
7291 113 T 110 7420 242 C 240.6 7549 371 C 370.3
7292 114 T 111 7421 243 A 241.6 7550 372 T 371.4
7293 115 G 112.3 7422 244 T 242.6 7551 373 C 372.3
7294 116 T 113.3 7423 245 C 243.6 7552 374 C 373.3
7295 117 G 114.4 7424 246 C 244.5 7553 375 T 374.4
7296 118 G 115.6 7425 247 A 245.5 7554 376 A 375.4
7297 119 T 116.6 7426 248 T 246.7 7555 377 C 376.2
7298 120 T 117.5 7427 249 T 247.8 7556 378 A 377.4
7299 121 C 118.2 7428 250 T 248.9 7557 379 T 378.3
7300 122 T 119.2 7429 251 T 250 7558 380 A 379.5
7301 123 G 120.4 7430 252 A 251 7559 381 T 380.4
7302 124 T 121.4 7431 253 T 252 7560 382 T 381.4
7303 125 G 122.5 7432 254 C 252.9 7561 383 T
7304 126 T 123.5 7433 255 C 253.8 7562 384 T
7305 127 G 124.6 7434 256 T 254.8 7563 385 G
7306 128 T 125.5 7435 257 A 255.9
7307 129 T 126.5 7436 258 C 256.8
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                     Table SI 2. Maxam-Gilbert Sequencing on HPV18 7179-7563  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genome 
Position
Real 
Position 
Sequence CE 
position
Genome 
Position
Real 
Position
Sequence CE 
position
Genome 
Position
Real 
Position
Sequence CE 
position
7563 1 C 7436 128 G 119.2 7306 258 A 250.4
7562 2 A 7435 129 T 120.5 7305 259 C 251
7561 3 A 7434 130 A 121.5 7304 260 A 252.2
7560 4 A 7433 131 G 122.3 7303 261 C 253.2
7559 5 A 7432 132 G 123.5 7302 262 A 254.2
7558 6 T 7431 133 A 124.6 7301 263 C 255.1
7557 7 A 7430 134 T 125.4 7300 264 A 256.1
7556 8 T 7429 135 A 126.4 7299 265 G 257
7555 9 G 7428 136 A 127.3 7298 266 A 258.2
7554 10 T 7427 137 A 128 7297 267 A 259.1
7553 11 A 7426 138 A 129 7296 268 C 260.1
7552 12 G 7425 139 T 129.9 7295 269 C 261.1
7551 13 G 7424 140 G 131.1 7294 270 A 261.9
7550 14 A 7423 141 G 132 7293 271 C 262.9
7549 15 G 7422 142 A 133.5 7292 272 A 263.9
7548 16 C 7421 143 T 134 7291 273 A 264.9
7547 17 A 7420 144 G 135.4 7290 274 A 265.9
7546 18 G 7419 145 C 136.6 7289 275 A 266.9
7545 19 T 7418 146 T 137.7 7288 276 C 267.8
7544 20 G 7417 147 G 138.4 7287 277 A 268.8
7543 21 C 7416 148 T 139.6 7286 278 T 269.8
7542 22 C 7415 149 A 140.5 7285 279 A 271
7541 23 C 7414 150 A 141.5 7284 280 T 272
7540 24 A 7413 151 G 142.4 7283 281 T 273
7539 25 A 7412 152 G 143.5 7282 282 T 274
7538 26 A 7411 153 C 144.7 7281 283 T 275
7537 27 A 7410 154 G 145 7280 284 A 276.1
7536 28 G 7409 155 T 146.9 7279 285 T 277.1
7535 29 A 7408 156 G 147.9 7278 286 T 278
7534 30 T 7407 157 C 149.1 7277 287 T
7533 31 T 7406 158 A 149.9 7276 288 A 280.2
7532 32 A 7405 159 G 150.9 7275 289 A 281.2
7531 33 A 7404 160 T 152 7274 290 T 282.1
7530 34 A 7403 161 T 153 7273 291 G 283.1
7529 35 G 7402 162 T 154 7272 292 C 284.3
7528 36 T 7401 163 T 155 7271 293 C
7527 37 T 7400 164 A 156.1 7270 294 A 286
7526 38 T 7399 165 T 157 7269 295 C 287
7525 39 G 7398 166 A 158.1 7268 296 A 288
7524 40 C 7397 167 A 159 7267 297 T 289
7523 41 A 7396 168 C 159.9 7266 298 A 290
7522 42 A 7395 169 T 160.8 7265 299 C 290.9
7521 43 T 7394 170 T 161.9 7264 300 C 291.8
7520 44 A 7393 171 G 163 7263 301 A 292.7
7519 45 G 7392 172 A 164.2 7262 302 A 293.7
7518 46 T 7391 173 A 165.1 7261 303 C 294.7
7517 47 G 7390 174 A 166 7260 304 A 295.7
7516 48 C 7389 175 T 167 7259 305 A 296.7
7515 49 C 7388 176 A 168 7258 306 A 297.7
7514 50 A 7387 177 C 169 7257 307 T 298.6
7513 51 G 7386 178 A 169.9 7256 308 A 299.7
7512 52 C 7385 179 G 170.8 7255 309 T 300.8
7511 53 G 7384 180 G 172.1 7254 310 A 301.7
7510 54 T 7383 181 A 173 7253 311 G 302.7
7509 55 A 7382 182 C 174.2 7252 312 T 303.9
7508 56 C 7381 183 A 175 7251 314 A 304.8
7507 57 T 7380 184 A 176 7250 315 A 305.8
7506 58 G 7379 185 T 177 7249 315 C 306.6
7505 59 T 7378 186 A 178 7248 316 A 307.7
7504 60 A 7377 187 T 179 7247 317 T 308.6
7503 61 T 7376 188 A 180.1 7246 318 A 309.7
7502 62 T 7375 189 T 181.1 7245 319 C 310.5
7501 63 G 7374 190 A 182.1 7244 320 A 311.5
7500 64 T 7373 191 G 183 7243 321 A 312.5
7499 65 G 7372 192 C 184 7242 322 C 313.6
7498 66 C 53.7 7371 193 C 7241 323 A 314.6
7497 67 A 54 7370 194 C 186 7240 324 T 315.5
7496 68 G 55 7369 195 A 187 7239 325 A 316.6
7495 69 A 56 7368 196 A 188 7238 326 C 317.8
7494 70 A 57 7367 197 C 189 7237 327 A 318.8
7493 71 A 58 7366 198 A 189.9 7236 328 A 319.6
7492 72 A 59 7365 199 A 191 7235 329 C 320.7
7491 73 C 60.7 7364 200 G 191.9 7234 330 A 321.5
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7490 74 C 61.7 7363 201 C 193.2 7233 331 A 322.5
7489 75 A 62.5 7362 202 A 194.1 7232 332 C 323.9
7488 76 C 63.7 7361 203 A 195.1 7231 333 A 324.4
7487 77 A 64.5 7360 204 C 196 7230 334 A 325.5
7486 78 G 65.5 7359 205 A 196.9 7229 335 C 326.6
7485 79 A 66.5 7358 206 C 198 7228 336 C 327.4
7484 80 C 68.4 7357 207 C 198.9 7227 337 A 328.5
7483 81 A 69.3 7356 208 C 199.8 7226 338 T 329.6
7482 82 T 70.5 7355 209 A 200.8 7225 339 A 330.6
7481 83 A 71.7 7354 210 T 201.8 7224 340 C 331.6
7480 84 A 72.7 7353 211 A 203.1 7223 341 A 332
7479 85 G 73.8 7352 212 C 204 7222 342 T 333
7478 86 C 75.2 7351 213 C 204.9 7221 343 A 334.6
7477 87 C 76.2 7350 214 A 205.8 7220 344 C 335.7
7476 88 A 7349 215 C 206.9 7219 345 C 336.7
7475 89 A 77.9 7348 216 A 207.8 7218 346 A 337.3
7474 90 A 78.9 7347 217 A 208.8 7217 347 T 338.4
7473 91 G 79.7 7346 218 A 209.8 7216 348 A 339.5
7472 92 G 81.4 7345 219 C 210 7215 349 C 340.5
7471 93 C 82.7 7344 220 A 211.7 7214 350 A 341.5
7470 94 A 93.7 7343 221 C 212.8 7213 351 A 342.5
7469 95 A 84.1 7342 222 A 213.7 7212 352 T 343.5
7468 96 C 85.1 7341 223 A 214.7 7211 353 G 344.5
7467 97 C 86 7340 224 A 215.8 7210 354 C 345.5
7466 98 G 87 7339 225 T 216.8 7209 355 A 346.6
7465 99 A 88 7338 226 A 217.9 7208 356 A 347.7
7464 100 A 89.6 7337 227 C 218.9 7207 357 T 348.6
7463 101 A 90.5 7336 228 A 219.8 7206 358 C
7462 102 T 91.5 7335 229 G 220.8 7205 359 A 350.5
7461 103 C 92.6 7334 230 T 222.1 7204 360 T 351.5
7460 104 G 93.5 7333 231 T 223.1 7203 361 A 352.5
7459 105 G 95 7332 232 G 224.2 7202 362 C 353.6
7458 106 T 96.2 7331 233 T 225.4 7201 363 A 354.5
7457 107 T 97.2 7330 234 T 226.6 7200 364 A 355.5
7456 108 G 98.4 7329 234 A 227.5 7199 365 C 356.4
7455 109 C 99.7 7328 236 C 228.3 7198 366 A 357
7454 110 A 100 7327 237 T 229.3 7197 367 A
7453 111 C 101.2 7326 238 C 230.3 7196 368 A 359.5
7452 112 A 102.5 7325 239 A 231.2 7195 369 C
7451 113 G 103.8 7324 240 C 232 7194 370 A
7450 114 C 105 7323 241 T 233 7193 371 C 363.4
7449 115 A 105.7 7322 242 A 234 7192 372 A 364.8
7448 116 A 106.5 7321 243 G 235.1 7191 373 A
7447 117 A 107.5 7320 244 G 236 7190 374 A
7446 118 A 108.5 7319 245 G 237.4 7189 375 C 368.4
7445 119 T 109.5 7318 246 C 238.5 7188 376 A
7444 120 G 110.6 7317 247 G 239.4 7187 377 C
7443 121 G 112 7316 248 C 240.5 7186 378 A
7442 122 A 113.1 7315 249 A 241.4 7185 379 G
7441 123 G 114 7314 250 A 242.3 7184 380 G
7440 124 G 115.2 7313 251 C 243.3 7183 381 A
7439 125 A 116.4 7312 252 C 244.1 7182 382 C
7438 126 T 117 7311 253 A 245.1 7181 383 A
7437 127 T 118.2 7310 254 C 264.2 7180 384 T
7309 255 A 247.2 7179 385 A
7308 256 T 248.2
7307 257 A 249.4
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Genome 
Position
Real 
Position 
Sequence CE 
position
Genome 
Position
Real 
Position
Sequence CE 
position
Genome 
Position
Real 
Position
Sequence CE 
position
7179 1 T 7308 130 A 126.1 7437 259 A 257.7
7180 2 A 7309 131 T 126.9 7438 260 A 258.7
7181 3 T 7310 132 G 129.7 7439 261 T 259.6
7182 4 G 7311 133 T 129.2 7440 262 C 260.8
7183 5 T 7312 134 G 130.2 7441 263 C 261.7
7184 6 C 7313 135 G 131.4 7442 264 T 262.7
7185 7 C 7314 136 T 132.5 7443 265 C
7186 8 T 7315 137 T 133,,4 7444 266 C
7187 9 G 7316 138 G 134.5 7445 267 A 265.5
7188 10 T 7317 139 C 135.6 7446 268 T 266.5
7189 11 G 7318 140 G 136.3 7447 269 T 267.6
7190 12 T 7319 141 C 137.5 7448 270 T 268.8
7191 13 T 7320 142 C 138.2 7449 271 T 269.8
7192 14 T 7321 143 C 139 7450 272 G 270.9
7193 15 G 7322 144 T 149.8 7451 273 C 272.1
7194 16 T 7323 145 A 141.1 7452 274 T
7195 17 G 7324 146 G 142.1 7453 275 G 274
7196 18 T 7325 147 T 143.3 7454 276 T 275.2
7197 19 T 7326 148 G 144.4 7455 277 G 276.3
7198 20 T 7327 149 A 145.6 7456 278 C 277.3
7199 21 G 7328 150 G 146.5 7457 279 A 277.9
7200 22 T 7329 151 T 147.7 7458 280 A 278.8
7201 23 T 7330 152 A 148.7 7459 281 C 279.6
7202 24 G 7331 153 A 149.6 7460 282 C 280.6
7203 25 T 7332 154 C 150.4 7461 283 G 281.5
7204 26 A 7333 155 A 151.3 7462 284 A 282.7
7205 27 T 7334 156 A 152.3 7463 285 T 283.8
7206 28 G 7335 157 C 153.2 7464 286 T 285
7207 29 A 7336 158 T 154.1 7465 287 T 286
7208 30 T 7337 159 G 155.4 7466 288 C 287
7209 31 T 7338 160 T 156.6 7467 289 G 287.9
7210 32 G 7339 161 A 157.6 7468 290 G 288.8
7211 33 C 7340 162 T 158.6 7469 291 T 290.2
7212 34 A 7341 163 T 159.6 7470 292 T 291.1
7213 35 T 7342 164 T 160.8 7471 293 G 292.1
7214 36 T 7343 165 G 161.8 7472 294 C 293.3
7215 37 G 7344 166 T 163.1 7473 295 C 294.5
7216 38 T 7345 167 G 164.4 7474 296 T 295.7
7217 39 A 7346 168 T 165.3 7475 297 T 296.8
7218 40 T 7347 169 T 166.3 7476 298 T
7219 41 G 7348 170 T 167.3 7477 299 G 298
7220 42 G 7349 171 G 168.3 7478 300 G 299
7221 43 T 7350 172 T 169.4 7479 301 C 300.3
7222 44 A 7351 173 G 170.4 7480 302 T 301
7223 45 T 7352 174 G 171.5 7481 303 T 301.7
7224 46 G 7353 175 T 172.7 7482 304 A 302.9
7225 47 T 7354 176 A 173.7 7483 305 T 303.8
7226 48 A 7355 177 T 174.5 7484 306 G 304.9
7227 49 T 7356 178 G 175.7 7485 307 T 305
7228 50 G 7357 179 G 176.7 7486 308 C 306
7229 51 G 7358 180 G 177.8 7487 309 T 307.1
7230 52 T 7359 181 T 178.9 7488 310 G 308.9
7231 53 T 7360 182 G 179.9 7489 311 T 310.1
7232 54 G 7361 183 T 181.1 7490 312 G 311.2
7233 55 T 43.4 7362 184 T 182 7491 313 G 312.2
7234 56 T 44.6 7363 185 G 183 7492 314 T 313.5
7235 57 G 45.9 7364 186 C 184.2 7493 315 T 314.5
7236 58 T 47.2 7365 187 T 184.9 7494 316 T
7237 59 T 48.4 7366 188 T 186 7495 317 T
7238 60 G 7367 189 G 187 7496 318 C
7239 61 T 7368 190 T 188.2 7497 319 T
7240 62 A 7369 191 T 189.2 7498 320 G 319.3
7241 63 T 54 7370 192 G 190.3 7499 321 C 320.6
7242 64 G 55.1 7371 193 G 191.4 7500 322 A 321.4
7243 65 T 55.8 7372 194 G 192.6 7501 323 C 322.4
7244 66 T 57 7373 195 C 193.7 7502 324 A 323.3
7245 67 G 58.6 7374 196 T 194.4 7503 325 A 324.1
7246 68 T 59.8 7375 197 A 195.6 7504 326 T 325.2
7247 69 A 60.7 7376 198 T 196.4 7505 327 A 326.3
7248 70 T 61.5 7377 199 A 197.5 7506 328 C 327.2
7249 71 G 62.6 7378 200 T 198.4 7507 329 A 328.2
7250 72 T 64.1 7379 201 A 199.4 7508 330 G 329.1
7251 73 T 65.2 7380 202 T 200.4 7509 331 T 330.4
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7251 73 T 65.2 7380 202 T 200.4 7509 331 T 330.4
7252 74 A 66.1 7381 203 T 201.4 7510 332 A 331.4
7253 75 C 67.1 7382 204 G 202.5 7511 333 C 332.4
7254 76 T 67.9 7383 205 T 203.7 7512 334 G 333.3
7255 77 A 69 7384 206 C 204.7 7513 335 C 334.7
7256 78 T 70.1 7385 207 C 205.5 7514 336 T
7257 79 A 71.2 7386 208 T 206.4 7515 337 G 336.4
7258 80 T 72.4 7387 209 G 207.5 7516 338 G 337.5
7259 81 T 73.6 7388 210 T 208.7 7517 339 C 338.6
7260 82 T 74.7 7389 211 A 209.8 7518 340 A 339.6
7261 83 G 75.7 7390 212 T 210.7 7519 341 C 340.5
7262 84 T 77.3 7391 213 T 211.8 7520 342 T
7263 85 T 78.3 7392 214 T 212.7 7521 343 A 342.4
7264 86 G 79.4 7393 215 C 213.9 7522 344 T 343.4
7265 87 G 80.8 7394 216 A 215.7 7523 345 T 344.5
7266 88 T 82.1 7395 217 A 7524 346 G 345.5
7267 89 A 83.3 7396 218 G 7525 347 C 346.7
7268 90 T 84 7397 219 T 217.7 7526 348 A
7269 91 G 85.1 7398 220 T 218.5 7527 349 A
7270 92 T 86.3 7399 221 A 219.9 7528 350 A 349.4
7271 93 G 87.4 7400 222 T 220.7 7529 351 C 350.6
7272 94 G 88.6 7401 223 A 221.8 7530 352 T
7273 95 C 89.7 7402 224 A 222.7 7531 353 T
7274 96 A 90.5 7403 225 A 223.6 7532 354 T
7275 97 T 91.3 7404 226 A 224.6 7533 355 A 355
7276 98 T 92.3 7405 227 C 225.4 7534 356 A
7277 99 A 93.3 7406 228 T 226.3 7535 357 T
7278 100 A 94.3 7407 229 G 227.5 7536 358 C
7279 101 A 95.3 7408 230 C 228.8 7537 359 T
7280 102 T 96.1 7409 231 A 229.6 7538 360 T
7281 103 A 97.3 7410 232 C 230.5 7539 361 T
7282 104 A 98.3 7411 233 A 231.5 7540 362 T
7283 105 A 99.3 7412 234 C 232.5 7541 363 G
7284 106 A 100.4 7413 235 C 233.3 7542 364 G
7285 107 T 101.9 7414 236 T 234.2 7543 365 G
7286 108 A 103.4 7415 237 T 235.3 7544 366 C
7287 109 T 104.6 7416 238 A 236.6 7545 367 A
7288 110 G 105.3 7417 239 C 237.5 7546 368 C
7289 111 T 106.6 7418 240 A 238.4 7547 369 T
7290 112 T 107.5 7419 241 G 239 7548 370 G
7291 113 T 108.4 7420 242 C 240.6 7549 371 C
7292 114 T 109.3 7421 243 A 241 7550 372 T
7293 115 G 110.2 7422 244 T 242.5 7551 373 C
7294 116 T 111.6 7423 245 C 243.7 7552 374 C
7295 117 G 112.5 7424 246 C 244.5 7553 375 T
7296 118 G 113.6 7425 247 A 245.5 7554 376 A
7297 119 T 114.8 7426 248 T 246.5 7555 377 C
7298 120 T 115.8 7427 249 T 247.7 7556 378 A
7299 121 C 116.7 7428 250 T 248.8 7557 379 T
7300 122 T 117.5 7429 251 T 249.9 7558 380 A
7301 123 G 118.5 7430 252 A 251 7559 381 T
7302 124 T 119.8 7431 253 T 251.9 7560 382
7303 125 G 120.9 7432 254 C 252.9 7561 383
7304 126 T 122 7433 255 C 253.8 7562 384
7305 127 G 123 7434 256 T 254.6 7563 385
7306 128 T 124.2 7435 257 A 255.8
7307 129 T 125.1 7436 258 C 256.7
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TATGT TACTATATTT GTTGG R 3 7251-7260 1.08 0.64 7252
ATACC AACAAATATA GTAAC R 5 7263-7254 1.48 0.96 7261
CACAA AACATATTTT ATTTA R 8 7290-7281 2.03 0.79 7288
ATTTC AAGTTATAAA ACTGC F 16 7394-7403 1.89 3.05 7401
GTTTG TTGTATGATT GCATT F 0 7200-7209 / /
GTATG TTGTATGTTA CTATA F 2 7243-7252 1.51 1.32 7245
TATGT TACTATATTT GTTGG F 3 7251-7260 1.08 0.64 7252
AAATA TAGTAACATA TACAA F 4 7255-7246 1.08 0.64 7252
ATACC AACAAATATA GTAAC F 5 7263-7254 1.48 0.96 7261
GTGGC ATTAAATAAA ATATG F 6 7274-7283 1.62 1.15 7281
TGGCA TTAAATAAAA TATGT F 6 7275-7284 1.62 1.15 7281
GGCAT TAAATAAAAT ATGTT F 6 7276-7285 1.62 1.15 7281
GCATT AAATAAAATA TGTTT F 6 7277-7286 1.62 1.15 7281
CATTA AATAAAATAT GTTTT F 6 7278-7287 1.62 1.15 7281
CATAT TTTATTTAAT GCCAC F 7 7283-7274 1.62 1.15 7281
ACATA TTTTATTTAA TGCCA F 7 7284-7275 1.62 1.15 7281
AACAT ATTTTATTTA ATGCC F 7 7285-7276 1.62 1.15 7281
AAACA TATTTTATTT AATGC F 7 7286-7277 1.62 1.15 7281
AAAAC ATATTTTATT TAATG F 7 7287-7278 1.62 1.15 7281
CACAA AACATATTTT ATTTA F 8 7290-7281 2.03 0.79 7288
GTAAC AACTGTATTT GTGTT R 11 7333-7342 2.05 1.66 7335
CCACA AACACAAATA CAGTT R 12 7347-7338 3.04 1.24 7343
TACAG GACAATATAT AGCCC R 15 7384-7375 2.14 7380
ATAAC TTGAAATACA GGACA F 16 7395-7386 1.89 3.05 7401
GTGTG CAGTTTTATA ACTTG F 17 7407-7396 1.89 0.87 7396
ACAGC ATCCATTTTA TCCTA R 18 7421-7430 2.20 1.37 7281
CAGCA TCCATTTTAT CCTAC R 18 7422-7431 2.20 1.37 7281
ATTGT AGGATAAAAT GGATG F 19 7434-7325 2.20 1.37 7281
GATTG TAGGATAAAA TGGAT F 19 7435-7326 2.20 1.37 7281
ATGGT ATGTATGGTT GTTGT F 1 7222-7231 / /
GTTAC TATATTTGTT GGTAT F 4 7254-7263 1.48 0.96 7261
CACAG AACCACAAAA CATAT R 9 7298-7289 1.88 1.69 7293
CGCCC TAGTGAGTAA CAACT F 10 7322-7331 2.42 3.52 7324
GTAAC AACTGTATTT GTGTT F 11 7333-7342 2.05 1.66 7335
CCACA AACACAAATA CAGTT F 12 7347-7338 3.04 1.24 7343
TGTTG GGCTATATAT TGTCC R 14 7371-7380 3.24 2.14 7380
TGGGC TATATATTGT CCTGT F 14 7374-7383 3.24 2.14 7380
ACAGG ACAATATATA GCCCA F 15 7383-7374 3.24 2.14 7380
TACAG GACAATATAT AGCCC F 15 7384-7375 3.24 2.14 7380
ACAGC ATCCATTTTA TCCTA F 18 7421-7430 2.20 1.37 7281
CAGCA TCCATTTTAT CCTAC F 18 7422-7431 2.20 1.37 7281
GAGGA TTGTAGGATA AAATG F 19 7427-7438 2.20 1.37 7281
CATAC AACATACAAC AACAA F 2 7244-7235 1.88 1.36 7238
CACAG AACCACAAAA CATAT F 9 7298-7289 1.88 1.69 7293
TGGTT CTGTGTGTTA TGTGG F 9 7299-7308 3.47 2.38 7305
GTTCT GTGTGTTATG TGGTT F 9 7301-7310 3.47 2.38 7305
GGGTG TTGCTTGTTG GGCTA F 13 7361-7370 3.64 4.37 7364
TGTTG GGCTATATAT TGTCC F 14 7371-7380 3.24 2.14 7380
GTTGG GCTATATATT GTCCT F 14 7372-7381 3.24 2.14 7380
TTGGG CTATATATTG TCCTG F 14 7373-7382 3.24 2.14 7380
GTAGG ATAAAATGGA TGCTG R 19 7431-7422 2.20 1.37 7281
AAGGC AACCGAAATC GGTTG R 21 7470-7461 3.74 4.86 7466
4 MM GGTTC TGTGTGTTAT GTGGT F 9 7300-7309 3.47 2.38 7305
1 MM
2 MM
 3 MM
Integration 
Peak         
(for Kd)
0 MM
# Mismatch 
(MM)
 NV1028                      
WWGWWWWWWW (FW) 
WWCWWWWWWW (RV)                   
DNA Sequence (5'-3')
FORWARD ( F ) 
REVERSE ( R )
Site
Genome 
Position
Hill Coefficient
Kds (Hill 
Model)
Table SI 3A. Binding affinity data of NV1028 on HPV 7179-7563 bp. 
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TATAA TAAAATATGTTTT GTGGT F 3/4 7280-7292 1.74 0.54 7281
CACAA AACATATTTTATT TAATG R 5 7290-7278 1.74 0.54 7281
TATGG TTGTTGTTGTATG TTGTA F 0 7230-7242 2.47 1.18 7245
GTTGT ATGTTACTATATT TGTTG F 1 7247-7259 1.72 0.77 0
TATGT TACTATATTTGTT GGTAT R 1 7251-7263 1.72 0.77 0
ATACC AACAAATATAGTA ACATA R 2 7263-7251 1.78 0.54 7261
GTGGC ATATAATAAAATA TGTTT F 3 7274-7286 1.74 0.54 7281
TGGCA TATAATAAAATAT GTTTT F 3 7275-7287 1.74 0.54 7281
TTTGT ATAAAATAATATA CGGTG F 4 7286-7274 1.74 0.54 7281
TTTTG TATAAAATAATAT ACGGT F 4 7287-7275 1.74 0.54 7281
CACAA AACATATTTTATT TAATG F 5 7290-7278 1.74 0.54 7281
CATAC CACAAACACAAAT ACAGT R 9 7351-7339 2.34 0.71 7343
TCCTG TATTTCAAGTTAT AAAAC F 11 7388-7400 3.56 0.71 7396
TGTAT TTCAAGTTATAAA ACTGC R 11 7391-7403 3.56 0.71 7396
AGTTT TATAACTTGAAAT ACAGG F 12 7401-7389 3.56 0.71 7396
TATGT TACTATATTTGTT GGTAT F 1 7251-7263 1.72 0.77 0
ATACC AACAAATATAGTA ACATA F 2 7263-7251 1.78 0.54 7261
TGTGG CATATAATAAAAT ATGTT F 3 7273-7285 1.74 0.54 7281
AACAT ATTTTATTTAATG CCACA F 4 7285-7273 1.74 0.54 7281
CCACA AAACATATTTTAT TTAAT F 5 7291-7279 1.74 0.54 7281
ACCAC AAAACATATTTTA TTTAA F 5 7292-7280 1.74 0.54 7281
GTGAG TAACAACTGTATT TGTGT F 8 7329-7341 2.04 1.36 7331
TGGGC TATATATTGTCCT GTATT F 10 7374-7386 2.43 1.09 7379
TGTAT TTCAAGTTATAAA ACTGC F 11 7391-7403 3.56 0.71 7396
GTGTG CAGTTTTATAACT TGAAA F 13 7407-7395 3.56 0.71 7396
AGGTG TGCAGTTTTATAA CTTGA R 13 7409-7397 3.56 0.71 7396
GAGGA TTGTAGGATAAAA TGGAT F 16 7438-7336 2.94 1.13 7436
GGCTT ATGTCTGTGGTTT TCTGC F 20 7482-7494 / / /
AGAAA ACCACAGACATAA GCCAA R 21 7492-7480 / / /
TATAT ATTGTCCTGTATT TCAAG F 10 7379-7391 2.43 1.09 7379
AGGTG TGCAGTTTTATAA CTTGA F 13 7409-7397 1.74 0.54 7281
CAGCA TCCATTTTATCCT ACAAT R 14 7422-7434 2.26 0.74 7428
GTAGG ATAAAATGGATGC TGTAA R 15 7431-7419 2.26 0.74 7428
ATCGG TTGCACAGCAAAA TGGAG R 18 7458-7446 / / /
CGCCC TAGTGAGTAACAA CTGTA F 7 7322-7335 2.39 1.65 7326
5 MM CACAT AACACACAGAACC ACAAA F 6 7307-7295 3.13 1.77 7308
2 MM
 3 MM
4 MM
Integration 
Peak         
(for Kd)
1 MM
Hill Coefficient 
Avg.
# Mismatch 
(MM)
Kd (Hill model) 
ɛ=147400 M x cm-1
 NV1042                      
WWGWWWWWGWWWW (FW) 
WWCWWWWWCWWWW (RV)                   
DNA Sequence
FORWARD ( F ) 
REVERSE ( R )
Site
Genome 
Position
Table SI 3B. Binding affinity data of NV1042 on HPV 7179-7563 bp. 
 
 
 
 
 
Red nucleotide indicate mismatch position 
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Table SI 3C. Binding affinity data of NV1028 on HPV 7479-7783 bp. 
 
 
 
  GCTCC TACATATTTT GAACA R 2 7553-7562 2.41 2.87 7557
AATTG TTCAAAATAT GTAGG R 3 7565-7557 1.84 0.92 7563
TCCCT AAGTAATAAA ACTGC F 9 7669-7678 2.11 1.08 7672
AAACA AACTAAAATA TGTGC R 12 7704-7695 1.73 0.79 7700
CCCAA AAGATTAAAG TTTGC F 1 7538-7529 2.07 1.23 7536
GCTCC TACATATTTT GAACA F 2 7553-7562 2.41 2.87 7557
AATTG TTCAAAATAT GTAGG F 3 7565-7557 1.84 0.92 7563
GCCAA TTGTTCAAAA TATGT F 3 7568-7559 1.74 1.74 7568
GGTAT TAGTCATTTT CCTGT F 5 7609-7618 1.59 0.92 7610
GGAAA ATGACTAATA CCAGG F 6 7615-7606 1.40 0.78 7613
AAAAG CAGTTTTATT ACTTA F 10 7682-7673 2.27 1.49 7680
AAACA AACTAAAATA TGTGC F 12 7704-7695 1.73 0.79 7700
TTAGT TTGTTTTTAC TTAAG F 12 7704-7713 CHC CHC CHC
AGCTT AAGTAAAAAC AAACT F 13 7715-7706 CHC CHC CHC
ACGCG ATGTTGTTAA CGAAC R 7 7634-7645 1.40 1.40 7638
AACGT TTGAAATTAG AAAAC R 0 7527-7536 / / /
ATATT TTGAACAATT GGCGC F 2-3 7561-7570 2.41 2.87 7557
TATTT TAGTTTGTTT TTACT F 11 7700-7709
GTAAA AACAAACTAA AATAT R 12 7708-7697
ATTGC AAACTTTAAT CTTTT F 0 7526-7535 / / /
TTGCA AACTTTAATC TTTTG F 0 7527-7536 / / /
AAACT TTAATCTTTT GGGCA F 0a 7531-7540 2.07 1.23 7536
GCCCA AAAGATTAAA GTTTG F 1 7540-7531 2.07 1.23 7536
CCTAC ATATTTTGAA CAATT F 2 7556-7565 2.41 2.87 7557
TGCGC TACAACAATT GCTTG F 7 7634-7645 1.40 1.40 7638
ATTGC TTGCATAACT ATATC F 8 7646-7655 1.74 1.37 7647.7651
TATGC AAGCAATTGT TGTAG F 8 7647-7638 1.89 1.96 7644.7647
ATGCA AGCAATTGTT GTAGC R 8 7646-7637 1.89 1.96 7644
TTGCT TGCATAACTA TATCC R 8 7647-7656 1.56 1.35 7651
GGATA TAGTTATGCA AGCAA F 8a 7656-7647 1.54 1.35 7659
GGCAC ATATTTTAGT TTGTT F 11 7694-7703 1.73 0.79 7700
GCACA TATTTTAGTT TGTTT F 11 7695-7704 1.73 0.79 7700
CACAT ATTTTAGTTT GTTTG F 11 7696-7705 1.73 0.79 7700
GCTAA TTGCATACTT GGCTT F 14 7723-7732 1.73 0.79 7700
GAGCA GTGCCCAAAA GATTA R 1a 7546-7537 1.77 2.28 7545
CTTTG GCGCATATAA GGCGC F 3a 7585-7594 3.77 2.74 7591
AAACC GCGTATATTC CGCGT R 3a 7586-7595 3.77 2.74 7591
GGTGC GCCTTATATG CGCCA R 4 7597-7588 3.77 2.74 7591
CTGGA CAGGAAAATG ACTAA F 6a 7622-7613
TTAGG GAGTGGATAT AGTTA F 8a 7665-7656 1.54 1.35 7659
4 MM GAGCA GTGCCCAAAA GATTA F 1a 7546-7537 1.77 2.28 7545
 3 MM
2 MM
Integration 
Peak         
(for Kd)
0 MM
# Mismatch 
(MM)
 NV1028                      
WWGWWWWWWW (FW) 
WWCWWWWWWW (RV)                   
DNA Sequence (5'-3')
FORWARD ( F ) 
REVERSE ( R )
Site
Genome 
Position
Hill Coefficient
Kds (Hill 
Model)  
ɛ=113300 M
-1 
cm
-1
1 MM
1 MM 
don't bind
Red nucleotide indicate mismatch position 
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Figure SI 1. Representative binding isotherms for NV1028 on HPV 7479-7783 
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Figure SI 2. Representative binding isotherms for NV1028 on HPV 7179-7563 
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Figure SI 3. Representative binding isotherms for NV1042 on HPV 7179-7563 
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CHAPTER 3 
IMPROVED ANTIVIRAL POLYAMIDES WITH BROAD-SPECTRUM 
ACTIVITY AGAINST HIGH-RISK HUMAN PAPILLOMAVIRUS 
 
 
 
 
 
 
 
 
The work presented in this chapter is based on the published paper “Improved 
Antiviral Polyamides with Broad-Spectrum Activity Against High-Risk Human 
Papillomavirus” from MedChemComm, 2016, 7, 2076-2082 
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3.1 Abstract 
 
  We report the synthesis of two novel pyrrole-imidazole polyamides with N-
terminal guanidinium or tetramethylguanidinium groups and evaluate their antiviral 
activity against three cancer-causing human papillomavirus strains. Introduction of 
guanidinium improves antiviral activity when compared to an unsubstituted analog, 
especially in IC90 values. These substitutions change DNA-binding preferences, while 
binding affinity remains unchanged.  
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3.2 Introduction  
 
  N-methylpyrrole (Py) and N-methylimidazole (Im) hairpin polyamides 
(PAs) are synthetic homologs of the natural antibiotics distamycin A and 
netropsin which bind AT-rich regions of DNA in the minor groove.
1
 The 
antiparallel nature of hairpin PAs allows for the side-by-side pairing of building 
blocks and recognition of DNA base pairs (bp) within a double strand 
(dsDNA). It has been extensively reported that Py/Py and Py/β-alanine (β) pairs 
recognize A/T and T/A base pairs, while an Im/Py pair distinguishes G/C from 
C/G.
2
 Furthermore, introduction of the flexible β linker in place of heterocycles 
resets the heterocycle-base pair register and allows targeting of longer DNA 
sequences.
3
  
  In numerous reports, hairpin PAs distinguish DNA sequences by binding 
to patterns of hydrogen-bond donors and acceptors in the minor groove of 
DNA,
4
 so synthetic PAs are attractive for many biomedical applications. These 
applications, for polyamides themselves and related minor groove binders, 
include the regulation of gene expression,
5
 biological imaging,
6
 and 
antimicrobial/antiviral applications.
7
 Antiviral polyamides include the long 
polyamides reported here which, as a class, access a new biological 
mechanism: they actively degrade the genome of dsDNA tumour viruses in 
cells while avoiding acute cytotoxicity. The DNA degradation is accomplished 
by inducing the DNA Damage Response (DDR) significantly, only in infected 
cells carrying small, circular, dsDNA genomes known as episomes.
8a,b 
As 
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discussed below, another characteristic of this new class of antiviral polyamides 
is their failure to follow the reported DNA recognition rules described above. 
  The process by which the DDR works in concert with the polyamides is 
not completely established at the molecular level, but many details have 
emerged as a result of a variety of experiments, a portion of which are 
summarized here. For example, 224 DDR genes were knocked down 
individually using siRNA, and we checked to see if the knockdowns affected 
polyamide activity in any way; 21 genes were found to affect PA activity, and 
the results were validated by additional experiments using QPCR (rather than 
relying on the PCR array data alone).
8a,b
 Some gene knockdowns enhanced PA 
activity and others opposed PA activity. Additional experiments used Mirin, a 
small molecule inhibitor of DDR enzyme Mre11. Mre11 has many activities 
alone and in protein complexes. For example, Mre11 is a member of the MRN 
complex, which participates in double-strand DNA break repair and telomere 
maintenance as a member of the ATM branch of the DDR.
8c
 As a standalone 
enzyme, one activity associated with MRE11 is that of an endonuclease. 
MRE11 inhibition experiments were carried out in the presence and absence of 
polyamides.
8a
 100 μM Mirin had no effect on its own, but it sensitized cells to 
PA25, making the compound 4× more active in terms of lower IC50 and IC90 
values. Part of the activation of the DDR was also followed by phosphorylation 
of Rad9, a protein that is phosphorylated upon DNA damage as part of the ATR 
pathway of the DDR, one of the two major DDR branches (the other being 
ATM).
8a,b,d
 Treatment of HPV16 episome bearing W12E cells with active 
polyamide causes Rad9 phosphorylation within 2–4 hours, but HPV-free 
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cervical cancer cell line C33A shows no phosphorylation of Rad9 upon 
treatment with polyamide.
8a,b 
  We previously reported a library of long hairpin PAs, including PA1 and 
PA25, which exhibits antiviral activity against three high-risk (oncogenic) 
HPVs.
9
 HPV is an AT-rich dsDNA virus
10
 that causes cervical cancer, among 
other diseases, and subtypes HPV16 and 18 are responsible for 70% of cervical 
cancer in most of the world.
11,12
 Although specific HPV vaccines are 
available,
13
 they are effective prophylactics, not therapies. PA1, our first 
preclinical lead, exhibits anti-HPV activity with no cytotoxicity up to its 
solubility limit in cell culture media of 200 μM.9 A characteristic of these active 
anti-HPV polyamides is that they bind at least ten bp, or one full turn of DNA.   
  Here, we report the antiviral activities and DNA-binding properties of 
two PAs of a new structural class, PA30, and PA31, where the des-amino N-
terminus of the parent compound PA1 has been substituted with either 
tetramethylguanidinium (TMG) or guanidinium (Guan), respectively. PA30 and 
PA31 are biomimetic in that netropsin has an N-terminal guanidinium, though 
PA30, 31 are not exact structural analogs of netropsin. While others have 
explored guanidinylated DNA-binding ligands, no biophysical studies on 
guanidinylated hairpin PAs have been undertaken, to our knowledge.
14
 We 
found that these substitutions at the N-terminus, which are small relative to the 
overall molecular size, can significantly improve anti-HPV activity. However, 
improvement in antiviral efficacy cannot be attributed to altered DNA binding 
strength, as will be shown. Nevertheless, PA30 and PA31 display noticeable 
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differences in binding distribution on a fragment of native HPV18 DNA in 
comparison with parent PA1. 
 
3.3 Methods 
 
3.3.1 Polyamides Synthesis and Characterization  
 
PA1 and its EDTA conjugate were synthesized and characterized as previously 
described.
9, 18
 PA30 and 31 were synthesized by virtually identical solid-phase 
methods up to the Im group (4-amino-N-methyl imidazole-2-carboxamide) and its 4-
N-attached guanidinyl substituent. For PA30, HATU
28
 was utilized as the final 
building block to incorporate the TMG group onto the H2N-Im moiety. For PA31, in 
parallel to the literature,
29
  treatment with N,N’-Bis (tert-butoxycarbonyl)-1H-
pyrazole-1-carboxamidine and diisopropylethylamine for 24 h, followed by TFA 
treatment to remove the BOC groups produced the desired, unsubstituted Guan group. 
The EDTA conjugate of PA30 was prepared via the same method as previously 
described for PA1’s conjugate.18 Briefly, to a vigorously-stirred mixture of EDTA 
dianhydride (15.8 mg, 0.060 mmol, 22 eq) in N,N-diisopropylethylamine (DIEA) (0.5 
mL), DMF (0.25 mL) and DMSO (0.25 mL) at 55 °C was added a mixture of PA30 
(5.9 mg, 0.0027 mmol, 1 eq) in DIEA (0.5 mL) and DMF (0.5 mL) dropwise over a 
period of 30 min. The reaction mixture was stirred at 55 °C for 30 min. Following 
addition of 0.1 N NaOH (1.03 mL), the mixture was stirred at 55 °C for an additional 
20 min. The bottom layer of the biphasic mixture was removed from the reaction 
vessel and neutralized with formic acid (0.013 mL). The mixture was diluted with 0.5 
mL DMSO, filtered through a 20 μm polyethylene filter, and purified by reversed-
 
74 
 
phase HPLC using a Phenomenex Luna 250 x 30 mm, 5 μm, 100 Å, C18 (version 2) 
column maintained at 25 ˚C. Mobile phases were 0.2% formic acid in water (A) and 
100 % methanol (B). The gradient was 35% B for 5 min followed by a ramp to 70% B 
over 40 min at 50 mL/min. Concentration of pooled fractions, followed by 
lyophilization, gave the PA30-EDTA conjugate (1.0 mg, 16% yield) as a white, fluffy 
solid: exact mass [M+H]
+
= 2282.0657, experimental (ESI) [M+H]
+
 = 2282.1257. The 
EDTA conjugate of PA31 was prepared via a virtually identical procedure to the one 
described for PA30, but with the following changes. PA31 (4.0 mg) was substituted 
for PA30. The preparative HPLC purification parameters were identical to those 
described above except mobile phase A consisted of 0.2% trifluoroacetic acid in 
water. Concentration of pooled fractions, followed by lyophilization gave the PA31-
EDTA conjugate (2.3 mg, 55% yield) as an off-white fluffy solid: exact mass 
[M+2H+Na]
+
 = 2250.0007, experimental (ESI) [M+2H+Na]
+
 = 2249.9562. Analytical 
HPLC characterization was performed using a Phenomenex Jupiter Proteo (C12), 4.6 
x 50 mm, 4 μm, 90 Å maintained at 40˚C. Mobile phases consisted of 0.1% formic 
acid in water (A) and 100 % acetonitrile (B). The gradient consisted of 5% B for 0.75 
min followed by a ramp to 60% B over 3.25 min at 2 mL/min. Retention times were 
2.641 min, 2.486 min and 2.437 min for PA1, PA30 and PA31 respectively. 
 
PA1 Im-Py-Py--Py-Py-Py--Py-Py--Py-Py-Py-Py--Ta (3 TFA): 
1
H NMR (600 MHz, DMSO-d6)  = 10.46 (s, 1 H), 9.93 (s, 1 H), 9.91 (s, 4 H), 9.90 - 
9.87 (m, 2 H), 9.86 (s, 1 H), 9.83 (s, 1 H), 9.63 (br. s., 2 H), 8.12 - 8.02 (m, 5 H), 7.98 
- 7.92 (m, 1 H), 7.88 (br. s., 3 H), 7.40 (s, 1 H), 7.28 (d, J = 1.8 Hz, 1 H), 7.24 - 7.21 
(m, 3 H), 7.21 - 7.18 (m, 4 H), 7.18 - 7.16 (m, 3 H), 7.15 (d, J = 1.8 Hz, 1 H), 7.08 (d, 
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J = 1.8 Hz, 1 H), 7.07 (d, J = 1.8 Hz, 1 H), 7.06 (s, 1 H), 7.04 (d, J = 1.8 Hz, 1 H), 
6.90 (d, J = 1.8 Hz, 1 H), 6.89 (d, J = 1.8 Hz, 1 H), 6.89 (s, 2 H), 6.85 (s, 2 H), 6.84 
(d, J = 1.2 Hz, 1 H), 3.99 (s, 3 H), 3.85 (s, 3 H), 3.85 (s, 3 H), 3.84 (s, 9 H), 3.82 (s, 6 
H), 3.81 (s, 3 H), 3.81 (s, 9 H), 3.49 - 3.42 (m, 4 H), 3.41 - 3.35 (m, 4 H), 3.25 - 3.16 
(m, 4 H), 3.16 - 3.10 (m, 2 H), 3.10 - 2.98 (m, 4 H), 2.87 (br. s, 2 H), 2.74 (d, J = 4.7 
Hz, 3 H), 2.55 - 2.51 (m, 2 H), 2.36 (t, J = 7.0 Hz, 2 H), 2.28 (t, J = 7.3 Hz, 2 H), 1.96 
- 1.87 (m, 2 H), 1.82 - 1.74 (m, 2 H) 
13
C NMR (151 MHz, DMSO-d6)  = 171.1, 169.3, 167.9, 167.8, 161.3, 158.6, 158.5, 
158.5, 158.4, 158.4, 158.4, 158.1, 157.9, 155.9, 138.7, 126.8, 126.3, 123.0, 122.9, 
122.8, 122.8, 122.8, 122.7, 122.7, 122.2, 122.2, 122.1, 122.1, 122.1, 122.0, 121.9, 
121.4, 118.6, 118.5, 118.4, 118.2, 118.1, 118.0, 117.8, 104.9, 104.8, 104.8, 104.7, 
104.3, 104.3, 104.2, 104.0, 104.0, 103.9, 53.3, 52.1, 40.0, 39.3, 38.2, 36.2, 36.1, 36.1, 
36.0, 35.8, 35.8, 35.6, 35.6, 35.5, 35.4, 35.1, 33.3, 25.7, 24.0, 21.8 
HRMS (ESI) calculated for C91H111N31O16 [MH]
+
, 1894.8908, found, 1894.8933. 
HPLC purity: 98%. (See Figure 1a). 
PA30 TMG-Im-Py-Py--Py-Py-Py--Py-Py--Py-Py-Py-Py--Ta (4 TFA): 
1
H NMR (600 MHz, DMSO-d6)  = 10.19 (s, 1 H), 10.08 (s, 1 H), 9.94 (s, 1 H), 9.92 
(s, 3 H), 9.91 (s, 1 H), 9.90 (s, 1 H), 9.87 (s, 1 H), 9.84 (s, 1 H), 9.45 (br. s., 1 H), 8.13 
- 8.03 (m, 5 H), 7.86 (br. s., 1 H), 7.80 (br. s., 3 H), 7.29 (d, J = 1.8 Hz, 1 H), 7.23 (d, 
J = 1.2 Hz, 2 H), 7.22 - 7.21 (m, 2 H), 7.21 - 7.18 (m, 4 H), 7.16 (s, 3 H), 7.15 (d, J = 
1.8 Hz, 1 H), 7.08 (d, J = 1.8 Hz, 1 H), 7.07 (d, J = 1.8 Hz, 1 H), 7.05 (d, J = 1.2 Hz, 1 
H), 6.91 (d, J = 1.8 Hz, 1 H), 6.89 (d, J = 1.8 Hz, 2 H), 6.88 (s, 1 H), 6.85 (s, 2 H), 
 
76 
 
6.84 (d, J = 1.2 Hz, 1 H), 6.56 (br. s., 2 H), 3.99 (s, 3 H), 3.85 (s, 3 H), 3.85 (s, 3 H), 
3.84 (s, 3 H), 3.84 (s, 3 H), 3.84 (s, 6 H), 3.81 (s, 6 H), 3.81 (s, 3 H), 3.80 (s, 6 H), 
3.50 - 3.26 (m, 6 H), 3.24 - 3.16 (m, 3 H), 3.16 - 3.09 (m, 2 H), 3.09 - 2.98 (m, 3 H), 
2.98 - 2.80 (m, 14 H), 2.74 (d, J = 5.3 Hz, 3 H), 2.55 - 2.51 (m, 4 H), 2.36 (t, J = 7.3 
Hz, 2 H), 2.27 (t, J = 7.3 Hz, 2 H), 1.94 - 1.85 (m, 2 H), 1.82 - 1.73 (m, 4 H) 
13
C NMR (151 MHz, DMSO-d6)  = 171.0, 169.3, 167.9, 167.8, 161.3, 158.5, 158.5, 
158.4, 158.4, 158.4, 158.2, 157.9, 157.8, 155.4, 135.9, 134.8, 123.1, 122.9, 122.8, 
122.8, 122.8, 122.7, 122.7, 122.2, 122.2, 122.1, 122.1, 122.1, 122.1, 122.0, 121.9, 
121.1, 118.9, 118.5, 118.5, 118.2, 118.1, 118.0, 117.8, 115.8, 105.0, 104.8, 104.8, 
104.7, 104.3, 104.3, 104.0, 104.0, 103.9, 53.3, 52.1, 40.0, 39.3, 38.2, 36.2, 36.1, 36.1, 
36.0, 35.8, 35.8, 35.6, 35.6, 35.5, 35.4, 33.3, 25.7, 24.0, 22.5, 21.8 
HRMS (ESI) calculated for C96H122N34O16 [M]
+
, 2006.9778, found, 2006.9653. 
HPLC purity: 99%.(See Figure 1b). 
PA31 Guan-Im-Py-Py--Py-Py-Py--Py-Py--Py-Py-Py-Py--Ta (4 TFA): 
1
H NMR (600 MHz, DMSO-d6)  = 10.46 (s, 1 H), 10.42 (s, 1 H), 9.94 (s, 1 H), 9.93 
(s, 1 H), 9.92 (s, 3 H), 9.91 (s, 1 H), 9.90 (s, 1 H), 9.87 (s, 1 H), 9.84 (s, 1 H), 9.46 (br. 
s., 1 H), 8.13 - 8.07 (m, 4 H), 8.06 (t, J = 5.6 Hz, 2 H), 7.86 (br. s., 1 H), 7.81 (br. s., 3 
H), 7.28 (d, J = 1.8 Hz, 1 H), 7.23 (d, J = 1.2 Hz, 2 H), 7.22 (d, J = 1.2 Hz, 1 H), 7.21 
- 7.18 (m, 5 H), 7.17 (s, 3 H), 7.14 (d, J = 1.8 Hz, 1 H), 7.08 (d, J = 1.2 Hz, 1 H), 7.07 
(d, J = 1.8 Hz, 1 H), 7.04 (d, J = 1.8 Hz, 1 H), 6.91 (d, J = 1.8 Hz, 1 H), 6.89 (s, 2 H), 
6.88 (d, J = 1.8 Hz, 1 H), 6.87 - 6.85 (m, 2 H), 6.84 (d, J = 1.8 Hz, 1 H), 6.69 (s, 1 H), 
6.56 (br. s., 2 H), 4.00 (s, 3 H), 3.86 (s, 3 H), 3.85 (s, 3 H), 3.84 (s, 3 H), 3.84 (s, 3 H), 
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3.84 (s, 6 H), 3.81 (s, 6 H), 3.81 (s, 3 H), 3.80 (s, 6 H), 3.51 - 3.32 (m, 6 H), 3.24 - 
3.16 (m, 3 H), 3.16 - 3.09 (m, J = 6.2, 12.5, 12.5 Hz, 2 H), 3.09 - 2.98 (m, 3 H), 2.90 - 
2.81 (m, 2 H), 2.74 (d, J = 4.7 Hz, 3 H), 2.55 - 2.51 (m, 4 H), 2.36 (t, J = 7.3 Hz, 2 H), 
2.27 (t, J = 7.3 Hz, 2 H), 1.94 - 1.85 (m, 2 H), 1.82 - 1.75 (m, 4 H) 
13
C NMR (151 MHz, DMSO-d6)  = 171.1, 169.3, 167.9, 161.3, 161.3, 158.6, 158.5, 
158.5, 158.4, 158.4, 158.3, 158.2, 158.0, 155.2, 154.6, 134.7, 134.4, 123.1, 122.9, 
122.8, 122.8, 122.7, 122.7, 122.2, 122.2, 122.1, 122.1, 122.1, 122.0, 121.9, 120.9, 
118.9, 118.5, 118.4, 118.2, 118.1, 118.0, 118.0, 117.8, 116.1, 113.7, 105.1, 104.8, 
104.8, 104.7, 104.3, 104.3, 104.2, 104.0, 104.0, 103.9, 53.3, 52.1, 40.0, 39.3, 38.2, 
36.2, 36.2, 36.1, 36.0, 36.0, 35.8, 35.8, 35.6, 35.6, 35.5, 35.4, 35.4, 33.3, 25.7, 24.1, 
22.5, 21.8 
HRMS (ESI) calculated for C92H114N34O16 [M]
+
, 1950.9152, found, 1950.9034. 
HPLC purity: 98%. (See Figure 1c). 
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Figure 3.1  HPLC Purity of PA1, PA30 and PA31 with λ monitored. 
(A) PA1 254.8 nm 
300.8 nm 
254.8 nm 
300.8 nm 
254.8 nm 
300.8 nm 
(B) PA30 
(C) PA31 
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3.3.2 Compound efficacy testing 
The antiviral activities were calculated by measuring the ability of PAs to 
decrease the viral DNA (or episomal) load in monolayer keratinocyte cultures. The 
episomal load was determined by Q-PCR as previously described.
9
 PA1 was already 
reported, along with extensive discussion of how antiviral parameters are defined for 
this new mechanism of antiviral action in which the viral genome is degraded while 
the host cells are unharmed as measured by standard MTT and LDH assays and 
observations of numbers of floating vs. adherent cells, etc.
8,9,10
 Typical assays were 
run for 48 h though much longer assays have also been run, and ref. 9 also describes 
organotypic, differentiated keratinocyte tissue culture assays as well as cell monolayer 
assays. Because PA1 has been central to our work for over a decade, it has been used 
as an internal standard to benchmark new compound series, so even though we cite 
the prior study, PA1 was studied side-by-side with PA30 and PA31 for the current 
work. The new PA1 results were indistinguishable from the dose-response curves 
previously reported. Dose-response curves for PA30 and PA31 are given below in 
Figure 2a and 2b. 
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Figure 3.2. Dose-response curves for PA30 and PA31 against HPV16, 18 and 31 from which IC50 
and IC90 values were determined as polyamide concentrations where 50 and 90% of viral DNA 
was undetectable relative to vehicle control. (a) Results for PA30. (b) Results for PA31.  
 
 
Note that the plots show reduction, or decrease, in HPV DNA as a % of control, so 
100% reduction corresponds to elimination of viral DNA on the scale plotted. Vehicle 
control was 0.1% DMSO in water, which is well tolerated by the keratinocytes.
8,9,10
 
Differences in efficacy between PA30 and PA31 are striking when HPV16 and 18 are 
considered: PA30 (Figure 2a) achieves close to 100% reduction in viral DNA only 
for HPV31, a high-risk but minor form of the disease that is still clinically important. 
PA31 is highly-active and essentially indistinguishably-active against all three high-
risk HPVs, on the scale plotted in Figure 2b. 
 
3.3.3 Quantitative DNase I footprinting 
The molar extinction coefficient for PA1 was determined as ε = 88,235 M-
1
cm
-1 
by fluorescence as previously described.
30
 The molar extinction coefficients for 
PA30 and PA31 were determined as ε = 91,164 M-1cm-1, ε = 89,263 M-1cm-1 by 
measuring the absorbance at 305 nm of solutions with known polyamide 
concentrations in the range 5 x 10
-7 
M to 7 x 10
-5 
M.  
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Quantitative DNase I footprinting experiments were performed as described 
previously.
18
 Briefly, a 305 bp DNA fragment corresponding to the nucleotides 7479-
7783 in the Long Control Region (LCR) of the HPV18 genome (Genbank accession 
number X05015) was PCR amplified and fluorescently-labeled at both 5’ ends using 
the following primers: (top strand) 5’-FAM-CT TAT GTC TGT GGT TTT CTG and 
(bottom strand) 5’-HEX-TT CAT GTT AAG GGT AGA CAG. The DNA fragment 
was diluted to 200 pM in TKMC buffer with 10 mM CHAPS and incubated with 
different concentrations of each polyamide (0.5-40 nM) for at least 4 h at 37 °C. The 
polyamide solutions were always added to DNA solutions not vice versa. At the end 
of this incubation period, each solution was subjected to ~0.08 U of DNase I for 5 
min. The reactions were then quenched with EDTA and the DNA fragments were 
purified using a QIAquick PCR purification kit. Each experiment was performed at 
least three times. 
 
Table 3.1. Kd Values Determined by Hill Equation for Sites 1-3 with Hill Coefficients and Overall 
Fit 
 
Table 3.2. Kd Values Determined by Langmuir Equation for Sites 1-3 with Overall Fit 
 PA1 PA30 PA31 
 
Kd 
(Hill) 
Hill 
Coeff. 
R 
Kd 
(Hill) 
Hill 
Coeff. 
R 
Kd 
(Hill) 
Hill 
Coeff. 
R 
Site 
1 
0.9 ± 
0.1 
1.6 ± 
0.4 
>0.99 
1.2 + 
0.2 
1.8 + 
0.2 
>0.99 
1.0 ± 
0.1 
2.0 ± 
0.3 
>0.99 
Site 
2 
0.9 ± 
0.2 
1.8 ± 
0.6 
1 
1.1 + 
0.2 
2.0 + 
0.3 
>0.98 
1.0 ± 
0.1 
1.6 ± 
0.2 
>0.99 
Site 
3 
2.7 ± 
0.5 
3.8 ± 
0.8 
>0.99 
3.2 + 
0.3 
3.4 + 
0.5 
>0.98 
2.2 ± 
0.2 
3.8 ± 
0.8 
1 
 PA1 PA30 PA31 
 Kd (Langmuir) R Kd (Langmuir) R Kd (Langmuir) R 
Site 
1 
1.0 ± 0.1 >0.98 1.4 + 0.3 >0.98 1.3 + 0.4 >0.97 
Site 
2 
1.0 ± 0.2 >0.97 1.3 + 0.3 >0.96 1.3 + 0.3 >0.99 
Site 
3 
3.5 ± 0.5 >0.92 6 + 1 >0.95 2.9 + 1.5 >0.95 
 
82 
 
3.3.4 Affinity cleavage 
 
Affinity cleavage experiments were performed as previously described. Briefly, 
PA-EDTA conjugates were complexed with 0.8 eq of Fe
2+
 in the form of ammonium 
iron(II) sulfate hexahydrate. 1 nM DNA fragment in 10 mM Tris, 10 mM CHAPS, pH 
7.5 was incubated with different concentrations of PA-EDTA-conjugates (5-200 nM) 
for at least 4 h at 37 °C. The reaction was initiated with 5 µL of 100 mM DTT and 
incubated at room temperature for 1-2 h. Each cleavage reaction was then quenched 
and fragments were purified using a QIAquick PCR purification kit. 
The samples from quantitative DNase I footprinting and affinity cleavage 
experiments were analyzed using capillary electrophoresis and indexed using Sanger 
and Maxam-Gilbert sequencing, respectively.
31
 Dissociation constant (Kd) values 
were calculated by normalizing the area from a peak in the footprint region to the area 
of a peak not sensitive to PA concentration. These values were plotted and fitted to 
Hill and Langmuir binding isotherms (as appropriate) with KaleidaGraph in methods 
reported in detail elsewhere.
 18,31.32
 
 
3.4 Results and Discussion 
 
  Polyamides were synthesized by Boc solid-phase methods
15
 as reported
9
 
(PA1) or followed by TMG (PA30) or Guan (PA31) conjugation. After 
cleavage from the resin, polyamides were purified by reverse-phase HPLC and 
characterized with 
1
H and 
13
C NMR and HR mass spectrometry. Structures of 
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PA1, PA30 and PA31 and their EDTA-conjugates used in affinity cleavage 
maps are shown in Figure 3.  
 
 
 
 
 
 
 
Figure 3.3.  Chemical structure of PA1, PA30 and PA31. RF refers to the substituent used for 
DNase I footprinting experiments, whereas RAC indicates the EDTA-Fe conjugate for affinity 
cleavage experiments. Inset: cartoon representation of the PA with building blocks represented 
by open circles for N-methylpyrrole, filled circles for N-methylimidazole, diamonds for β, + for 
the Ta tail and  for γ-aminobutyric acid. PA1, PA30, and PA31 share the same predicted 
DNA binding site (5’-WWGWWWWWWW-3’, where W = A or T) and a general PA 
representing all three is depicted between two complementary DNA strands. 
 
 
  Anti-HPV activities and MTT cell toxicity assays (shown for PA1, 
Figure SI 1A) were determined as previously described.
9a
 However, new side-
by-side, concentration-dependent assays were performed for previously 
reported PA1.
9a
 Table 3 provides the resulting pseudo IC50 and IC90 values for 
PA1, PA30 and PA31 corresponding to the PA concentration that causes a 50% 
or 90% decrease in viral DNA concentration. Figure 2 gives dose-response 
curves for PA30 and PA31 while data are given for PA1 and HPV16 and 
HPV31 in Figure SI 1; data for PA1 were the same as previously reported.
26,9a
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Although IC50 values for the compounds are comparable against HPV16 and -31, 
PA30 and PA31 afforded somewhat improved IC50 values against HPV18. In 
contrast, significant improvement in IC90 for HPV16 and -18 was observed with 
PA31. However, PA30 activity plateaus just below a 90% decrease in viral DNA and, 
in two days, does not quite reach an IC90, an important measure of antiviral activity. 
We will explore longer time intervals, but higher concentrations do not seem 
promising based on the dose–response curves, and would make PA30 a poor 
competitor with the more-active PA31. 
 HPV16 HPV18 HPV31 
 IC50 
(µM) 
IC90 
(µM) 
n 
IC50 
(µM) 
IC90 
(µM) 
n 
IC50 
(µM) 
IC90 
(µM) 
n 
PA1 0.1(1) 1.1(8) 4 0.7(4) >10 3 0.1(1) 1.0(5) 4 
PA30 0.3(1) >10 3 0.2(2) >10 3 0.13(4) 0.9(7) 3 
PA31 0.10(1) 0.38(8) 3 0.2(2) 0.9(6) 3 0.14(4) 0.8(2) 3 
Table 3.3 IC50 and IC90 values of PA1,
a
 PA30, and PA31 against high-risk HPV16, -18 and -31 
types. The numbers in parentheses are sample standard deviations; n is the number of independent 
measurements. [a] IC50 values for PA1 were first reported in reference 9; we re-measured them and 
found them unchanged. 
 
  Because only PA31 showed an improved IC90 against HPV18, we 
investigated the DNA-binding properties of these hairpin PAs on a natural 
HPV18 sequence and compared them to the parent compound, PA1. Based on 
well-established PA-DNA pairing rules,
4a
 PA1, PA30, and PA31 were 
expected to target the ten base-pair DNA sequence WWGWWWWWWW, 
where W=A or T (Figure 3 inset). A PA-DNA mismatch refers to any 
deviation from this recognition motif, i.e. where a PA building block pair binds 
to a noncanonical Watson-Crick base pair: one not predicted by the pairing 
rules.
1a
 We used quantitative DNase I footprinting
16
 to obtain dissociation 
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constants (Kd) and affinity cleavage experiments to assign binding orientations 
of the compounds on a 305 bp DNA fragment corresponding to nucleotides (nt) 
7479 to 7783 in the Long Control Region of HPV18, a viral genomic region 
containing regulatory elements for replication.
17
 We determined Kd values and 
orientation for all PA binding events along the entire 305 bp DNA fragment, 
and representative dissociation constants at three binding sites are given in 
Table 4. Similar results were observed in the rest of the DNA fragment (Figure 
S1 2a-2b). Kd was determined by the Hill or Langmuir equation, based on the 
magnitude of the derived Hill coefficient and overall fit (see Table 1 and 2).
18 
 There is no significant difference in DNA-binding affinities of PA1, PA30, 
and PA31, indicating that the addition of a potential H-bond donor and a positive 
charge for PA30 and PA31 vs. PA1 does not explain enhanced antiviral activity. It is 
noteworthy that since we are sampling an ensemble of different binding 
conformations in multiple linear, cell-free DNA molecules, binding affinities are the 
sum of these binding events at a particular binding site. Furthermore the negative 
supercoiling of the viral genome, and bound viral and host proteins in vivo, probably 
affect binding (see Conclusions). We are currently examining these matters 
experimentally. All three PAs bind to Sites 1 and 2 (single-mismatch sites) with Kd 
values ranging from 0.9-1.2 nM, and it is noteworthy that they all tolerate a triple 
base-pair mismatch at Site 3 with Kd values ranging from 2.2-3.2 nM (Table 4). The 
high Hill coefficients at this site are explained by previously-reported polyamide 
binding cooperativity,
4d
 in which the binding of one polyamide can preorganize the 
minor groove for the binding of a second (and more) polyamides, for example by 
widening the minor groove. This cooperativity would be most expected in areas of 
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high polyamide density on the DNA, which is what we found in the Long Control 
Region. We need to point out that we used a single-site binding model to analyze 
binding thermodynamics. If we had parameterized binding to allow multiple Hill 
coefficients to float simultaneously, we would more accurately have accounted for the 
statistics of multi-site binding. The results would likely have been that some Hill Kd 
values and coefficients would have decreased, and others would have increased. 
However, we were not convinced that our data would hold up to the introduction of so 
many additional parameters (a Hill coefficient per binding site and orientation), and 
did not believe that the outcome would change significantly in a scientific sense with 
a more precise handling of the statistical question. We will revisit this with more 
complete data sets for multiple compounds to test whether our approximation, which 
is normal in polyamide literature,
1-4
 is suitable or not. 
 
Table 3.4. Representative PA binding sites on nt 7479-7783 of the HPV18 LCR as determined by 
quantitative DNase I footprinting and affinity cleavage. DNA sequences are illustrated so that the 
middle block represents the PA binding site along with 5 flanking nt. In each sequence, the underlined 
base is bound by imidazole/pyrrole (or pyrrole/imidazole) pair of the polyamide. The bold bases in 
column 2 correspond to mismatches according to recognition "rules." Kd values were calculated from 
DNase I experiments performed at least in triplicate (Table  1 and 2). 
 
  Thus, large antiviral hairpin PAs tolerate reportedly unfavourable DNA 
interactions without a significant decrease in binding affinity, which agrees 
with our prior work on HPV16.
18
 In fact, in that prior work we found for 14-
 Kd (nM) 
Site Sequence Position Site Type PA1 PA30 PA31 
1 CCTGG TATTAGTCAT  TTTCC 7606-7615 Single-mismatch 0.9 ± 0.1 1.2 ± 0.2 1.0 ± 0.1 
2 ACATA TTTTGAACAA TTGGC 7559-7568 Single-mismatch 0.9 ± 0.2 1.1 ± 0.2 1.0 ± 0.1 
3 CTTTG GCGCATATAA GGCGC 7585-7594 Triple-mismatch 2.7 ± 0.5 3.2 ± 0.3 2.2 ± 0.2 
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ring PA1 that numerous “mismatch” sites were bound with higher affinity than 
so-called canonical sites. Also, up to four mismatches were tolerated with 2 nM 
dissociation constants identical to numerous “perfect-match” sites. For a larger, 
20-ring antiviral polyamide (PA25), four mismatches were even more common 
than with PA1, leading to a complete blanketing of the HPV16 long control 
region when only sparse binding, at best, was predicted.
18b
 
 Data for HPV18-polyamide binding to a portion of the LCR is reported here 
and allow us to expand our understanding (polyamide-HPV18 binding was previously 
reported for the E2-protein binding sites).
7a
 We hypothesize that a deviation from 
established binding rules occurs for our unusually large hairpin PAs because they 
form many H-bonds with DNA and significant internal π-stacking compared to the 
smaller PAs typically found in the literature.
19
 Thus, a few unfavourable enthalpic 
interactions are likely insignificant. The entropy of binding is likely very favourable 
for long PAs from the loss of many water molecules previously resident in the minor 
groove and from loss of exposed nonpolar surface area upon π-stacking.  Entropy and 
enthalpy are being determined by the CM Dupureur group. Since we determined 
polyamide-DNA binding properties in the context of a large, natural DNA sequences 
instead of a small artificial, DNA sequences designed to examine sequence 
preferences at a single location, our results are much more complex than those found 
in the literature. Published binding rules are not obeyed with significant fidelity, and 
“mismatches” are very well tolerated (see also He et al.18 and Qiao et al.20). 
  Binding sites for PA1, PA30, and PA31 in a region of HPV18 DNA 
spanning nt 7601-7620 are shown in Figure 4A. In this part of the viral 
genome, there are two predicted single-mismatch binding sites, sequence (i) 5’-
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TATTAGTCAT-3’ (7606-7615) and sequence (ii) 5’-TAGTCATTTT-3’ 
(7609-7618). Our data indicate that PA1 and PA31 bind both of these sites, 
while PA30 only binds to (i). 
 Raw DNase I footprinting data of dsDNA (top strand) is shown in Figures 
4B (control) and 4C (5 nM PA). Inspection of the footprints generated by the 
three PAs reveals subtle differences in the protected regions. For instance, the 
peaks at the left-hand edge of the protected region corresponding to nt 7606-09 
(Figure 4* shows 7606) display increased nuclease accessibility in the case of 
PA1 vs. PA30 and PA31. At the right-hand edge of the protected region, the 
peak corresponding to nt 7619 (Figure 4C
†
) is less protected from DNase I by 
PA30 (Figure 4C middle panel) than by PA1 (Figure 4C left panel) at 
equivalent PA concentrations. In contrast, PA31 affords more-extended 
nuclease protection than either PA1 or PA30, with a footprint including extra nt 
7619-7626; this extra nuclease protection corresponds to the double-mismatch 
site (iii) at 7612-7621. For steric reasons, the TMG group of PA30 may not 
bind to DNA, decreasing productive enthalpic interactions compared to PA1 
and PA31. Footprinting differences are supported by affinity cleavage (AC) 
results.
21 
  Patterns generated by PA1-, PA30- and PA31-EDTA conjugates are 
given in Figure 4D. For PA1 and PA31 there are two binding events, each 
corresponding to a distinct AC pattern, agreeing with DNase I data that both 
PAs bind at both available single-mismatch sites, (i) and (ii). 
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Figure 3.4.  (A) Binding sites for PA1, PA30, and PA31 from a section of HPV18 LCR 
corresponding to 7600-7620 as determined by capillary electrophoresis, DNase I 
footprinting and AC. The relative heights above the DNA sequence correspond to observed 
AC intensities. The remaining panels show the top strand of ten more base pairs than panel A, 
7600–7630. Representative electropherograms showing the top strand for (B) DNase I 
footprinting controls (0 nM PA), (C) DNase I-protected regions upon the addition of 5 nM of 
PA and (D) AC patterns at 50 nM PA. The red line below each plot corresponds to the DNA 
sequence shown in panel (A). The 
*
 and 
† 
symbols mark nt 7606 and 7619. Arrows inside the 
plots show the PA binding direction, with the arrowhead in the position of the PA tail. PA 
building blocks as defined in Fig. 1; TMG and Guan groups are open and filled triangles. 
 
  However, an extra AC pattern was observed for PA31 corresponding to 
the double mismatch site (iii). Conversely, only one of the predicted single-
mismatch sites is occupied by PA30: a single AC pattern corresponding to site 
(i) was observed. The AC pattern for site (ii) did not appear even upon 
increasing the concentration of PA30 from 50 nM to 200 nM (data not shown). 
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 Our results with these 14-ring PAs agree with previous 8-ring PAs studies 
reporting that substitution at the N-terminal imidazole can modulate orientation 
and DNA-binding preferences of hairpin polyamides.
22 
 
 
3.5 Conclusions  
 
  In summary, we show that N-terminal substitution of anti-HPV 
polyamide PA1 improves antiviral activity against the two most high-risk HPV 
types that are most prevalent (HPV16 and -18). N-terminal substitution with 
TMG leads to improvement in anti-HPV activity (IC50) against HPV18. N-
terminal substitution with guanidinium itself enhanced anti-HPV activity even 
further relative to PA1 by decreasing IC50 against HPV18 and IC90 for both 
HPV16 and 18. For antiviral agents in general, a dosage above IC90 decreases 
viral load, the magnitude, and frequency of viral rebound,
23
 and the probability 
of viral mutation, so improvements in IC90 are significant for therapy, as they 
are for EC90.
24
  
  Although the dissociation constants for the reported PAs are similar and 
cannot account for the differences in antiviral activity, differences in PA-DNA 
binding distribution were observed: PA31 binds more sites on the LCR of 
HPV18 than PA1 or PA30. Binding kinetics may be more important for 
activity
25
 and remain under investigation. Polyamide uptake is also under 
investigation. We note that PA1 and its analogs PA30 and PA31 are among the 
smallest molecule in a library of 75+ active compounds that reach nearly twice 
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the molecular weight of PA1. We have also prepared a series of compounds 
based on the highly-active PA25 and other active series, and they will be 
described subsequently. PA25 was our second preclinical lead because of its 
IC50/IC90 data (μM) as follows: HPV16, 0.036/0.35; HPV18, 0.056/1.5; 
HPV31, 0.030/0.51.
9,26
 The first biophysical studies of PA25 were reported 
recently.
18b 
However, PA25 is a more difficult synthetic and purification 
challenge than PA1 and its derivatives, though we have scaled up both PA1 and 
PA25 to 10 g, and the cost-of-goods is much higher for the 20-ring PA25 than 
the 14-ring PA1, so we were interested to see if modifications to PA1 could 
increase its activity significantly. That goal was successful with PA31.  
  Long hairpin polyamides of this general class function by a novel 
polyamide mechanism that invokes the host DNA Damage Response to destroy 
the viral genome.
8,10
 Their activity is not limited to HPV but is also found for 
other small, double-stranded DNA tumour viruses, including polyomaviruses.
26 
This mechanism is unrelated to any prior polyamide literature that we can 
determine, even though our work was initially inspired by early PA research. 
PA30/31 represent an improved class of long polyamide that invokes this new 
mechanism to combat cancer-causing HPV. More recently, Dervan has reported 
a similar, non-sequence-specific, polyamide-induced DNA Damage 
Response.
27
 
Why might this nonspecific binding, or poorly-specific binding, be so 
relevant? We have come to hypothesize and are performing experiments to test the 
idea, that the interaction of large polyamides with small, circular, double-stranded 
DNA genomes is biologically important more from physical than chemical reasons. 
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Hydrogen bonding does go on in the minor groove, albeit at moderate selectivity, but 
of great importance is the binding of many hundreds or more of rigid, crescent-shaped 
molecules to supercoiled DNA targets. This must result in considerable strain on the 
supercoiled viral genomes, and could in the most extreme case result in single-
stranded DNA regions appearing, which would be rapidly noticed and acted upon by 
the DNA Damage Response machinery. However, the process may be simpler: the 
dsDNA viruses evolved to use parts of the DDR for their life cycles but otherwise to 
hide, to avoid having their genomes recognized as foreign or damaged in any way. 
When the supercoiled genomes are distorted by the effect of many bound polyamides, 
and 50% of HPV DNA is bound by active polyamides, at least for the linearized 
pieces we have reported on to date,
18,9c
 the viral genome may no longer remain 
hidden. The strain imposed by all of the bound polyamides may change the shape 
enough so that the DDR naturally notices unwanted additions to the chromatin and is 
automatically activated. Support for this hypothesis is found in our recently published 
patent application, where, as mentioned above, we showed that the same polyamides 
active against HPV are also active against three polyomaviruses having little in 
common with HPV except a small, dsDNA genome that is supercoiled.
26
 The DNA 
Damage Response is also activated for these disparate viruses.  
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3.8 Supporting Information 
Figure SI 3.1. Dose‐response curves for PA1 against HPV16 and 31 from which IC50 
and IC90 values were determined. (A) Results for HPV16 and 31 with cell toxicity data. 
(B) Expanded detail of results for HPV16, plotted as the inverse of the other results (as the 
percent decrease of viral DNA vs. control, 
reaching 100% decrease at maximum efficacy, instead of the simple decrease in DNA vs. 
control). 
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Figure SI 3.2a. Map of NV1115 binding sites on HPV18 7479-7563  
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Figure SI 3.2b. Map of NV1128 binding sites on HPV18 7479-7563 
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Table SI 3.1. Kd values determined for NV1115 on HPV 7479-7783 (Kd values for 
NV1028 are reported in the supplementary material in Chapter 1). 
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Figure SI 3.3. Representative isotherms of NV1115 binding on HPV18 7479-7783 
Site 7563 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Site 7616 
 
 
 
 
 
 
 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 10 12
FAM 79, 200 pM DNA, nt. 7563, Set. 2
F
ra
c
ti
o
n
 B
o
u
n
d
PA (nM)
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.067111.0327m1 
0.155771.588m2 
NA0.0075321Chisq
NA0.99552R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.145360.79013m1 
0.0654961.1706m2 
NA0.013949Chisq
NA0.99169R
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 10 12
FAM 79, 200 pM DNA, nt. 7563, Set. 4
F
ra
c
ti
o
n
 B
o
u
n
d
PA (nM)
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0556331.1744m1 
0.0850361.3473m2 
NA0.0034943Chisq
NA0.99801R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.119981.07m1 
0.028521.0718m2 
NA0.0075247Chisq
NA0.99572R
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 10 12
FAM 79, 200 pM DNA, nt. 7563, Set.5
F
ra
c
ti
o
n
 B
o
u
n
d
PA (nM)
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0252630.87675m1 
0.0640141.5307m2 
NA0.0018202Chisq
NA0.99905R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.108740.73928m1 
0.0442051.1129m2 
NA0.013985Chisq
NA0.99269R
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 10 12
FAM 130, 200 pM DNA, nt. 7616, Set. 3
F
ra
c
ti
o
n
 B
o
u
n
d
PA (nM)
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0327711.098m1 
0.0825571.718m2 
NA0.0020577Chisq
NA0.99895R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.190790.98928m1 
0.0521961.1087m2 
NA0.023954Chisq
NA0.98771R
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 10 12
FAM 130, 200 pM DNA, nt. 7616, Set. 4
F
ra
c
ti
o
n
 B
o
u
n
d
PA (nM)
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.124851.1604m1 
0.336951.8287m2 
NA0.028336Chisq
NA0.98619R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.291441.062m1 
0.0736471.1278m2 
NA0.049936Chisq
NA0.97554R
 
103 
 
 
 
 
 
 
 
 
 
 
 
Site 7610 
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 10 12
FAM 130.6, 200 pM DNA, nt. 7613, Set.1
F
ra
c
ti
o
n
 B
o
u
n
d
PA (nM)
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0301380.85394m1 
0.180212.4602m2 
NA0.0038315Chisq
NA0.99825R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.216880.55585m1 
0.176241.3014m2 
NA0.067913Chisq
NA0.96842R
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 10 12
FAM 127, 200 pM DNA, nt. 7610, Set. 1
F
ra
c
ti
o
n
 B
o
u
n
d
PA (nM)
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0143170.97206m1 
0.0676192.2908m2 
NA0.00060718Chisq
NA0.9997R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.225650.6797m1 
0.13361.2497m2 
NA0.049361Chisq
NA0.97558R
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 10 12
FAM 127, 200 pM DNA, nt. 7610, Set. 2
F
ra
c
ti
o
n
 B
o
u
n
d
Pa (nM)
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.01661.0034m1 
0.0454832.1424m2 
NA0.00025291Chisq
NA0.99987R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.294780.74382m1 
0.135811.2226m2 
NA0.038592Chisq
NA0.97975R
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 10 12
FAM  127, 200 pM DNA, nt. 7610, Set. 3
F
ra
c
ti
o
n
 B
o
u
n
d
PA (nM)
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0214811.0862m1 
0.095652.1636m2 
NA0.00084821Chisq
NA0.99959R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.257590.88589m1 
0.0774181.1243m2 
NA0.040508Chisq
NA0.98024R
104 
 
 
 
 
 
 
 
 
CHAPTER 4 
SOLUBILITY AND CELL UPTAKE STUDIES OF GUAN- AND TMG-
SUBSTITUTED PYRROLE-IMIDAZOLE POLYAMIDES 
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4.1 Abstract 
 
Our group has previously reported that substitution at the polyamide N-terminus 
with a guanidinium (Guan) or tetramethylguanidiunium (TMG) group can positively 
affect antiviral activity against Human Papillomavirus (HPV). Since a guanidinium 
moiety has often been used to enhance cellular uptake and solubility of biomolecules, 
here we investigate the effect of this motif on polyamide solubility and cellular uptake in 
HPV-infected keratinocytes.  
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4.2 Introduction 
 
Minor groove binders represent a class of agents with disparate potential 
applications, spanning from biotechnology to clinic (e.g. DNA detection, antitumor and 
antimicrobial activity, gene expression modulation, etc.).
1-4
 In order to be functional, 
however, their ability to permeate the cell membrane and reach the nucleus to interact 
with the DNA are of primary importance. Compared to other minor groove binders, 
pyrrole-imidazole polyamides do not need a carrier to be delivered into cells, but instead 
have the peculiarity to easily access many live cells despite their high molecular weight 
(although the entrance mechanism has not yet been fully understood).  
Uptake studies have been undertaken by other groups,
5-7
 mainly to elucidate the 
relationship between polyamide structure and cell accessibility. The outcomes of these 
studies have shown that polyamide uptake is cell-line dependent and that the N-
methylimidazole position and β-alanine content may affect cellular permeability.8,9 While 
some studies reported a correlation between uptake and molecular size,
10
 no dependency 
on polyamide length has been found in other studies.
5
 Furthermore small polyamides can 
accumulate in cytoplasmic vesicles, a process dependent on polyamide charge.
6
 
Nevertheless an exhaustive structure-cell permeability correlation was not deduced and 
rather uptake appears to be very complex and not easily predictable. 
The techniques employed so far to evaluate cell uptake include confocal 
microscopy, flow cytometry and cell-based reporter assays.
5,7
 Fluorescence microscopy 
and flow cytometry require the conjugation of a dye, normally to the C-terminus of the 
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polyamide (or less frequently to other positions), which reportedly influences the 
mechanisms of transport and accumulation inside cells. Furthermore, labeling of large 
polyamides with a dye has been hindered by solubility issues (our research group, 
unpublished data). Cell-based reporter assays or PCR-based assays overcome these 
limitations but polyamide quantification is based on indirect measurements that may not 
correlate linearly with concentration.  
Here we investigate the cellular uptake of large polyamides in live cells by means 
of High Pressure Liquid Chromatography (HPLC), which provides a direct approach to 
quantify intracellular polyamide concentration and does not require structure alteration of 
the analyte. Specifically, we aim to study the uptake of guanidine- (PA31) or TMG- 
(PA30) substituted polyamides (Figure 4.1) which have been previously reported to have 
greater anti-HPV activity compared to their unsubstituted analog (PA1).
11
 Given the 
known use of the guanidinium moiety to facilitate the cellular delivery of peptides and 
drugs,
12,13
 we aim to evaluate the effect of this substitution on polyamides cell 
permeability and solubility. 
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Figure 4.1. PA, PA30 and PA31 Chemical Structures
11
 
 
 
4.3 Methods 
 
4.3.1 Materials  
Dimethyl sulfoxide (DMSO), acetonitrile (ACN) dimethylformamide (DMF), 
culture dishes, insulin, hydrocortisone, adenine, transferrin, penicillin-streptomycin, 
cholera toxin, 3′,5-triiodo-L-thyronine sodium salt, Hepes and Tris·HCl (pH 7.5) buffers 
were purchased from Sigma Aldrich (St. Louis, MO). Mitomycin-C, Epidermal Grow 
Factor, Dulbecco’s modified Eagle medium, Ham’s Nutrient Mixture F-12 (F12), 
Hoechst
®
 33342, trypsin, were obtained from Thermo Fisher Scientific (Waltham, MA). 
Phosphate Buffer Saline (PBS) was purchased from GE-Healthcare Bio-
Sciences (Pittsburgh, PA). 
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4.3.2 Cell Culture 
J2-3T3 fibroblasts and W12E keratinocytes were a kind gift of the Paul Lambert 
lab at The University of Wisconsin, Madison Medical School. 
The embryonic mouse fibroblasts J2-3T3, used as feeder cells for the 
keratinocytes, were maintained in Dulbecco’s modified Eagle medium (DMEM), 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cells 
were incubated at 37 ˚C in a 5% CO2 incubator and passaged at 70-80% confluence. 
W12E cells, cervical keratinocytes harboring HPV16 episomes (~ 300-500 
copies/cells), were cultured in Dulbecco’s modified Eagle medium (DMEM)/ Ham’s 
Nutrient Mixture F-12 (F12) supplemented with 5% fetal bovine serum (FBS), 5 µg/mL 
insulin, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.4 µg/mL hydrocortisone, 10 
ng/mL cholera toxin, 20 pM 3,3’,5-triiodo-thyronine (T3), 5 µg/mL transferrin, 24 µg/mL 
adenine and 5 ng/mL epidermal grow factor (EGF). Cells were cultured on top of 
mitomycin-C (Mit-C) treated 3T3 cells and grown at 37 ˚C in a 5% CO2 incubator 
(Figure 4.2). Cells used for 24 h uptake experiments were from passage 14 through 16. 
 
 
 
 
 
 
 
Figure 4.2. (A) 3T3 fibroblasts and (B) W12E keratinocytes cell cultures 
(A) (B) 
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4.3.3 Uptake Experiments 
W12E cells were seeded onto 6-well culture dishes at a density of ~ 5x10
4
 
cells/well on top of Myt-C treated fibroblasts and grown until reaching ~ 50% 
confluence. Lyophilized polyamide was dissolved in DMSO at a 4 mM concentration and 
further diluted to 0.4 mM in MQH2O. Cells were incubated with polyamide diluted in 
fresh cell medium at a final concentration of 2.5 µM and 0.1% DMSO and incubated for 
24 h. Following medium removal, cells were washed twice with phosphate buffer saline 
(PBS) and once with 0.02 % EDTA/PBS for 30 seconds.  After 10 minutes incubation 
with 0.02 % EDTA/PBS at 37 ˚C to remove 3T3 fibroblasts, W12E were harvested by 
trypsinization and counted using a Nexcelom Bioscience Cellometer Auto T4 instrument. 
Cells were collected by centrifugation at 500 g for 5 min and polyamides extracted by 
treating the cell pellet with DMF. The solution was incubated for 20 min with frequent 
vortexing at high speed. The sample was then centrifuged at 16000 g for 20 min and the 
supernatant filtered with a 0.2 µM polytetrafluoroethylene (PTFE) filter and analyzed by 
HPLC. 
All experiments were performed in triplicate and PA concentration determined 
based on comparison to standard curves. Total cellular uptake was normalized to cell 
number. 
 
4.3.4 Active and Passive Uptake Studies 
Active and passive uptake experiments were performed by incubating W12E cells 
with polyamides at different temperatures for 2 h. Cells were cultured in cell medium 
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n200 300 400 500 nm 
supplemented with 20 mM Hepes at 4 ˚C to evaluate passive uptake or at 37 ˚C to 
evaluate both passive an active transport. After 2 h, the cells were treated as described in 
section 4.3.3. 
 
4.3.5 Hoechst Treatment 
A 1:2000 Hoechst
®
 33342 solution in cell medium was prepared by adding 1 µL 
of Hoechst (16 mM) to 1999 µL cell medium. This solution was added to the W12E cells 
and incubated for 30 minutes. Medium was removed and saved for analysis while the 
cells were treated as described in section 
4.3.3 to extract and quantify the dye. A 
portion of the cell medium (200 µL) was 
mixed with 200 µL of ACN to 
precipitate  proteins, centrifuged at 
16000 g for 20 min and the supernatant 
analyzed by HPLC. A representative 
chromatogram showing the Hoechst dye 
peak (2.14 min) is reported in Figure 4.3. Both the medium and the cell dye 
concentrations were compared to standards made in the same conditions.  
Figure 4.4. HPLC trace of Hoechst in W12E 
cells. 
 
Figure 3.4. HPLC-DAD data for peak at 2.142 min; 
absorbance at 350 nm corresponds to the Hoechst 
maximum absorbance 
nm 
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4.3.6 HPLC Conditions and Calibration Curves 
Chromatography was performed using a Jupiter Proteo (C12) column (90 Å pore 
size, 4 µm particle size, 4.6 x 50 mm, Phenomenex, Torrance, CA, USA) at 40 ˚C. 
Mobile phase consisted of 100 % acetonitrile (Solvent B) and 0.1% formic acid in water 
(Solvent A) and the gradient was as follow: 5% B (0-3 min, 2.0 mL/min), 60% B (4 min, 
2.0 mL/min), 60% B (4.25 min, 2.0 mL/min), 5% B (5.5 min, 2.0 mL/min), and 5% B 
(6.5 min, 2.0 mL/min). Flow rate was maintained at 2.0 mL/min and total run was 6.5 
min. Detection wavelength was 300.8 nm and injection volume was 20 µL. Data were 
processed with Agilent ChemStation software.   
Calibration curve samples (Figure 4.6) were prepared in DMF after finding that 
measurement of polyamide concentration in DMF alone or in a W12E cell lysate was 
comparable by HPLC (to within a tolerance of 5%). Standards were made at 5.00, 10.0, 
20.0, 40.0 µM polyamide concentration using DMSO stocks at 1.00, 2.50, 4.00 mM.   
 
Figure 4.5. W12E nuclei stained with Hoechst
®
 33342 (A) Hoechst 
fluorescence; (B) overlap of bright and fluorescence field images. 
(A) (B) 
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Figure 4.6. HPLC calibration standards for (A) PA1, (B) PA30 and (C) 
PA31. Each calibration was done in triplicate. 
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4.3.7 Solubility Assay 
Polyamide stock solutions (4 mM) were prepared in DMSO using single-use 0.1 
mg lyophilized aliquots. Work solutions were made by adding 0.5 µL of polyamide to 
500 µL of the desired solvent. Samples were analyzed before and after centrifugation 
(16000 g, 20 min) by measuring the absorbance at 304 nm with an UV-Vis spectrometry 
(Thermo Scientific Evolution 260 BIO UV spectrophotometer). Molar extinction 
coefficients (ɛ) were 88,235 M-1cm-1 for PA1, 91,557 M-1cm-1 for PA30 and 89,263 M-
1
cm
-1 
for PA31.
11
 
 
4.4 Results and Discussion 
 
4.4.1 Solubility Studies 
The guanidine group has often been employed to improve drugs and peptides 
solubility
12,14,15
 especially in aqueous environment; therefore we investigated the 
solubility properties of these compounds in physiologically relevant solvents. The 
solubility was determined by measuring the concentration of each polyamide at a final 
concentration of 4 µM in H2O, Phosphate buffer saline (PBS) and Tris·HCl buffer by 
UV-Vis spectroscopy. Absorbance was measured before and after a centrifugation step 
intended to remove aggregates. 
In H2O, all three polyamides (PAs) exhibit high solubility, but incorporation of a 
Guan group leads to a greater solubility than for TMG or the parent PA. Upon 
centrifugation, the concentrations of PA1 and PA31 remain more or less unchanged, 
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indicating that not many aggregates are formed, while for PA30 a slightly decrease in 
concentration was observed after centrifugation. Overall, the guanidinylated PA shows a 
better solubility in H2O than the other two PA investigated. In PBS, the solubility was 
somehow lower than in water for all PAs and further decreased upon centrifugation, 
showing that probably some of the compound may be in the aggregated form. 
Interestingly, PA30 shows the highest solubility. A similar result was observed in Tris, 
where the TMG displays a greater solubility before centrifugation, and especially after 
centrifugation.  
Pyrrole-imidazole polyamides solubility studies have been also undertaken at 
Caltech by Peter Dervan
16
 with the goal of investigating the solubility of several short 
polyamides in PBS. The outcomes of these studies have shown that although chemical 
modifications such acetylation could slightly increase polyamide solubility, overall none 
of the polyamide analyzed was fully soluble in PBS, reaching a concentration below 50 
% of the maximum estimated concentration. An improvement in polyamide solubility 
was achieved only upon addition of formulating agents such as cyclodextrins and other 
carbohydrate-based solubilizing agents.  Similarly, the Sugiyama’s lab has reported the 
poor solubility of polyamides in Milli-Q H2O and a solubility improvement afforded by 
polyamide PEGylation or liposome incorporation.
17,18
 
In summary, here we show that all the analyzed polyamides show good solubility 
properties when diluted in Milli–Q water.  In particular, the guanidinylated substitution 
improves the solubility compared to the other analogs. In buffers, all the three 
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compounds show lower solubility than in H2O upon centrifugation; surprisingly the TMG 
analog shows the highest solubility. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              Figure 4.7 Polyamides solubility in (A) H2O, (B) PBS and (C) Tris 
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4.4.2 Cellular uptake in W12 keratinocytes 
Polyamide uptake was examined in W12E cells, cervical keratinocytes harboring 
the HPV genome in an extra-chromosomal form. Antiviral assays performed in these 
cells have previously shown that PA1, PA30 and PA31 are able to reduce the viral DNA 
load, with IC50 (polyamide concentration required to reduce viral DNA to 50 %)  and IC90 
(polyamide concentration required to eliminate 90 % of viral DNA) values in the 
nanomolar range.
11
 Although all three PAs show good antiviral properties, the TMG and 
especially the Guan analog exhibit improved antiviral activity. Therefore we investigated 
how the substitution with a Guan or TMG group affects PA cellular uptake, using High 
Pressure Liquid Chromatography (HPLC). This study was followed up by HPLC/MS and 
HPLC/MS/MS studies as described in the following Chapter. 
We first employed this method to detect the uptake of Hoechst
®
 33342 in W12E, 
a compound known to permeate cell membranes easily.
19,20
  After 30 minutes incubation, 
the dye is already detected in the nucleus as shown by confocal microscopy in Figure 
4.5. The response determined in both cell culture media and cell pellets was compared to 
standards prepared under the same conditions and reported in Table 4.1.  
The amount of dye used to treat the cells was equal to 7.22 µg and the amount of dye 
found was 7.42 µg. 
 
 STANDARD  SAMPLE 
Peak Area in Media  34.37 27.81 
Peak Area in Cells 393.0 85.93 
% Recovered 102.8 % 
Table 4.1. Hoechst amount in cell pellet and medium 
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Next, W12E cells were incubated with PAs at 2.5 µM for 24 h and the 
concentration of cell-associated PA was determined by HPLC by comparing the response 
with that obtained from standard curves. The results were then normalized to cell 
number. Polyamide was not detected in untreated cells or after 30 minutes of treatment 
(at least for PA1), but it was detected after 2 h.  As shown in Figure 4.9, the amount of 
polyamide associated with cells after 24 h incubation was greater for PA31 and PA30 
than PA1. The uptake increase from 2 hours to 24 h for all three PAs is shown in Figure 
4.10. For PA1, the amount accumulated at 2 h was already comparable to that at 24 h. 
We also analyzed the uptake of a small polyamide, PA11, which was previously 
reported to be inactive and unable to decrease levels of HPV-episomes from infected 
cells.
21
 The chemical structure is showed in Figure 4.8. 
 
Figure 4.8. PA11 Chemical Structure 
 Surprisingly, almost no polyamide was detected in cells (less than 1 %), and 
instead, the bulk of it remained in the medium after 24 h. Pre-treatment of W12E cells 
with Verapamil (30, 100, 200 µM), a multi drug resistant inhibitor, did not have any 
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           Figure 4.9. Uptake of PA1, PA30 and PA31 in W12E cells after 24 h (P < 0.05) 
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Figure 4.10. Uptake in W12E at 2h and 24h 
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4.4.3 Characterization of passive and active transport  
Next, we wanted to evaluate if the tested polyamides are transported inside the 
cells by passive uptake or by an energy-dependent process. Previous studies suggest that 
uptake may be energy dependent,
22
 but the general mode of uptake remains elusive. 
Although both active and passive pathways are affected by temperature variations, active 
transport is reduced more significantly than passive transport at temperatures below 22 ˚C 
and blocked at 4 ˚C.23,24 
We investigated PA uptake in keratinocytes after 2 h incubation at 37 ˚C and 4 ˚C.  
Figure 10 shows that for all three PAs a more or less pronounced decrease in uptake is 
observed at 4 ˚C relative to 37 ˚C. The major change was observed for PA30 with a ~ 81 
% decrease, followed by PA31 and PA1.  These data are in line with few reports 
indicating that an energy-dependent transport may be the primary mechanism of 
polyamide uptake
22
. It would be interesting to evaluate the effect of endocytosis 
inhibitors on polyamide uptake to confirm these results, since also passive uptake may be 
affected by temperature changes, although to a lesser extent.  
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4.5 Conclusions 
 
This study aimed at investigating the uptake and solubility properties of a series 
of polyamides known to have antiviral properties but differing in their potency.  
Overall the three analyzed polyamides show noteworthy high solubility in H2O 
without the aid of solubilizing agents, with the TMG and Guan analogs displaying a 
greater solubility than the unsubstituted analog. In buffers, a more pronounced 
aggregation takes place as expected, and the TMG analog displays the better solubility. 
Uptake studies show that PAs are detected in cultured cells after about 2 h and a 
greater amount of PA seems to be associated with the cells in the case of the TMG and 
Guan analogs after 24 h incubation. The transport seems to be energy-dependent since a 
remarkable decrease in uptake was observed for the Guan and TMG PAs, and a less 
extensive decrease for PA1. Interestingly, negligible uptake was observed for PA11, a 
small inactive polyamide. It would be of interest in the future to extend the uptake studies 
on other small inactive PAs and evaluate nuclear drug localization as well as the effect of 
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Figure 4.11. PA1 (A), PA30 (B) and PA31 (C) uptake in W12E at 37 ˚C and 4 ˚C after 2 h 
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endocytosis blocking agents on uptake to gain insights on the polyamide mechanism of 
transport. 
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CHAPTER 5 
 LC-MS/MS UPTAKE AND SOLUBILITY STUDIES OF TWO DIFFERENT 
PYRROLE-IMIDAZOLE POLYAMIDE SALTS 
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5.1 Abstract 
 
A Liquid Chromatography - Tandem Mass Spectrometry (LC-MS/MS) method 
was developed to determine pyrrole-imidazole polyamide uptake in cells cultures. This 
method was used to evaluate the cellular internalization in W12E keratinocytes of PA1 
and PA1F, two polyamides sharing the same chemical structure but paired with different 
counterions. The substitution results in a difference between the two polyamides in terms 
of antiviral efficacy against three HPV strains, with PA1F showing higher efficacy. 
Solubility studies were also undertaken to determine the effect of the different 
counterion. 
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5.2 Introduction 
 
Antiviral assays in cervical keratinocytes (W12E) have shown that large pyrrole-
imidazole polyamides, chemical agents used mostly to modulate gene expression, can 
elicit the elimination of viral DNA from infected cells and therefore have the potential to 
be used as antiviral agents.
1-3
 Their activity is manifested against different viruses,
4
 
including Human Papillomavirus (HPV). 
PA1, a twelve ring compound paired with a trifluoroacetate (TFA) counterion, is 
one of the first compounds reported by our group to show antiviral efficacy.
1
 A simple 
counterion substitution, from a TFA to the formate anion, leads to PA1F, which exhibits 
higher potency against three oncogenic HPV strains (unpublished data from T.G. 
Edwards, C. Fisher, NanoVir, LLC). The chemical structures of these compounds are 
shown in Figure 5.1. The concentrations of polyamides that induce 50% (IC50) or 90% 
(IC90) decrease in viral DNA are reported in Table 5.1 for HPV16 and show that both 
values are more than three-fold lower for the formic analog. A better activity was also 
observed for other two oncogenic HPV strains (data not shown). Pairing a drug with 
different counterions is a common strategy in preformulation studies to improve the 
physicochemical or biopharmaceutical properties of the parent compound.
5,6
 Very often, 
different salt forms are used specifically to overcome solubility issues in aqueous 
environments while avoiding major changes in structure.
7
  
Here, we investigate the effect of the counterion on aqueous solubility and on 
cellular uptake in keratinocyte monolayers. With this aim we developed a novel Liquid 
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Chromatography - Tandem Mass Spectrometry method to quantitate the concentration of 
polyamides in W12E cells. This method provides the advantage of keeping the polyamide 
structure unaltered, while other methods previously used to study polyamide cellular 
uptake such as confocal microscopy or flow cytometry require labeling, which may alter 
the compound permeability. Furthermore, the coupling of mass spectrometry with 
chromatography provides the advantage of greatly increased sensitivity vs. HPLC alone, 
as well as high specificity and confidence in the analysis using a minimal amount of 
compound.
8,9
 Solubility studies were performed using UV-Vis Spectroscopy as before 
(Chapter 4). 
 
 
 
 
Polyamide HPV16 IC50 [µM] HPV16 IC90 [µM] 
PA1 0.100 ± 0.015 1.113 ± 0.627 
PA1F 0.026 ± 0.004 0.299 ± 0.082 
Table 5.1. Antiviral activity of PA1 and PA1F against HPV 
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                 Figure 5.1. Polyamides (A) PA1 and (B) PA1F chemical structures 
 
5.3 Methods 
 
5.3.1 Materials  
Dimethyl sulfoxide (DMSO), acetonitrile (ACN), dimethylformamide (DMF), 
HPLC grade water, culture dishes, insulin, hydrocortisone, adenine, transferrin, 
penicillin-streptomycin, cholera toxin, 3′,5-triiodo-L-thyronine sodium salt, HEPES, and 
Tris·HCl buffers were purchased from Sigma Aldrich (St. Louis, MO). Mitomycin-C, 
Epidermal Growth Factor, Dulbecco’s modified Eagle medium, Ham’s Nutrient Mixture 
(A) 
(B) 
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F-12 (F12), and trypsin, were obtained from Thermo Fisher Scientific (Waltham, MA). 
Phosphate Buffer Saline (PBS) was purchased from GE-Healthcare Bio-
Sciences (Pittsburgh, PA). 
  
5.3.2 Cell Culture 
J2-3T3 fibroblasts and W12E keratinocytes were a kind gift of Paul Lambert lab 
at The University of Wisconsin, Madison. The embryonic mouse fibroblasts J2-3T3, used 
as feeder cells for the keratinocytes, were maintained in Dulbecco’s modified Eagle 
medium (DMEM), supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin. Cells were incubated at 37 ˚C in a 5% CO2 incubator and 
passaged at 70% confluence. 
W12E cells, cervical keratinocytes harboring HPV16 episomes (~ 300-500 
copies/cells), were cultured in Dulbecco’s modified Eagle medium DMEM/F12 
supplemented with 5% fetal bovine serum (FBS), 5 µg/mL insulin, 100 U/mL penicillin, 
100 µg/mL streptomycin, 0.4 µg/mL hydrocortisone, 10 ng/mL cholera toxin, 20 pM 
3,3’,5-triiodo-thyronine (T3), 5 µg/mL transferrin, 24 µg/mL adenine and 5 ng/mL 
epidermal grow factor (EGF). Cells were cultured on top of mitomycin-C treated 3T3 
cells and grown at 37 ˚C in a 5% CO2 incubator. Cells used for 24 h uptake experiments 
were from passage 10 throught 14. 
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5.3.3 Uptake Experiment and Sample Preparation 
W12E cells were seeded onto 6-well culture dishes at a density of ~5x10
4
 
cells/well on top of Myt-C treated fibroblasts and grown until reaching ~50% confluence. 
Lyophilized polyamide was dissolved in DMSO at a 4 mM concentration and further 
diluted to 0.4 mM in Milli-Q H2O. Cells were incubated with polyamide diluted in fresh 
cell medium at a final concentration of 2.5 µM and 0.1% DMSO and incubated for 24 h. 
Following medium removal, cells were washed twice with phosphate buffer saline (PBS) 
and once with 0.02 % EDTA/PBS for 30 seconds.  After 10 minutes incubation with 0.02 
% EDTA/PBS at 37 ˚C to remove 3T3 fibroblasts, W12E were harvested by 
trypsinization and counted using a Nexcelom Bioscience Cellometer Auto T4 instrument. 
Cells were collected by centrifugation at 500 g for 5 minutes and polyamides extracted by 
treating the cell pellet with a DMF solution containing the internal standard at a 5 µg/ml 
concentration. The mixture was incubated for 20 minutes and subjected to frequent 
vortexing at high speed. The sample was then centrifuged at 16000 g for 20 minutes and 
the supernatant filtered with a 0.2 µm polytetrafluoroethylene (PTFE) filter (Xpertek, 
Cobert Associates Lab Store, St. Louis) and analyzed by LC-MS/MS. All experiments 
were performed at least in triplicate. 
 
5.3.4 Chromatography and Mass Spectrometry Conditions  
Chromatography was performed on a Dionex Ultima 3000 µHPLC system using a 
Zorbax Eclipse Plus C18 column (95 Å pore size, 1.8 µm particle size, 2.1 x 50 mm), 
Phenomenex, Torrance, CA, USA) maintained at 40 ˚C. Mobile phase consisted of 100 % 
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acetonitrile (Solvent B) and 0.1% formic acid in water (Solvent A) and the gradient 
consisted of 5% ACN followed by a ramp to 65 % ACN over 6 minutes.  
Flow rate was maintained at 0.50 mL/min and total run time was 15 min. Masses 
were acquired on a Bruker MaXis plus quadrupole time-of-flight mass spectrometer 
using positive mode electro-spray ionization (ESI). The following settings were used for 
the analysis: the source temperature was 250 °C, capillary voltage was 3500 V, collision 
energy was 25 eV and N2 gas flow was 12 L/min. 
The mass spectrometer was operated in the multiple reaction monitoring mode (MRM) 
and quantitation was performed using the total ion abundance generated from the 
fragmentation of the [M+3H]
3+
 parent ion. Data were analyzed using Bruker Daltonik 
Data Analysis software.    
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5.3.5 Stock Solution Preparation 
Stock solutions of PA1 and PA1F (0.5 mg/ml) were prepared by dissolving a fresh 
lyophilized aliquot of polyamide (0.1 mg) in 200 µl DMF. The stock solution of Internal 
Standard (IS) PA57 (1 mg/ml) was prepared by dissolving a lyophilized 0.1 mg aliquot in 
100 µL of DMSO. Analyte working solutions were made by further diluting each stock 
with DMF at the desired concentration. 
 
5.3.6 Calibration Standards 
Calibration curves were prepared fresh for each run by adding the appropriate 
working solution of analyte and internal standard to a W12E cell pellet previously treated 
with DMF, centrifuged at 16000 g for 20 minutes and filtered through a 0.2 µm PTFE 
filter (see section 5.3.3). Standards were made at concentrations of 0.5, 1, 5, 10, 17.5, 25, 
35, 50 µg/ml analyte and 5 µg/ml IS. Quality control samples (QC) were made in the 
same conditions at 2 (low), 15 (medium), 45 (high) µg/ml concentrations. 
 
5.3.7 Solubility Assay 
Polyamide stock solutions (4 mM) were prepared in DMSO using single-use 0.1 
mg lyophilized aliquots. Working solutions were made by adding 0.5 µL of polyamide to 
500 µL of the desired solvent. Samples were analyzed before and after centrifugation 
(16000 g, 20 min) by measuring the absorbance at 304 nm with an UV-Vis spectrometry 
(Thermo Scientific Evolution 260 BIO UV spectrophotometer). The molar extinction 
coefficient (ɛ) used was 88,235 M-1cm-1.3 
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5.4 Results and Discussion 
 
5.4.1 LC/MS/MS Analysis 
For these studies, the internal Standard (IS) was the demethylated version of the 
analyte PA1, i.e. demethylated at both nitrogen atoms on the C-terminal (Figure 5.3). 
Both compounds eluted at 3.9 min. Representative MS spectra are showed in Figure 5.4 
with the observed ions being [M+2H]
2+
, [M+3H]
3+ 
and [M+4H]
4+  
. The triply charged 
ion [M+3H]
3+
 was the dominant form, therefore was chosen as the precursor ion for 
fragmentation. [M+3H]
3+
 ions were monitored at m/z 632.6 (PA1, PA1F)  and m/z 627.9 
(IS), while product ions were monitored at m/z 898.4 for PA1 and m/z 884.4 for IS. 
Relative concentrations were determined using the peak area ratio of the analyte over the 
IS of the total ion abundance and the MRM chromatogram is shown in Figure 5.5. 
   
 
                       Figure 5.3. Internal Standard Chemical Structure 
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Figure 5.4 Representative MS spectra of PA1 parent ions. 
 
 
 
 
 
 
 
 
 
Figure 5.5 Representative MRM chromatogram of PA1 (Peak 4) and IS (Peak 3) from cell-extracted 
samples. Inset shows an expansion of peaks 3 and 4. 
 
5.4.2 Selectivity 
Selectivity was examined by comparing a blank cell culture matrix sample and 
matrix treated with PA1. As observed in Figure 5.6 no peak interference was observed at 
the polyamide retention time.  
4 
3 
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Figure 5.6. Blank sample (cell extracts without added polyamides). No peak interference was 
observed at the PA retention time. 
 
 
5.4.3 Calibration Curves and Linearity 
The eight point standard curves for PA1 and PA1F were generated by plotting 
peak area ratios against concentration ratios of analyte over internal standard. Curves 
showed a linear response over the concentration range of 0.5 to 50 µg/ml analyte and 
representative calibration curves are showed in Figure 5.7. R
2
 values were 0.9983 and 
0.9982 for PA1 and PA1F respectively. 
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Figure 5.7. Representative calibration curves for (A) PA1 and (B) PA1F from triplicate 
experiments 
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5.4.4 Uptake Studies 
The LC-MS/MS method was employed to study the uptake of two long pyrrole-
imidazole antiviral polyamides, PA1 and PA1F.  The only structural difference between 
the two compounds is their counterion: PA1 was produced as a TFA salt while PA1F as a 
formate salt. PA1F was found to be three-fold more active than PA1 against HPV16 in 
antiviral assays. Therefore, the effect of counterion on uptake was evaluated in 
keratinocytes infected with HPV16 episomes. The percentages of polyamide associated 
with cells after 24 h were 51% (PA1) and 87% (PA1F) of the total amount used to treat 
the cells (55929 ng/ml and 50829 ng/ml) (Figure 5.8). In order to evaluate the 
relationship between uptake and PA concentration, cells were also incubated with 
different PA concentrations (0.5 µM, 6.5 µM) and, as expected, an increase in 
concentration is associated with an increase in polyamide uptake (Figure 5.9).  
 
 
 
                                        
 
 
 
 
 
 
Figure 5.8. PA1 and PA1F uptake in W12E cells after 24 h  
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Figure 5.9. Concentration Dependent Uptake 
 
5.4.5 Solubility Studies 
Since the two polyamides differ only for their counterion, their solubility was an 
obvious property to investigate. The solubility was determined by measuring the 
concentration of each polyamide at a final concentration of 4 µM in H2O, phosphate 
buffer saline (PBS) and Tris·HCl buffer by UV-Vis spectroscopy (Figure 5.10). 
Absorbance was measured before and after a centrifugation step intended to remove 
aggregates.  
In H2O, although both polyamides exhibited a good solubility, the formic salt 
analog showed a greater solubility after centrifugation (4.26±0.13 µM for PA1F, 
2.99±0.27 µM for PA1). In PBS (pH = 7.4) and Tris (pH = 7.5) buffers, the overall 
solubility of both compounds was reduced especially upon centrifugation, probably due 
to aggregation. While in PBS there was no appreciable difference between the two PAs, 
in Tris the formic salt analog showed a better solubility (1.73±0.39 µM for PA1F and 
0.73±0.09 µM for PA1). 
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Figure 5.10. Solubility of PA1 and PA1F in (A) H2O, (B) PBS and (C) Tris buffers 
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A major difference was however 
observed in their long term solubility. 
The solubility in DMSO was evaluated 
after one week from the stock preparation 
and analyzed as described above for the 
other solvents (Figure 5.11). In this case, 
the concentration of PA1F was almost 
double than PA1 and it was associated 
with a change in the UV-Vis spectrum 
profile, where a shoulder appears at 
~365 nm for PA1 but not for PA1F 
(Figure 5.12). Furthermore, analysis of 
the same samples by High Pressure 
Liquid Chromatography (HPLC) shows  
only a negligible peak for PA1 (2.8 
min), while the characteristic peak was 
observed for PA1F. The altered 
chromatogram and UV spectrum of PA1 may be due to chemical instability of PA1 or to 
a different aggregation state in solution. The long term stability of PA1F  may represent 
an advantage especially in terms of costs, since the high concentration stock may be 
utilized multiple times, as opposite as using a fresh aliquot for every experiment (Figure 
Figure 5.11. Solubility of PA1 and PA1F in DMSO 
after one week 
Figure 5.12. UV spectrum of PA1 and PA1F 
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5.13). Even after one month, the UV-Vis spectrum of PA1F and its HPLC trace were 
unaltered.  
 
 
5.5 Conclusion 
 
We developed an LC-MS/MS method to evaluate polyamide uptake in cell 
culture. We obtained a linear response within the concentration range of 0.5 to 50 µg/ml. 
The limit of quantification (LOQ) was 0.5 µg/ml, a fairly high value for standard 
LC/MS/MS methods. In fact, LOQ in the nano or picograms is usually obtained. 
However, the determined LOQ value was either lower or comparable to LOQ values 
determined by other groups for polyamides quantitation in plasma. The only method 
Figure 5.13. HPLC traces of (A) PA1 and (B) PA1F samples analyzed after one week of sample 
preparation 
(A) 
(B) 
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reporting a lower LOQ value was developed by Sugiyama in plasma. However, no 
internal standard was used in the method. Furthermore our method was developed in 
accordance to the concentration of polyamide used to treat the cells, a concentration that 
was rather high. By lowering the range of polyamide concentration used to treat the cells 
along with a new set of calibration curves at lower concentration it will certainly be 
possible to increase the method sensitivity.  
The developed method was used to evaluate uptake of PA1 and PA1F in HPV-
infected keratinocytes after 24 h incubation. The results showed that cell-associated 
concentration was higher for the formic analog. The uptake increased when the cells were 
treated at higher polyamide concentration, as expected. Since the only structural change 
between the PAs is a counterion, it is likely that the improved uptake is due to improved 
solubility of the compound in cell culture media. Although we tried to evaluate the 
solubility in cell media by UV-Vis spectroscopy, the results were ambiguous, mostly due 
to the complexity in terms of components present in it and possible interaction between 
PAs and medium components. An interesting finding was the apparent improved stability 
of the formic salt compared to the TFA salt. The concentration measured in the primary 
stock in DMSO was stable for over a month. Probably, the formate salt does not confer 
immediate solubility advantages, but maybe it does confer advantages on the long term 
and most likely at high concentrations. 
Further studies include the improvement of the method’s sensitivity so that it 
could be utilized to detect lower polyamide concentrations and the investigation of the 
structural stability of these analogs by LC-MS/MS.  
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6.  Appendix 
 
 Preparation of MJS-KA1007-Ta (DesImImβPyɣPyImPyPyβ-Ta) 
 Preparation of MJS-KA1002-Ta (DesImImPyPyɣPyImPyPyβ-Ta) 
 Preparation of MJS-KA1011-Ta (DesImImPyImɣPyPyβPyβ-Ta) 
 Preparation of MJS-KA1013-Ta (DesImImβImɣPyPyPyPyβ-Ta) 
 Preparation of MJS-KA1033-Ta (DesImImPyImɣPyPyPyPyβ-Ta) 
 Preparation of MJS-KA1055 (KA1041)-Ta (DesImImPyPyɣPyImβPyβ-Ta) 
 
 Preparation of MJS-KA1007-EDTA (DesImImβPyɣPyImPyPyβ-Ta-EDTA) 
 Preparation of MJS-KA1002-EDTA (DesImImPyPyɣPyImPyPyβ-Ta-EDTA) 
 Preparation of MJS-KA1011-EDTA (DesImImPyImɣPyPyβPyβ-Ta-EDTA) 
 Preparation of MJS-KA1013-EDTA (DesImImβImɣPyPyPyPyβ-Ta-EDTA) 
 Preparation of MJS-KA1033-EDTA (DesImImPyImɣPyPyPyPyβ-Ta-EDTA) 
 Preparation of MJS-KA1055 (KA1041)-EDTA (DesImImPyPyɣPyImβPyβ-Ta-
EDTA) 
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Preparation of MJS-KA1007 -Ta (DesImImβPyɣPyImPyPyβ-Ta) 
 
 
300 mg of resin bound to the polyamide (KA1007B) was placed in a 1 dram vial 
and incubated with 2 mL of 3,3’-Diamino-N-methyldipropylamine (Ta) at 60 ºC in a 
heating block, vortexing the mixture every 30 minutes. 
The reaction was monitored by High Pressure Liquid Chromatography (HPLC) and LC-
MS (ESI) using an Agilent 1100 Series G1956B LC-MSD system. Briefly, 10 µL 
aliquots were withdrawn from the reaction mixture, diluted with 600 µL DMSO and 
filtered with a 0.2 µm syringe filter before analysis.  
After 4 h, the reaction was stopped and the resin was removed by filtration through a 20 
µM polyethylene filter. The vial was rinsed with 1 mL of DMSO which was added to the 
filtrate. After addition of 1 mL of water to the filtrate, the mixture was purified on a 
Dionex prep HPLC (Ultimate 3000) using a Phenomenex Jupiter C12 column (250 x 30 
mm, 10 um particle size, 90A pore size). Mobile phases consisted of MeOH (0.1% 
TFA)/H2O (0.1% TFA) and the gradient was from 25% to 85% methanol. Compound 
eluted at 25 min. Fractions were collected in a 250 mL round bottom flask, concentrated 
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under reduced pressure and transferred to a 20 mL scintillation vial, rinsing the flask with 
a 1:1 ACN:H2O (0.1 % TFA) solution. The concentrated solution was frozen on dry ice 
and lyophilized overnight yielding 61.7 mg of MJS-KA1007-Ta (Purity: 99%, [M+H]
+ 
1215.40 m/z). 
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Preparation of MJS-KA1002 (DesImImPyPyɣPyImPyPyβ-Ta) 
 
 
300 mg of resin bound to the polyamide (KA1002A) was placed in a 1 dram vial 
and incubated with 2 mL of 3,3’-Diamino-N-methyldipropylamine (Ta) at 60 ºC in a 
heating block, vortexing the mixture every 30 minutes. 
The reaction was monitored by High Pressure Liquid Chromatography (HPLC) and LC-
MS (ESI) using an Agilent 1100 Series G1956B LC-MSD system. Briefly, 10 µL 
aliquots were withdrawn from the reaction mixture, diluted with 600 µL DMSO and 
filtered with a 0.2 µm syringe filter before analysis.  
After 4 h, the reaction was stopped and the resin was removed by filtration through a 20 
µM polyethylene filter. The vial was rinsed with 1 mL of DMSO which was added to the 
filtrate. After addition of 1 mL of water to the filtrate, the mixture was purified on a 
Dionex prep HPLC (Ultimate 3000) using a Phenomenex Jupiter C12 column (250 x 30 
mm, 10 um particle size, 90A pore size). Mobile phases consisted of MeOH (0.1% 
TFA)/H2O (0.1% TFA) and the gradient was from 25% to 85% methanol. Compound 
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eluted at 25 min. Fractions were collected in a 250 mL round bottom flask, concentrated 
under reduced pressure and transferred to a 20 mL scintillation vial, rinsing the flask with 
a 1:1 ACN:H2O (0.1 % TFA) solution. The concentrated solution was frozen on dry ice 
and lyophilized overnight yielding 65.2 mg of MJS-KA1002-Ta (Purity: 95%, [M+H]
+ 
1267.60 m/z). 
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Preparation of MJS-KA1011-Ta (DesImImPyImɣPyPyβPyβ-Ta) 
 
 
300 mg of resin bound to the polyamide (KA1011B) was placed in a 1 dram vial 
and incubated with 2 mL of 3,3’-Diamino-N-methyldipropylamine (Ta) at 60 ºC in a 
heating block, vortexing the mixture every 30 minutes. 
The reaction was monitored by High Pressure Liquid Chromatography (HPLC) and LC-
MS (ESI) using an Agilent 1100 Series G1956B LC-MSD system. Briefly, 10 µL 
aliquots were withdrawn from the reaction mixture, diluted with 600 µL DMSO and 
filtered with a 0.2 µm syringe filter before analysis.  
After 4 h, the reaction was stopped and the resin was removed by filtration through a 20 
µM polyethylene filter. The vial was rinsed with 1 mL of DMSO which was added to the 
filtrate. After addition of 1 mL of water to the filtrate, the mixture was purified on a 
Dionex prep HPLC (Ultimate 3000) using a Phenomenex Jupiter C12 column (250 x 30 
mm, 10 um particle size, 90A pore size). Mobile phases consisted of MeOH (0.1% 
TFA)/H2O (0.1% TFA) and the gradient was from 25% to 85% methanol. Compound 
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eluted at 45 min. Fractions were collected in a 250 mL round bottom flask, concentrated 
under reduced pressure and transferred to a 20 mL scintillation vial, rinsing the flask with 
a 1:1 ACN:H2O (0.1 % TFA) solution. The concentrated solution was frozen on dry ice 
and lyophilized overnight yielding 64.4 mg of MJS-KA1011-Ta (Purity: 95%, [M+H]
+ 
1215.40 m/z). 
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Preparation of MJS-KA1013-Ta (DesImImβImɣPyPyPyPyβ-Ta) 
 
 
300 mg of resin bound to the polyamide (KA1013B) was placed in a 1 dram vial 
and incubated with 2 mL of 3,3’-Diamino-N-methyldipropylamine (Ta) at 60 ºC in a 
heating block, vortexing the mixture every 30 minutes. 
The reaction was monitored by High Pressure Liquid Chromatography (HPLC) and LC-
MS (ESI) using an Agilent 1100 Series G1956B LC-MSD system. Briefly, 10 µL 
aliquots were withdrawn from the reaction mixture, diluted with 600 µL DMSO and 
filtered with a 0.2 µm syringe filter before analysis.  
After 4 h, the reaction was stopped and the resin was removed by filtration through a 20 
µM polyethylene filter. The vial was rinsed with 1 mL of DMSO which was added to the 
filtrate. After addition of 1 mL of water to the filtrate, the mixture was purified on a 
Dionex prep HPLC (Ultimate 3000) using a Phenomenex Jupiter C12 column (250 x 30 
mm, 10 um particle size, 90A pore size). Mobile phases consisted of MeOH (0.1% 
TFA)/H2O (0.1% TFA) and the gradient was from 25% to 85% methanol. Compound 
eluted at 27 min. Fractions were collected in a 250 mL round bottom flask, concentrated 
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under reduced pressure and transferred to a 20 mL scintillation vial, rinsing the flask with 
a 1:1 ACN:H2O (0.1 % TFA) solution. The concentrated solution was frozen on dry ice 
and lyophilized overnight yielding 59.6 mg of MJS-KA1013-Ta (Purity: 99%, [M+H]
+ 
1215.40 m/z). 
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Preparation of MJS-KA1033-Ta (DesImImPyImɣPyPyPyPyβ-Ta) 
 
 
300 mg of resin bound to the polyamide (KA1033) was placed in a 1 dram vial 
and incubated with 2 mL of 3,3’-Diamino-N-methyldipropylamine (Ta) at 60 ºC in a 
heating block, vortexing the mixture every 30 minutes. 
The reaction was monitored by High Pressure Liquid Chromatography (HPLC) and LC-
MS (ESI) using an Agilent 1100 Series G1956B LC-MSD system. Briefly, 10 µL 
aliquots were withdrawn from the reaction mixture, diluted with 600 µL DMSO and 
filtered with a 0.2 µm syringe filter before analysis.  
After 4 h, the reaction was stopped and the resin was removed by filtration through a 20 
µM polyethylene filter. The vial was rinsed with 1 mL of DMSO which was added to the 
filtrate. After addition of 1 mL of water to the filtrate, the mixture was purified on a 
Dionex prep HPLC (Ultimate 3000) using a Phenomenex Jupiter C12 column (250 x 30 
mm, 10 um particle size, 90A pore size). Mobile phases consisted of MeOH (0.1% 
TFA)/H2O (0.1% TFA) and the gradient was from 25% to 85% methanol. Compound 
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eluted at 30 min. Fractions were collected in a 250 mL round bottom flask, concentrated 
under reduced pressure and transferred to a 20 mL scintillation vial, rinsing the flask with 
a 1:1 ACN:H2O (0.1 % TFA) solution. The concentrated solution was frozen on dry ice 
and lyophilized overnight yielding 48 mg of MJS-KA1033-Ta (Purity: 97%, [M+H]
+ 
1266.40 m/z). 
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 Preparation of MJS-KA1055 (1041)-Ta (DesImImPyPyɣPyImβPyβ-Ta) 
 
 
300 mg of resin bound to the polyamide (KA1041B) was placed in a 1 dram vial 
and incubated with 2 mL of 3,3’-Diamino-N-methyldipropylamine (Ta) at 60 ºC in a 
heating block, vortexing the mixture every 30 minutes. 
The reaction was monitored by High Pressure Liquid Chromatography (HPLC) and LC-
MS (ESI) using an Agilent 1100 Series G1956B LC-MSD system. Briefly, 10 µL 
aliquots were withdrawn from the reaction mixture, diluted with 600 µL DMSO and 
filtered with a 0.2 µm syringe filter before analysis.  
After 4 h, the reaction was stopped and the resin was removed by filtration through a 20 
µM polyethylene filter. The vial was rinsed with 1 mL of DMSO which was added to the 
filtrate. After addition of 1 mL of water to the filtrate, the mixture was purified on a 
Dionex prep HPLC (Ultimate 3000) using a Phenomenex Jupiter C12 column (250 x 30 
mm, 10 um particle size, 90A pore size). Mobile phases consisted of MeOH (0.1% 
TFA)/H2O (0.1% TFA) and the gradient was from 25% to 85% methanol. Compound 
eluted at 25 min. Fractions were collected in a 250 mL round bottom flask, concentrated 
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under reduced pressure and transferred to a 20 mL scintillation vial, rinsing the flask with 
a 1:1 ACN:H2O (0.1 % TFA) solution. The concentrated solution was frozen on dry ice 
and lyophilized overnight yielding 50.5 mg of MJS-KA1055 (1041)-Ta ([M+H]
+ 
1215.40 
m/z). 
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Preparation of MJS-KA1007 -Ta (DesImImβPyɣPyImPyPyβ-Ta-EDTA) 
 
14.4 mg of EDTA dianhydride were placed in a 1 dram vial and added 0.5 mL 
DIEA, 0.25 mL DMF and 0.25 mL DMSO. After vigorous vortexing, the mixture was 
placed in a heating block and stirred at 55 ºC. To the EDTA mixture, a biphasic mixture 
of MJS-KA1007-Ta (5 mg) in 0.5 mL N,N-Diisopropylethylamine (DIEA) and 0.5 mL 
DMF was added dropwise via syringe over 15 min. The mixture was stirred for 30 min at 
55 ºC and the reaction monitored by HPLC. Briefly, a 10 µL aliquot from the bottom 
phase (DMF/DMSO) was diluted with 100 µL of DMSO and analyzed by LC-MS. 
Following addition of 1.12 mL of 0.1 N NaOH, the mixture was then stirred at 55 ºC for 
20 min and further analyzed by LC-MS. The bottom layer of the biphasic solution was 
transferred to a 20 mL vial and neutralized with 1.4 mL of 1 M trifluoroacetic acid 
(TFA). The mixture was diluted with 1 mL of DMSO and filtered through a 20 µm 
polyethylene filter. After purification by reverse-phase HPLC on a Dionex prep HPLC 
(Ultimate 3000), fractions containing the desired product were transferred into a 50 mL 
round bottom flask, concentrated under reduced pressure and transferred to a 20 mL vial, 
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rinsing the flask with a 1:1 ACN:H2O (0.1% TFA) solution. The concentrated mixture 
was frozen on dry ice and lyophilized overnight to give 3.5 mg of MJS-KA1007-EDTA 
([M+H]
+
 1489.61 m/z, purity: 85%).  
 
 
Preparation of MJS-KA1002-EDTA (DesImImPyPyɣPyImPyPyβ-Ta-EDTA) 
 
 
13.95 mg of EDTA dianhydride were placed in a 1 dram vial and added 0.5 mL 
DIEA, 0.25 mL DMF and 0.25 mL DMSO. After vigorous vortexing, the mixture was 
placed in a heating block and stirred at 55 ºC. To the EDTA mixture, a biphasic mixture 
of MJS-KA1002-Ta (5 mg) in 0.5 mL N,N-Diisopropylethylamine (DIEA) and 0.5 mL 
DMF was added dropwise via syringe over 15 min. The mixture was stirred for 30 min at 
55 ºC and the reaction monitored by HPLC. Briefly, a 10 µL aliquot from the bottom 
phase (DMF/DMSO) was diluted with 100 µL of DMSO and analyzed by LC-MS. 
Following addition of 1.09 mL of 0.1 N NaOH, the mixture was then stirred at 55 ºC for 
20 min and further analyzed by LC-MS. The bottom layer of the biphasic solution was 
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transferred to a 20 mL vial and neutralized with 600 µL of 1 M trifluoroacetic acid 
(TFA). The mixture was diluted with 1 mL of DMSO and filtered through a 20 µm 
polyethylene filter. After purification by reverse-phase HPLC on a Dionex prep HPLC 
(Ultimate 3000), fractions containing the desired product were transferred into a 50 mL 
round bottom flask, concentrated under reduced pressure and transferred to a 20 mL vial, 
rinsing the flask with a 1:1 ACN:H2O (0.1% TFA) solution. The concentrated mixture 
was frozen on dry ice and lyophilized overnight to give 2.9 mg of MJS-KA1002-EDTA 
([M+H]
+
 1540.6 m/z, purity: 88%).  
 
 
Preparation of MJS-KA1011-Ta-EDTA (DesImImPyImɣPyPyβPyβ-EDTA) 
 
14.3 mg of EDTA dianhydride were placed in a 1 dram vial and added 0.5 mL 
DIEA, 0.25 mL DMF and 0.25 mL DMSO. After vigorous vortexing, the mixture was 
placed in a heating block and stirred at 55 ºC. To the EDTA mixture, a biphasic mixture 
of MJS-KA1011-Ta (5 mg) in 0.5 mL N,N-Diisopropylethylamine (DIEA) and 0.5 mL 
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DMF was added dropwise via syringe over 15 min. The mixture was stirred for 30 min at 
55 ºC and the reaction monitored by HPLC. Briefly, a 10 µL aliquot from the bottom 
phase (DMF/DMSO) was diluted with 100 µL of DMSO and analyzed by LC-MS. 
Following addition of 1.12 mL of 0.1 N NaOH, the mixture was then stirred at 55 ºC for 
20 min and further analyzed by LC-MS. The bottom layer of the biphasic solution was 
transferred to a 20 mL vial and neutralized with 450 µL of 1 M trifluoroacetic acid 
(TFA). The mixture was diluted with 1 mL of DMSO and filtered through a 20 µm 
polyethylene filter. After purification by reverse-phase HPLC on a Dionex prep HPLC 
(Ultimate 3000), fractions containing the desired product were transferred into a 50 mL 
round bottom flask, concentrated under reduced pressure and transferred to a 20 mL vial, 
rinsing the flask with a 1:1 ACN:H2O (0.1% TFA) solution. The concentrated mixture 
was frozen on dry ice and lyophilized overnight to give 2.4 mg of MJS-KA1011-EDTA 
([M+H]
+
 1489.4 m/z, purity: 88%).  
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Preparation of MJS-KA1013-EDTA (DesImImβImɣPyPyPyPyβ-Ta-EDTA) 
 
 
14.3 mg of EDTA dianhydride were placed in a 1 dram vial and added 0.5 mL 
DIEA, 0.25 mL DMF and 0.25 mL DMSO. After vigorous vortexing, the mixture was 
placed in a heating block and stirred at 55 ºC. To the EDTA mixture, a biphasic mixture 
of MJS-KA1013-Ta (5 mg) in 0.5 mL N,N-Diisopropylethylamine (DIEA) and 0.5 mL 
DMF was added dropwise via syringe over 15 min. The mixture was stirred for 30 min at 
55 ºC and the reaction monitored by HPLC. Briefly, a 10 µL aliquot from the bottom 
phase (DMF/DMSO) was diluted with 100 µL of DMSO and analyzed by LC-MS. 
Following addition of 1.12 mL of 0.1 N NaOH, the mixture was then stirred at 55 ºC for 
20 min and further analyzed by LC-MS. The bottom layer of the biphasic solution was 
transferred to a 20 mL vial and neutralized with 650 µL of 1 M trifluoroacetic acid 
(TFA). The mixture was diluted with 1 mL of DMSO and filtered through a 20 µm 
polyethylene filter. After purification by reverse-phase HPLC on a Dionex prep HPLC 
(Ultimate 3000), fractions containing the desired product were transferred into a 50 mL 
163 
 
round bottom flask, concentrated under reduced pressure and transferred to a 20 mL vial, 
rinsing the flask with a 1:1 ACN:H2O (0.1% TFA) solution. The concentrated mixture 
was frozen on dry ice and lyophilized overnight to give 2.8 mg of MJS-KA1013-EDTA 
([M+H]
+
 1489.61 m/z, purity: 93%).  
 
 
Preparation of MJS-KA1033-Ta-EDTA (DesImImPyImɣPyPyPyPyβ-Ta-EDTA) 
 
 
21 mg of EDTA dianhydride were placed in a 1 dram vial and added 0.5 mL 
DIEA, 0.25 mL DMF and 0.25 mL DMSO. After vigorous vortexing, the mixture was 
placed in a heating block and stirred at 55 ºC. To the EDTA mixture, a biphasic mixture 
of MJS-KA1033-Ta (5 mg) in 0.5 mL N,N-Diisopropylethylamine (DIEA) and 0.5 mL 
DMF was added dropwise via syringe over 15 min. The mixture was stirred for 30 min at 
55 ºC and the reaction monitored by HPLC. Briefly, a 10 µL aliquot from the bottom 
phase (DMF/DMSO) was diluted with 100 µL of DMSO and analyzed by LC-MS. 
Following addition of 1.62 mL of 0.1 N NaOH, the mixture was then stirred at 55 ºC for 
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20 min and further analyzed by LC-MS. The bottom layer of the biphasic solution was 
transferred to a 20 mL vial and neutralized with 350 µL of 1 M trifluoroacetic acid 
(TFA). The mixture was diluted with 1 mL of DMSO and filtered through a 20 µm 
polyethylene filter. After purification by reverse-phase HPLC on a Dionex prep HPLC 
(Ultimate 3000), fractions containing the desired product were transferred into a 50 mL 
round bottom flask, concentrated under reduced pressure and transferred to a 20 mL vial, 
rinsing the flask with a 1:1 ACN:H2O (0.1% TFA) solution. The concentrated mixture 
was frozen on dry ice and lyophilized overnight to give 1.3 mg of MJS-KA1033-EDTA 
([M+H]
+
 1540.4 m/z, purity: 80%).  
 
 
Preparation of MJS-KA1055 (KA1041)-EDTA (DesImImPyPyɣPyImβPyβ-Ta-EDTA) 
 
14.4 mg of EDTA dianhydride were placed in a 1 dram vial and added 0.5 mL 
DIEA, 0.25 mL DMF and 0.25 mL DMSO. After vigorous vortexing, the mixture was 
placed in a heating block and stirred at 55 ºC. To the EDTA mixture, a biphasic mixture 
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of MJS-KA1055 (KA1041)-Ta (5 mg) in 0.5 mL N,N-Diisopropylethylamine (DIEA) and 
0.5 mL DMF was added dropwise via syringe over 15 min. The mixture was stirred for 
30 min at 55 ºC and the reaction monitored by HPLC. Briefly, a 10 µL aliquot from the 
bottom phase (DMF/DMSO) was diluted with 100 µL of DMSO and analyzed by LC-
MS. Following addition of 1.12 mL of 0.1 N NaOH, the mixture was then stirred at 55 ºC 
for 20 min and further analyzed by LC-MS. The bottom layer of the biphasic solution 
was transferred to a 20 mL vial and neutralized with 400 µL of 1 M trifluoroacetic acid 
(TFA). The mixture was diluted with 1 mL of DMSO and filtered through a 20 µm 
polyethylene filter. After purification by reverse-phase HPLC on a Dionex prep HPLC 
(Ultimate 3000), fractions containing the desired product were transferred into a 50 mL 
round bottom flask, concentrated under reduced pressure and transferred to a 20 mL vial, 
rinsing the flask with a 1:1 ACN:H2O (0.1% TFA) solution. The concentrated mixture 
was frozen on dry ice and lyophilized overnight to give 3.3 mg of MJS-KA1055 
(KA1041)-EDTA ([M+H]
+
 1489.4 m/z, purity: 86%).  
 
